WO1993004088A1 - Hepatitis c assay utilizing recombinant antigens to ns1 - Google Patents

Hepatitis c assay utilizing recombinant antigens to ns1 Download PDF

Info

Publication number
WO1993004088A1
WO1993004088A1 PCT/US1992/007188 US9207188W WO9304088A1 WO 1993004088 A1 WO1993004088 A1 WO 1993004088A1 US 9207188 W US9207188 W US 9207188W WO 9304088 A1 WO9304088 A1 WO 9304088A1
Authority
WO
WIPO (PCT)
Prior art keywords
ala
val
leu
gly
arg
Prior art date
Application number
PCT/US1992/007188
Other languages
French (fr)
Inventor
Stephen H. Dailey
Suresh M. Desai
Sushil G. Devare
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to EP92918853A priority Critical patent/EP0600009A4/en
Priority to JP5504658A priority patent/JPH06510191A/en
Publication of WO1993004088A1 publication Critical patent/WO1993004088A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates generally to an assay for identifying the presence in a sample of an antibody which is immunologically reactive with a hepatitis C virus antigen and specifically to an assay for detecting a complex of an antibody and recombinant antigens representing distinct regions of the HCV genome.
  • Recombinant antigens derived from the molecular cloning and expression in a heterologous expression system of the synthetic DNA sequences representing distinct antigenic regions of the HCV genome can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to hepatitis C virus (HCV).
  • Acute viral hepatitis is clinically diagnosed by a well-defined set of patient symptoms, including jaundice, hepatic tenderness, and an increase in the serum levels of alanine am inotransf erase (ALT) and aspartate aminotransferase.
  • ALT alanine am inotransf erase
  • Additional serologic immunoassays are generally performed to diagnose the specific type of viral causative agent. Historically, patients presenting clinical hepatitis symptoms and not otherwise infected by hepatitis A, hepatitis B, Epstein-Barr or cytomegalovirus were clinically diagnosed as having non-A non-B hepatitis
  • NANBH neurotrophic neoplasm
  • hepatitis A virus HAV
  • HBV hepatitis B virus
  • HBV hepatitis D virus
  • HDV High-V-V
  • HCV hepatitis C virus
  • the cDNA sequences associated with HCV were isolated from a cDNA library prepared from the RNA obtained from pooled serum from a chimpanzee with chronic HCV infection.
  • the cDNA library contained cDNA sequences of approximate mean size of about 200 base pairs.
  • the cDNA library was screened for encoded epitopes expressed in clones that could bind to antibodies in sera from patients who had previously experienced NANBH.
  • SOD superoxide dismutase fusion polypeptides
  • c100-3 The most complex SOD fusion polypeptide described in the European Patent Application, designated c100-3, was described as containing 154 amino acids of human SOD at the aminoterminus, 5 amino acid residues derived from the expression of a synthetic DNA adapter containing a restriction site, EcoRI, 363 amino acids derived from the expression of a cloned HCV cDNA fragment, and 5 carboxyl terminal amino acids derived from an MS2 cloning vector nucleotide sequence.
  • the DNA sequence encoding this polypeptide was transformed into yeast cells using a plasmid. The transformed cells were cultured and expressed a 54,000 molecular weight polypeptide which was purified to about 80% purity by differential extraction.
  • SOD-NANB5-1-1 and SOD- NANB 81 were expressed in recombinant bacteria.
  • the E.coli fusion poiypeptides were purified by differential extraction and by chromatography using anion and cation exchange columns. The purification procedures were able to produce SOD- NANB 5- 1 -1 as about 80% pure and SOD-NAN38, as about 50% pure.
  • microtiter wells or polystyrene beads coated on microtiter wells or polystyrene beads and used to assay serum samples. Briefly, coated microtiter wells were incubated with a sample in a diluent. After incubation, the microtiter wells were washed and then developed using either a radioactively labelled sheep anti-human antibody or a mouse antihuman IgG-HRP (horseradish peroxidase) conjugate. These assays were used to detect both post acute phase and chronic phase HCV infection.
  • assay specificity required adding yeast or E.coli extracts to the samples in order to prevent undesired immunological reactions with any yeast or E.coli antibodies present in samples.
  • Ortho Diagnostic Systems Inc. have developed a immunoenzyme assay to detect antibodies to HCV antigens.
  • the Ortho assay procedure is a three-stage test for serum/plasma carried out in a microwell coated with the recombinant yeast/hepatitis C virus SOD fusion polypeptide c100-3.
  • a test specimen is diluted directly in the test well and incubated for a specified length of time. If antibodies to HCV antigens are present in the specimen, antigen-antibody complexes will be formed on the microwell surface.
  • anti-human IgG murine monoclonal antibody horseradish peroxidase conjugate is added to the microwell.
  • the conjugate binds specifically to the antibody portion of the antigen-antibody complexes. If antigen-antibody complexes are not present, the unbound conjugate will also be removed by a washing step.
  • an enzyme detection system composed of o- phenyienediamine 2HCI (OPD) and hydrogen peroxide is added to the test well. If bound conjugate is present, the OPD will be oxidized, resulting in a colored end product. After formation of the colored end product, dilute sulfuric acid is added to the microwell to stop the color-forming detection reaction.
  • OPD o- phenyienediamine 2HCI
  • the intensity of the colored end product is measured with a microwell reader.
  • the assay may be used to screen patient serum and plasma.
  • HCV may be transmitted by contaminated blood and blood products.
  • transfused patients as many as 10% will suffer from post- transfusion hepatitis. Of these, approximately 90% are the result of infections diagnosed as HCV.
  • the prevention of transmission of HCV by blood and blood products requires reliable, sensitive and specific diagnosis and prognostic tools to identify HCV carriers as well as contaminated blood and blood products.
  • an HCV assay which uses reliable and efficient reagents and methods to accurately detect the presence of HCV antibodies in samples.
  • the present invention provides an improved assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with at least one recombinant protein representing a distinct antigenic region of the HCV genome.
  • Recombinant antigens which are derived from the molecular cloning and expression of synthetic DNA sequences in heterologous hosts are provided. Briefly, synthetic DNA sequences which encode the desired proteins representing distinct antigenic regions of the HCV genome are optimized for expression in E.coli by specific codon selection. Specifically, recombinant proteins representing five distinct antigenic regions of NS1 of the HCV genome are described. The proteins are expressed as chimeric fusions with E.coli CMP-KDO synthetase (CKS) gene.
  • the first protein, expressed by plasmid pHCV-77 (identified as SEQ. ID. NO. 1) represents amino acids 365-579 of the HCV sequence of NS1 and, based on analogy to the genomic organization of other flaviviruses, has been named HCV CKS-NS1S1.
  • pHCV-77 will also refer to the fusion protein itself and that pHCV-77' will be the designation for a polypeptide representing the NS1 region from about amino acids 365-579 of the HCV sequence prepared using other recombinant or synthetic methodologies. Other recombinant methodologies would include the preparation of pHCV-77', utilizing different expression systems.
  • the methodology for the preparation of synthetic peptides of HCV is described in U.S. Serial No. 456,162, filed December 22, 1989, and U.S. Serial No. 610,180, filed November 7, 1990, which enjoy common ownership and are incorporated herein by reference.
  • the next protein is expressed by plasmid pHCV-65, identified as SEQ. ID. NO.
  • pHCV-65 has been named HCV CKS-NS1S2 and is expressed by the plasmid pHCV-65.
  • the fusion protein itself will also be referred to as pHCV-65 and pHCV- 65' shall be the designation for a polypeptide from the NS-1 region representing from about amino acids 565-731 of the HCV sequence prepared using other recombinant or synthetic methodologies.
  • the next recombinant antigen represents amino acids 717-847 of the NS1 region of the HCV sequence, and is expressed by the plasmid pHCV-78 (identified by SEQ. ID. NO. 3).
  • the fusion protein will be referred to as pHCV-78 and pHCV-78' shall be the designation for a polypeptide from the NS1 region representing from about amino acids 717-847 of the HCV sequence prepared using other recombinant or synthetic methodologies. It has been designated clone HCV CKS-NS1S3 based on the strategy used in its construction. Figure 44 illustrates the position of pHCV-77, pHCV-65 and pHCV-78 in the NS1 region of the HCV genome.
  • the recombinant antigen produced by pHCV-80 is identified as SEQ. ID. NO.4 and is designated HCV CKS-NS1S1-NS1S2.
  • the fusion protein is also designated by pHCV-80 and pHCV-80' refers to the polypeptide located in the NS1 region of HCV, representing amino acids 365-731 of the HCV genome prepared using different recombinant methodologies.
  • Figure 45 illustrates the position of pHCV-80 within the HCV genome.
  • HCV CKS-Full Length NS1 is the designation for the recombinant protein pHCV-92 (SEQ. ID. NO. 5). It represents amino acids 365-847 of the HCV genome.
  • the fusion proteins will be referred to as pHCV-92 and pHCV 92' shall be the designation for the polypeptide from the NS1 region representing amino acids 365-847 of the HCV sequence prepared using other recombinant or synthetic methodologies.
  • Figure 46 illustrates the position of pHCV-92 in the HCV genome.
  • One assay format provides a screening assay for identifying the presence of an antibody that is immunologically reactive with an HCV antigen. Briefly, a fluid sample is incubated with a solid support containing the commonly bound recombinant proteins. Finally, the antibody-antigen complex is detected. In a modification of the screening assay the solid support additionally contains recombinant polypeptide c100-3.
  • Another assay format provides a confirmatory assay for unequivocally identifying the presence of an antibody that is immunologically reactive with an HCV antigen.
  • the confirmatory assay includes synthetic peptides or recombinant antigens representing the epitopes contained within the NS1 region of the HCV genome, which are the same regions represented by the recombinant proteins described in the screening assay. These are pHCV-77, pHCV-65, pHCV-78, pHCV-
  • Recombinant proteins used in the confirmatory assay should have a heterologous source of antigen to that used in the primary screening assay (i.e. should not be an E.coli-derived recombinant antigen nor a recombinant antigen composed in part, of CKS sequences).
  • specimens repeatedly reactive in the primary screening assay are retested in the confirmatory assay. Aliquots containing identical amounts of specimen are contacted with a synthetic peptide or recombinant antigen individually coated onto a solid support. Finally, the antibody antigen complex is detected.
  • poiypeptides or recombinant proteins can be utilized as indicated or combined with other poiypeptides and recombinant proteins a described herein and also described in U.S. Serial No. 456,162 entitled “Hepatitis C Assay", filed December 22, 1989, which enjoys common ownership and is incorporated herein by reference.
  • Another assay format provides a competition assay or neutralization assay directed to the confirmation that positive results are not false by identifying the presence of an antibody that is immunologically reactive with an HCV antigen in a fluid sample where the sample is used to prepare first and second immunologically equivalent aliquots.
  • the first aliquot is contacted with solid support containing a bound polypeptide which contains at least one epitope of an HCV antigen under conditions suitable for complexing with the antibody to form a detectable antibodypolypeptide complex and the second aliquot is first contacted with the same solid support containing bound polypeptide.
  • the preferred recombinant poiypeptides include pHCV-77, pHCV-65, pHCV-78, pHCV-80 and pHCV-92.
  • Another assay format provides an immunodot assay for identifying the presence of an antibody that is immunologically reactive with an HCV antigen by concurrently contacting a sample with recombinant poiypeptides each containing distinct epitopes of an HCV antigen under conditions suitable for complexing the antibody with at least one of the poiypeptides and detecting the antibodypolypeptide complex by reacting the complex with colorproducing reagents.
  • the preferred recombinant poiypeptides employed include those recombinant poiypeptides derived from pHCV-77, pHCV-65, pHCV-78, pHCV-80, as well as pHCV-92.
  • the sample is preferably diluted before contacting the polypeptide absorbed on a solid support.
  • Samples may be obtained from different biological samples such as whole blood, serum, plasma, cerebral spinal fluid, and lymphocyte or cell culture supernatants.
  • Solid support materials may include cellulose materials, such as paper and nitrocellulose, natural and synthetic polymeric materials, such as poiyacrylamide, polystyrene, and cotton, porous gels such as silica gel, agarose, dextran and gelatin, and inorganic materials such as deactivated alumina, magnesium sulfate and glass.
  • Suitable solid support materials may be used in assays in a variety of well known physical configurations, including microtiter wells, test tubes, beads, strips, membranes, and microparticles.
  • a preferred solid support for a non-immunodot assay is a polystyrene bead.
  • a preferred solid support for an immunodot assay is nitrocellulose.
  • Suitable methods and reagents for detecting an antibody-antigen complex in an assay of the present invention are commercially available or known in the relevant art. Representative methods may employ detection reagents such as enzymatic, radioisotopic, fluorescent, luminescent, or chemiluminescent reagents. These reagents may be used to prepare hapten-labelled antihapten detection systems according to known procedures, for example, a biotin-labelled antibiotin system may be used to detect an antibody-antigen complex.
  • the present invention also encompasses assay kits including poiypeptides which contain at least one epitope of an HCV antigen bound to a solid support as well as needed sample preparation reagents, wash reagents, detection reagents and signal producing reagents.
  • E.coli strains containing plasmids useful for constructs of the invention have been deposited at the American Type Culture Collection, Rockville, Maryland on August 10, 1990, under the accession Nos. ATCC 68380 (pHCV-23), ATCC 68381 (pHCV-29), ATCC 68382 (pHCV-31), ATCC 68383 (pHCV-34) and on November 6, 1990 for E.coli strains containing plasmids useful for constructs under the accession Nos.
  • ATCC 68458 (pHCV-50), ATCC 68459 (pHCV-57), ATCC 68460 (pHCV-103), ATCC 68461 (pHCV-102), ATCC 68462 (pHCV-51), ATCC 68463 (pHCV-105), ATCC 68464 (pHCV-107), ATCC 68465 (pHCV-104), ATCC 68466 (pHCV-45), ATCC 68467 (pHCV-48),ATCC 68468 (pHCV-49), ATCC 68469 (pHCV-58) and ATCC 68470 (pHCV-101).
  • E. coli strains containing plasmids useful for constructs of the invention have been deposited at the A.T.C.C. on
  • FIGURE 1 illustrates the HCV genome.
  • FIGURE 2 illustrates the use of recombinant poiypeptides to identify the presence of antibodies in a chimpanzee inoculated with HCV.
  • FIGURE 3 illustrates the sensitivity and specificity increase in using the screening assay using pHCV-34 and pHCV-31 antigens.
  • FIGURE 4 illustrates the construction of plasmid pHCV-34.
  • FIGURE 5 illustrates fusion protein pHCV-34.
  • FIGURE 6 illustrates the expression of pHCV-34 proteins in E.coli
  • FIGURE 7 illustrates the construction of plasmid pHCV-23.
  • FIGURE 8 illustrates the construction of plasmid pHCV-29.
  • FIGURE 9 illustrates the construction of plasmid pHCV-31.
  • FIGURE 10 illustrates the fusion protein pHCV-31.
  • FIGURE 11 illustrates the expression of pHCV-29 in E.coli.
  • FIGURE 12 illustrates the expression of pHCV-23 in E.coli.
  • FIGURE 13 illustrates the expression of pHCV-31 in E.coli.
  • FIGURE 14 illustrates the increased sensitivity using the screening assay utilizing the pHCV-34.
  • FIGURE 15 illustrates the increased specificity with the screening assay utilizing pHCV-34 and pHCV-31.
  • FIGURE 16 illustrates the results in hemodialysis patients using the screening and confirmatory assays.
  • FIGURE 17 illustrates earlier detection of HCV in a hemodialysis patient using the screening assay.
  • FIGURE 18 illustrates the results of the screening assay utilizing pHCV-34 and pHCV-31 on samples from individuals with acute NANBH.
  • FIGURE 19 illustrates the results of the confirmatory assay of the same population group as in Figure 18.
  • FIGURE 20 illustrates the results of the screening and confirmatory assays on individuals infected with chronic NANBH.
  • FIGURE 21 illustrates preferred buffers, pH conditions, and spotting concentrations for the HCV immunodot assay.
  • FIGURE 22 illustrates the results of the HCV immunodot assay.
  • FIGURE 23 illustrates the fusion protein pHCV-45.
  • FIGURE 24 illustrates the expression of pHCV-45 in E.coli.
  • FIGURE 25 illustrates the fusion protein pHCV-48.
  • FIGURE 26 illustrates the expression of pHCV-48 in E.coli.
  • FIGURE 27 illustrates the fusion protein pHCV-51.
  • FIGURE 28 illustrates the expression of pHCV-51 in E.coli.
  • FIGURE 29 illustrates the fusion protein pHCV-50.
  • FIGURE 30 illustrates the expression of pHCV-50 in E.coli.
  • FIGURE 31 illustrates the fusion protein pHCV-49.
  • FIGURE 32 illustrates the expression of pHCV-49 in E.coli.
  • FIGURE 33 illustrates an immunoblot of pHCV-23, pHCV-45, pHCV-48, pHCV-51 , pHCV-50 and pHCV-49.
  • FIGURE 34 illustrates the fusion proteins pHCV-24, pHCV-57, pHCV-58.
  • FIGURE 35 illustrates the expression of pHCV-24, pHCV-57, and pHCV-58 in E.coli.
  • FIGURE 36 illustrates the fusion protein pHCV-105.
  • FIGURE 37 illustrates the expression of pHCV-105 in E.coli.
  • FIGURE 38 illustrates the fusion protein pHCV-103.
  • FIGURE 39 illustrates the fusion protein pHCV-101.
  • FIGURE 40 illustrates the fusion protein pHCV-102.
  • FIGURE 41 illustrates the expression of pHCV-102 in E.coli.
  • FIGURE 42 illustrates the fusion protein pHCV-107.
  • FIGURE 43 illustrates the fusion protein pHCV-104.
  • FIGURE 44 illustrates the NS1 region of the HCV genome, and in particular, the locations of pHCV-77, pHCV-65 and pHCV-78.
  • FIGURE 45 illustrates the NS1 region of the HCV genome, and in particular, the location of pHCV-80.
  • FIGURE 46 illustrates the NS1 region of the HCV genome, and in particlar, the location of pHCV-92.
  • FIGURE 47A illustrates the expression of pHCV-77 in E. coli: and FIGURE 47B illustrates an immunblot of pHCV-77 in E. coli.
  • FIGURE 48A illustrates the expression of pHCV-65 in E. coli and FIGURE 48B illustrates an immunoblot of pHCV-65 in E. coli.
  • FIGURE 49A illustrates the expression of pHCV-80 in E. coli and FIGURE
  • 49B illustrates an immunoblot of pHCV-80 in E. coli.
  • the present invention is directed to an assay to detect an antibody to an HCV antigen in a sample.
  • Human serum or plasma is preferably diluted in a sample diluent and incubated with a polystyrene bead coated with a recombinant polypeptide that represents a distinct antigenic region of the HCV genome. If antibodies are present in the sample they will form a complex with the antigenic polypeptide and become affixed to the polystyrene bead. After the complex has formed, unbound materials and reagents are removed by washing the bead and the bead-antigen- antibody complex is reacted with a solution containing horseradish peroxidase labeled goat antibodies directed against human antibodies.
  • This peroxidase enzyme then binds to the antigen-antibody complex already fixed to the bead.
  • the horseradish peroxidase is contacted with o-phenylenediamine and hydrogen peroxide which results in a yellow-orange color.
  • the intensity of the color is proportional to the amount of antibody which initially binds to the antigen fixed to the bead.
  • the preferred recombinant poiypeptides having HCV antigenic epitopes were selected from portions of the HCV genome which encoded poiypeptides which possessed amino acid sequences similar to other known immunologically reactive agents and which were identified as having some immunological reactivity.
  • the immunological reactivity of a polypeptide was initially identified by reacting the cellular extract of E.coli clones which had been transformed with cDNA fragments of the HCV genome with HCV infected serum. Poiypeptides expressed by clone containing the incorporated cDNA were immunologically reactive with serum known to contain antibody to HCV antigens.)
  • An analysis of a given amino acid sequence only provides rough guides to predicting immunological reactivity. There is no invariably predictable way to ensure immunological activity short of preparing a given amino acid sequence and testing the suspected sequence in an assay.
  • pHCV-34 and pHCV-31 expressed by the plasmids pHCV-34 and pHCV-31, respectively.
  • the assay utilizing the recombinant pHCV-34 and pHCV-31 proteins detected plasma antibody three weeks prior to detection of antibody by the assay using c100-3.
  • This test is sufficiently sensitive to detect seroconversion during the acute phase of this disease, as defined as an elevation in ALT levels, in most animals. Equally important is the high degree of specificity of the test as no pre-inoculation specimens were reactive.
  • the poiypeptides useful in the practice of this invention are produced using recombinant technologies.
  • the DNA sequences which encode the desired poiypeptides are preferably assembled from fragments of the total desired sequence. Synthetic DNA fragments of the HCV genome can be synthesized based on their corresponding amino acid sequences. Once the amino acid sequence is chosen, this is then reverse translated to determine the complementary DNA sequence using codons optimized to facilitate expression in the chosen system.
  • the fragments are generally prepared using well known automated processes and apparatus. After the complete sequence has been prepared the desired sequence is incorporated into an expression vector which is transformed into a host cell. The DNA sequence is then expressed by the host cell to give the desired polypeptide which is harvested from the host cell or from the medium in which the host cell is cultured.
  • PCR polymerase chain reaction
  • Vector systems which can be used include plant, bacterial, yeast, insect, and mammalian expression systems. It is preferred that the codons are optimized for expression in the system used.
  • a preferred expression system utilizes a carrier gene for a fusion system where the recombinant HCV proteins are expressed as a fusion protein of an E.coli enzyme, CKS (CTP:CMP-3-deoxy-mann o -octulosonate cytidylyl transferase or CMP-KDO synthetase).
  • CKS CTP:CMP-3-deoxy-mann o -octulosonate cytidylyl transferase or CMP-KDO synthetase.
  • lambda PL vector system whose features include a strong lambda pL promoter, a strong three-frame translation terminator rrnBtl, and translation starting at an ATG codon.
  • the amino acid sequences encoding for the recombinant HCV antigens of interest were reverse translated using codons optimized to facilitate high level expression in E.coli.
  • Individual oligonucleotides were synthesized by the method of oligonucleotide directed double-stranded break repair disclosed in U.S. Patent Application Serial No. 883,242, filed July 8, 1986 by Mandecki (EPO 87109357.1) which enjoys common ownership and is incorporated herein by reference.
  • the individual oligonucleotides may be synthesized on the Applied Biosystem 380A DNA synthesizer using methods and reagents recommended by the manufacturer.
  • the DNA sequences of the individual oligonucleotides were confirmed using the Sanger dideoxy chain termination method (Sanger et al., J. Mole. Biol., 162:729 (1982)). These individual gene fragments were then annealed and ligated together and cloned as EcoRI-BamHI subfragments in the CKS fusion vector pJO200. After subsequent DNA sequence confirmation by the Sanger dideoxy chain termination method, the subfragments were digested with appropriate restriction enzymes, gel purified, ligated and cloned again as an EcoRI-BamHI fragment in the CKS fusion vector pJO2OO.
  • the resulting clones were mapped to identify a hybrid gene consisting of the EcoRI-BamHI HCV fragment inserted at the 3' end of the CKS (CMP-KDO synthetase) gene.
  • the resultant fusion proteins under control of the la c promoter, consist of 239 amino acids of the CKS protein fused to the various regions of HCV.
  • Examples 1 and 2 describe the synthesis and cloning of CKS-Core and CKS-33-BCD, respectively.
  • Example 3 describes a screening assay.
  • Example 4 describes a confirmatory assay.
  • Example 5 describes a competition assay.
  • Example 6 describes an immunodot assay.
  • Example 7 describes the synthesis and cloning of HCV CKS-NS5E, CKS-NS5F, CKS-NS5G, CKS-NS5H and CKS-NS5I.
  • Example 8 describes the preparation of HCV CKS-C100 vectors.
  • Example 9 describes the preparation of HCV PCR derived expression vectors.
  • Example 10 describes the synthesis and characterization of pHCV-77 of NS1.
  • Example 11 describes the synthesis and characterization of pHCV-65 of NS1.
  • Example 12 describes the synthesis and characterization of pHCV-78 of NS1.
  • Example 13 describes the synthesis and characterization of pHCV-80 of NS1.
  • Example 14 describes the synthesis and characterization of pHCV-92 of NS1.
  • Horseradish peroxidase (HRPO) labeled secondary antibodies were obtained from Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Maryland. Seaplaque® agarose (low melting agarose) was purchased from FMC Bioproducts, Rockland, Maine.
  • T50E10 contained 50mM Tris, pH 8.0, 10mM EDTA; 1X TG contained 100mM Tris, pH 7.5 and 10% glycerol; 2X SDS/PAGE loading buffer consisted of 15% glycerol, 5% SDS, 100mM Tris base, 1 M ⁇ -mercaptoethanol and 0.8%
  • E,coli JM103 cells, pUC8, pUC18, pUC19 and M13 cloning vectors were purchased from Pharmacia LKB Biotechnology, Inc., Piscataway, New Jersey;
  • Competent EpicureanTM coli stains XL1 -Blue and JM109 were purchased from
  • RR1 cells were obtained from Coli Genetic Stock Center, Yale University, New Haven, Connecticut; and E.coli CAG456 cells from Dr. Carol Gross, University of Wisconsin, Madison, Wisconsin.
  • Vector pRK248.clts was obtained from Dr. Donald R. Helinski, University of California, San Diego, California.
  • the cloning vector pJO200 allows the fusion of recombinant proteins to the
  • the plasmid consists of the plasmid pBR322 with a modified Jac promoter fused to a KdsB gene fragment (encoding the first 239 of the entire 248 amino acids of the E.coli CMP-KDO synthetase of CKS protein), and a synthetic linker fused to the end of the KdsB gene fragment.
  • the cloning vector pJO200 is a modification of vector pTB210.
  • the synthetic linker includes: multiple restriction sites for insertion of genes; translational stop signals, and the trpA rho- independent transcriptional terminator.
  • the pHCV-34 plasmid and the CKS plasmid pTB210 were transformed into E.coli K-12 strain xL-1 (recAI, endAI, gyrA96, thi-1 , hsdRI7, supE44, relAI, lac/F', proAB, laclqZDMl 5, TN10) cells made competent by the calcium chloride method.
  • E.coli K-12 strain xL-1 recAI, endAI, gyrA96, thi-1 , hsdRI7, supE44, relAI, lac/F', proAB, laclqZDMl 5, TN10
  • pHCV-34/XL-1 culture was grown overnight at 37°C in growth media consisting of yeast extract, trytone, phosphate salts, glucose, and ampicillin. When the culture reached an OD600 of 1.0, IPTG was added to a final concentration of 1 mM to induce expression. Samples (1.5 ml) were removed at 1 hour intervals, and cells were pelleted and resuspended to an OD600 of 1.0 in 2X SDS/PAGE loading buffer. Aliquots (15ul) of the prepared samples were separated on duplicate 12.5% SDS/PAGE gels.
  • One gel was fixed in a solution of 50% methanol and 10% acetic acid for 20 minutes at room temperature, and then stained with 0.25% Coomassie blue dye in a solution of 50% methanol and 10% acetic acid for 30 minutes. Destaining was carried out using a solution of 10% methanol and 7% acetic acid for 3-4 hours, or until a clear background was obtained.
  • Figure 6 presents the expression of pHCV-34 proteins in E.coli.
  • Molecular weight standards were run in Lane M.
  • Lane 1 contains the plasmid pJ0200-the CKS vector without the HCV sequence.
  • the arrows on the left indicate the mobilities of the molecular weight markers from top to bottom: 110,000; 84,000; 47,000; 33,000; 24,000; and 16,000 daltons.
  • the arrows on the right indicate the mobilities of the recombinant HCV proteins.
  • Lane 2 contains the E.coli lysate containing pHCV-34 expressing CKS-Core (amino acids 1 to 150) prior to induction; and Lane 3 after 3 hours of induction.
  • the results show that the recombinant protein pHCV-34 has an apparent mobility corresponding to a molecular size of 48,000 daltons. This compares acceptably with the predicted molecular mass of 43,750 daltons.
  • Proteins from the second 12.5% SDS/PAGE gel were electrophoretically transferred to nitrocellulose for immunoblotting.
  • the nitrocellulose sheet containing the transferred proteins was incubated with Blocking Solution for one hour and incubated overnight at 4°C with HCV patients' sera diluted in TBS containing E.coli K-12 strain XL-I lysate.
  • the nitrocellulose sheet was washed three times in TBS, then incubated with HRPO-labeled goat anti-human IgG, diluted in TBS containing 10% fetal calf sera.
  • the nitrocellulose was washed three times with TBS and the color was developed in TBS containing 2 mg/ml 4-chloro-1- napthol, 0.02% hydrogen peroxide and 17% methanol.
  • Clone HCV-34 demonstrated a strong immu no reactive band at 48,000 daltons with the HCV patients' sera.
  • the major protein in the Coomassie stained protein gel was immunoreactive.
  • HCV CKS-33c-BCD Expression Vector The construction of this recombinant clone expressing the HCV CKS-33-BCD antigen was carried out in three steps described below. First, a clone expressing the HCV CKS-BCD antigen was constructed, designated pHCV-23. Second, a clone expressing the HCV CKS-33 antigen was constructed, designated pHCV-29. Lastly, the HCV BCD region was excised from pHCV-23 and inserted into pHCV-29 to construct a clone expressing the HCV CKS-33-BCD antigen, designated pHCV-31 (SEQ.ID.NO. 8 and 9).
  • pHCV-23 To construct the plasmid pHCV-23, thirteen individual oligonucleotides representing amino acids 1676-1931 of the HCV genome were ligated together and cloned as three separate EcoRI-BamHI subfragments into the CKS fusion vector pJO200. After subsequent DNA sequence confirmation, the three subfragments, designated B, C, and D respectively, were digested with the appropriate restriction enzymes, gel purified, ligated together, and cloned as a 781 base pair EcoRI-BamHI fragment in the CKS fusion vector pJO200, as illustrated in Figure 7. The resulting plasmid, designated pHCV-23, expresses the HCV CKS-BCD antigen under control of the jac promoter.
  • the HCV CKS-BCD antigen consists of 239 amino acids of CKS, seven amino acids contributed by linker DNA sequences, 256 amino acids from the HCV NS4 region (amino acids 1676-1931 , and 10 additional amino acids contributed by linker DNA sequences.
  • the resulting plasmid expresses the CKS-33 antigen under control of the jac promoter.
  • the HCV CKS-33 antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 266 amino acids from the HCV NS3 region (amino acids 1192- 1 457) .
  • pHCV-31 To construct the plasmid pHCV-31 , the 781 base pair EcoRI-BamHI fragment from pHCV-23 representing the HCV-BCD region was linker-adapted to produce a Cla1-BamHl fragment which was then gel purified and ligated into pHCV- 29 at the Cla1-BamHl sites as illustrated in Figure 9.
  • the resulting plasmid, designated pHCV-31 expresses the pHCV-31 antigen under control of the lac
  • the complete DNA sequence of pHCV-31 and the entire amino acid sequence of the HCV CKS-33-BCD recombinant antigen produced is presented in SEQ.ID.NO. 8 and 9.
  • the HCV CKS-33-BCD antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, 266 amino acids of the HCV NS3 region (amino acids 1192-1457), 2 amino acids contributed by linker DNA sequences, 256 amino acids of the HCV NS4 region (amino acids 1676-1931), and 10 additional amino acids contributed by linker DNA sequences.
  • Figure 12 presents a schematic representation of the pHCV-31 antigen.
  • the pHCV-31 plasmid was transformed into E.coli K-12 strain XL-I in a manner similar to the pHCV-34 and CKS-pTB210 plasmids of Example 1.
  • pHCV CKS-33-BCD Characterization of pHCV CKS-33-BCD was carried out in a manner similar to pHCV CKS-Core of Example 1.
  • pHCV-23, pHCV SDS/PAGE gels were run for E.coli lysates containing the plasmids pHCV-29 ( Figure 11), pHCV-23 ( Figure 12), and pHCV-31 ( Figure 13) expressing the recombinant fusion proteins CKS- 33c, CKS-BCD, and CKS-33-BCD, respectively.
  • molecular weight standards were run in Lane M, with the arrows on the left indicating mobilities of the molecular weight markers the from top to bottom: 110,000;
  • Lane 1 contained the E.coli lysate containing pHCV-29 expressing HCV CKS-33c (amino acids 1192 to 1457) prior to induction and lane 2 after 4 hours induction. These results show that the recombinant pHCV-29 fusion protein has an apparent mobility corresponding to a molecular size of 60,000 daltons. This compares acceptably to the predicted molecular mass of 54,911.
  • Lane 1 contained the E.coli lysate containing pJO200- the CKS vector without the HCV sequence.
  • Lane 2 contained pHCV-20 expressing the
  • HCV CKS-B (amino acids 1676 to 1790).
  • Lane 3 contained the fusion protein pHCV-23 (amino acids 1676-1931).
  • Lane 1 contained the E.coli lysate containing pJO200 the CKS vector without the HCV sequences.
  • Lane 2 contained pHCV-31 expressing the CKS- 33C-BCD fusion protein (amino acids 1192 to 1447 and 1676 to 1931) prior to induction and lane 3 after 2 hours induction.
  • pHCV-31 (CKS-33c-BCD) fusion protein has an apparent mobility corresponding to a molecular size of 90,000 daltons. This compares acceptably to the predicted molecular mass of 82,995 daltons.
  • An immunoblot was also run on one of the SDS/PAGE gels derived from the PHCV-31/X1-1 culture. Human serum from an HCV exposed individual reacted strongly with the major pHCV-31 band at 90,000 daltons. Normal human serum did not react with any component of the pHCV-31 (CKS-33-BCD) preparations.
  • the procedure uses two E.coli expressed recombinant proteins, CKS-Core (pHCV-34) and CKS-33-BCD (pHCV- 31), representing three distinct regions of the HCV genome. These recombinant poiypeptides were prepared following procedures described above. In the screening assay, both recombinant antigens are coated onto the same polystyrene bead. In a modification of the screening assay the polystyrene bead may also be coated with the SOD-fusion polypeptide c100-3.
  • the polystyrene beads are first washed with distilled water and propanol and then incubated with a solution containing recombinant pHCV-31 diluted to 0.5 to 2.0 ug/ml and pHCV-34 diluted to 0.1 to 0.5 ug/ml in 0.1 M NaH2PO 4 ⁇ H 2 O with
  • the beads are incubated in the antigen solution for 2 hours (plus or minus 10 minutes) at 38-42°C, washed in PBS and soaked in 0.1% (w/v) Triton X-100 in PBS for 60 minutes at 38-42°C. The beads are then washed two times in phosphate buffered saline (PBS), overcoated with a solution of 5.0% (w/v) bovine serum albumin (BSA) in PBS for 60 minutes at 38-42°C and washed one time in PBS. Finally, the beads are overcoated with 5% (w/v) sucrose in PBS, and dried under nitrogen or air.
  • PBS phosphate buffered saline
  • BSA bovine serum albumin
  • the polystyrene beads coated with pHCV-31 and pHCV-34 are used in an antibody capture format. Ten microliters of sample are added to the wells of the reaction tray along with 400 ul of a sample diluent and the recombinant coated bead.
  • the sample diluent consists of 10% (v/v) bovine serum and 20% (v/v) goat serum in 20 mM Tris phosphate buffer containing 0.15% (v/v) Triton X-100, 1%(w/v) BSA, 1% E.coli lysate and 500 ug/ml or less CKS lysate.
  • yeast extracts typically about 200 ug/ml. The addition of yeast extracts to the sample diluent is used to prevent false positive results.
  • the final material is sterile filtered and filled in plastic bottles, and preserved with 0.1% sodium azide.
  • the beads After one hour of incubation at 40°C, the beads are washed and 200 ul of conjugate is added to the wells of the reaction tray.
  • the preferred conjugate is goat anti-human IgG horseradish peroxidase conjugate.
  • Concentrated conjugate is titered to determine a working concentration.
  • a twenty-fold concentrate of the working conjugate solution is then prepared by diluting the concentrate in diluent.
  • the 20X concentrate is sterile filtered and stored in plastic bottles.
  • the conjugate diluent includes 10% (v/v) bovine serum, 10% (v/v) goat serum and 0.15% Triton-X100 in 20 mM Tris buffer, pH 7.5 with 0.01% gentamicin sulfate, 0.01% thimerosal and red dye.
  • the conjugate is sterile filtered and filled in plastic bottles.
  • Anti-HCV positive control is prepared from plasma units positive for antibodies to HCV.
  • the pool of units used includes plasma with antibodies reactive to pHCV-31 and pHCV-34.
  • the units are recalcified and heat inactivated at 59-61°C for 12 hours with constant stirring.
  • the pool is aliquoted and stored at -20°C or at 2-8°C.
  • the stock solution is diluted with negative control containing 0.1% sodium azide as a preservative.
  • the final material is sterile filtered and filled in plastic bottles.
  • Anti-HCV negative control is prepared from recalcified human plasma, negative for antibodies to pHCV-31 and pHCV-34 proteins of HCV.
  • the plasma is also negative for antibodies to human immunodeficiency virus (HIV) and negative for hepatitis B surface antigen (HBsAg).
  • HCV human immunodeficiency virus
  • HBsAg hepatitis B surface antigen
  • the units are pooled, and 0.1% sodium azide is added as a preservative.
  • the final material is sterile filtered and filled in plastic bottles.
  • the cutoff for the assay should be at least 5-7 standard deviations above the absorbance value of the normal population mean.
  • S/CO sample to cutoff
  • Cutoff value 0.25 PCx + NCx.
  • Testing may be performed by two methods which differ primarily in the degree of automation and the mechanism for reading the resulting color development in the assay.
  • One method is referred to as the manual or QuantumTM method because Quantum or Quantumatic is used to read absorbance at 492 nm. It is also called the manual method because sample pipetting, washing and reagent additions are generally done manually by the technician, using appropriately calibrated pipettes, dispensers and wash instruments.
  • the second method is referred to as the PPC method and utilizes the automated Abbott Commander® system.
  • This system employs a pipetting device referred to as the Sample Management Center (SMC) and a wash/dispense/read device referred to as the Parallel Processing Center (PPC) disclosed in E.P.O. Publication No. 91114072.1.
  • SMC Sample Management Center
  • PPC Parallel Processing Center
  • the optical reader used in the PPC has dual wavelength capabilities that can measure differential absorbencies (peak band and side band) from the sample wells. These readings are converted into results by the processor's Control Center
  • Table I summarizes the results of a study which followed the course of HCV infection in seven chimpanzees using a screening assay which utilized the c100-3 polypeptide, and the screening assay which utilized pHCV-31 and pHCV-34. Both assays gave negative results before inoculation and both assays detected the presence of antibodies after the animal had been infected with HCV. However, in the comparison of the two assays, the assay utilizing pHCV- 31 and pHCV-34 detected seroconversion to HCV antigens at an earlier or equivalent bleed date in six of the seven chimpanzees. Data from these chimpanzee studies clearly demonstrate that overall detection of HCV antibodies is greatly increased with the assay utilizing the pHCV-31 and pHCV-34 proteins. This test is
  • Non-A. Non-B Panel II ( ⁇ . Alter. NIH)
  • probable infectious were three samples taken from the same post transfusion hepatitis patient.
  • the first two acute phase samples were negative in both assays, but the third sample was reactive in both assay.
  • the disease control samples and pedigreed negative controls were uniformly negative.
  • Specimen 39 was initially reactive in the screening test utilizing pHCV-34 and pHCV-31 , but upon retesting was negative and could not be confirmed by the confirmatory assays.
  • both screening tests identified 6 of 6 chronic NANBH carriers and 1 of 4 acute NANBH samples. Paired specimens from an implicated donor were non-reactive in the screening test utilizing c100-3 but were reactive in the screening test with pHCV-31 and pHCV-34. Thus, the screening test utilizing the recombinant antigens pHCV-31 and pHCV-34 appears to be more sensitive than the screening assay utilizing c100-3. None of the disease control specimens or pedigreed negative control specimens were reactive in either screening assay.
  • a reference panel for antibody to Hepatitis C was received from the Center for Biologies Evaluation and Research (CBER).
  • This 10 member panel consists of eight reactive samples diluted in normal human sera negative for antibody to HCV and two sera that contain no detectable antibody to HCV.
  • This panel was run on the Ortho first generation HCV EIA assay, the screening assay utilizing d 00-3 and the screening assay utilizing pHCV-31 and pHCV-34. The assay results are presented in Figure 15.
  • the screening assay utilizing pHCV-31 and pHCV-34 detected all six of the HCV positive or borderline sample dilutions.
  • the two non-reactive sample dilutions (709 and 710) appear to be diluted well beyond endpoint of antibody detectabiiity for both screening assays.
  • a marked increase was observed in the sample to cutoff values for three of the members on the screening assay utilizing pHCV-31 and pHCV-34 compared to the screening assay utilizing c100-3 or the Ortho first generation test. All repeatably reactive specimens were confirmed.
  • the confirmatory assay provides a means for unequivocally identifying the presence of an antibody that is immunologically reactive with an HCV antigen.
  • the confirmatory assay includes synthetic peptides or recombinant antigens
  • Recombinant proteins used in the confirmatory assay should have a heterologous source of antigen to that used in the primary screening assay (i.e. should not be an E.coli-derived recombinant antigen nor a recombinant antigen composed in part, of CKS sequences). Specimens repeatedly reactive in the primary screening assay are retested in the confirmatory assay. Aliquots containing identical amounts of specimen are contacted with a synthetic peptide or recombinant antigen individually coated onto a polystyrene bead.
  • Sero reactivity for epitopes within the c100-3 region of the HCV genome are confirmed by use of the synthetic peptides sp67 and sp65.
  • the synthetic peptide sp117 can also be used to confirm seroreactivity with the c100-3 region.
  • the assay protocols were similar to those described in Example 3 above.
  • the peptides are each individually coated onto polystyrene beads and used in an antibody capture format similar to that described for the screening assay.
  • Ten microliters of specimen are added to the wells of a reaction tray along with 400 ul of a specimen diluent and a peptide coated bead.
  • the beads After one hour of incubation at 40°C, the beads are washed and 200 ul of conjugate (identical to that described in Example 3) is added to the wells of the reaction tray.
  • the beads After one hour of incubation at 40°C, the beads are washed, exposed to the OPD substrate for 30 minutes at room temperature and the reaction terminated by the addition of 1 N H 2 SO 4 .
  • the absorbance is read at 492 nm.
  • the cutoff value for the peptide assay is 4 times the mean of the negative control absorbance value.
  • a group of 233 specimens representing 23 hemodialysis patients all with clinically diagnosed NANBH were supplied by Gary Gitnick, M.D. at the University of California, Los Angeles Center for the Health Sciences. These samples which were tested in by the screening assay utilizing d 00-3 were subsequently tested in the screening assay which uses pHCV-31 and pHCV-34. A total of 7/23 patients (30.44%) were reactive in the c100-3 screening assay, with a total of 36 repeat reactive specimens. Ten of 23 patients (43.48%) were reactive by the screening assay utilizing pHCV-31 and pHCV-34, with a total of 70 repeatable reactives among the available specimens (Figure 16). Two specimens were unavailable for testing.
  • a population of specimens was identified from individuals diagnosed as having acute or chronic NANBH. Specimens from individuals with acute cases of NANBH were received from Gary Gitnick, M.D. at the University of California, Los
  • hepatitis was based on the presence of a cytolytic syndrome (ALT levels greater than 2X the upper normal limit) on at least 2 serum samples for a duration of less than 6 months with or without other biological abnormalities and clinical symptoms. All specimens were also negative for IgM antibodies to Hepatitis A Virus (HAV) and were negative for Hepatitis B surface Ag when tested with commercially available tests. Specimens from cases of chronic NANBH were obtained from two clinical sites. Individuals were diagnosed as having chronic NANBH based on the following criteria:
  • Specimens with biopsy results were further categorized as either chronic active NANBH, chronic persistent NANBH, or chronic NANBH with cirrhosis.
  • the c100-3 screening assay detected 2 of 10 specimens (20.00%) as repeatedly reactive, both of which were confirmed.
  • the screening assay utilizing pHCV-34 and pHCV-31 detected both of these specimens plus and additional 2 specimens ( Figure 18). These 2 specimens were confirmed by sp75 (see Figure 1 9) .
  • the c100-3 assay detected 4 of 32 specimens (12.50%) as repeatedly reactive, all of which was confirmed.
  • the screening assay utilizing pHCV-34 and pHCV-31 detected 3 out of these 4 specimens (75%) as reactive.
  • the one sample that was missed had an S/CO of 0.95 by the latter screening test.
  • This sample was confirmed by the sp67 peptide ( Figure 18).
  • the screening assay utilizing pHCV-34 and pHCV-31 detected 11 specimens not reactive in the c100-3 screening assay. Of the 9 specimens available for confirmation, 8 were confirmed by sp75 and 1 could not be confirmed but had an S/CO of 0.90 in the sp65
  • the recombinant poiypeptides containing antigenic HCV epitopes are useful for competition assays.
  • a recombinant polypeptide representing epitopes within the c100-3 region such as CKS-BCD (pHCV-23) is solubilized and mixed with a sample diluent to a final concentration of 0.5-50 ug/ml.
  • Ten microliters of specimen or diluted specimen is added to a reaction well followed by 400 ul of the sample diluent containing the recombinant polypeptide and if desired, the mixture may be preincubated for about fifteen minutes to two hours.
  • a bead coated with c100-3 antigen is then added to the reaction well and incubated for one hour at 40°C. After washing, 200 ul of a peroxidase labeled goat anti-human IgG in conjugate diluent is added and incubated for one hour at 40°C. After washing, OPD substrate is added and incubated at room temperature for thirty minutes. The reaction is terminated by the addition of 1 N sulfuric acid and the absorbance read at 492 nm.
  • Samples containing antibodies to the c1 00-3 antigen generate a reduced signal caused by the competitive binding of the peptides to these antibodies in solution.
  • the percentage of competitive binding may be calculated by comparing the absorbance value of the sample in the presence of a recombinant polypeptide to the absorbance value of the sample assayed in the absence of a recombinant polypeptide at the same dilution.
  • EXAMPLE 6. IMMUNODOT ASSAY
  • the immunodot assay system uses a panel of purified recombinant poiypeptides placed in an array on a nitrocellulose solid support.
  • the prepared solid support is contacted with a sample and captures specific antibodies to HCV antigens.
  • the captured antibodies are detected by a conjugate-specific reaction.
  • the conjugate specific reaction is quantified using a reflectance optics assembly within an instrument which has been described in U.S. Patent Applications Serial No. 07/227,408 filed August 2, 1988.
  • the related U.S. Patent Applications Serial Nos. 07/227,272, 07/227,586 and 07/227,590 further describe specific methods and apparatus useful to perform an immunodot assay.
  • the assay has also been described in U.S. Application Serial No.
  • a nitrocellulose-base test cartridge is treated with multiple antigenic poiypeptides. Each polypeptide is contained within a specific reaction zone on the test cartridge. After all the antigenic poiypeptides have been placed on the nitrocellulose, excess binding sites on the nitrocellulose are blocked. The test cartridge is then contacted with a sample such that each antigenic polypeptide in each reaction zone will react if the sample contains the appropriate antibody. After reaction, the test cartridge is washed and any antigen-antibody reactions are identified using suitable well known reagents.
  • the recombinant poiypeptides pHCV-23, pHCV-29, pHCV-34, and c100-3 were diluted in the preferred buffers, pH conditions, and spotting concentrations as summarized in Figure 21 and applied to a preassembled nitrocellulose test cartridge. After drying the cartridge overnight at room temperature 37°C, the non-specific binding capacity of the nitro-cellulose phase was blocked.
  • the blocking solution contained 1% porcine gelatin, 1% casein enzymatic hydrolysate, 5% Tween-20, 0.1% sodium azide, 0.5 M sodium chloride and 20 mM Tris, pH 7.5.
  • sample A00642 was from a convalescent non-A, non-B hepatitis patient, diluted in negative human plasma from 1 :100 to 1 :12800.
  • the other sample, 423 was from a paid plasma donor which tested positive in an assay using a recombinant c100-3 polypeptide, diluted in negative human plasma from 1 :40 to 1 :2560.
  • sample A00642 was greatest with pHCV-29, and decreased for the remaining antigens pHCV-23, c100-3, and pHCV-34.
  • Sample 423 most strongly reacted with the recombinant proteiss expressing pHCV-29 and pHCV-34, and to a lesser extent with pHCV-23 and c100- 3.
  • HCV-45 Eight individual oligonucleotides representing amino acids 1932-2191 of the HCV genome were ligated together and cloned as a 793 base pair EcoRI-BamHI fragment into the CKS fusion vector pJ0200.
  • the resulting plasmid designated pHCV-45 (SEQ.ID.NO 8), expresses the HCV CKS-NS5E antigen under control of the ]ac promoter.
  • the HCV CKS-NS5E antigen consists of 239 amino acids of CKS, nine amino acids contributed by linker DNA sequences, and 260 amino acids from the HCV NS4/NS5 region (amino acids 1932-2191).
  • Figure 23 presents a schematic representation of the recombinant antigen expressed by pHCV-45.
  • SEQ.ID.NO. 10 and 11 presents the DNA and amino acid sequence of the HCV CKS-NS5E recombinant antigen produced by pHCV-45.
  • Figure 24 presents the expression of pHCV-45 proteins in E.coli.
  • Lane 1 contained the E.coli lysate containing pHCV-45
  • HCV-48 expresses the HCV CKS-NS5F antigen under control of the lac promoter.
  • the HCV CKS-NS5F antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 294 amino acids from the HCV NS5 region (amino acids 2188-2481).
  • Figure 25 presents a schematic representation of the recombinant antigen expressed by pHCV-48. SEQ.ID.NO.
  • FIG. 12 and 13 presents the DNA and amino acid sequence of the HCV CKS-NS5F recombinant antigen produced by pHCV-48.
  • Figure 26 presents the expression of pHCV-48 proteins in E.coli.
  • Lane 1 contained the E.coli lysate containing pHCV-48 expressing the HCV CKS-NS5F antigen (amino acids 2188-2481) prior to induction and lanes 2 and 3 after 2 and 4 hours post induction, respectively.
  • These results show that the pHCV-48 fusion protein has an apparent mobility corresponding to a molecular size of 65,000 daltons. This compares acceptably to the predicted molecular mass of 58,985 daltons.
  • HCV-51 Seven individual oligonucleotides representing amino acids 2480-2729 of the HCV genome were ligated together and cloned as a 769 base pair EcoRI-BamHI fragment into the CKS fusion vector pJ0200.
  • the resulting plasmid designated pHCV-51 (SEQ.ID.NO. 10), expresses the HCV CKS-NS5G antigen under control of the lac promoter.
  • the HCV CKS-NS5G antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 250 amino acids from the HCV NS5 region (amino acids 2480-2729).
  • Figure 27 presents a schematic representation of the recombinant antigen expressed by pHCV-51.
  • SEQ.NO.ID NO.14 and 15 presents the DNA and amino acid sequence of the HCV CKS-NS5G recombinant antigen produced by pHCV-51.
  • Figure 28 presents the expression of pHCV-51 proteins in E.coli.
  • Lane 1 contained the E.coli lysate containing pHCV-51 expressing the HCV CKS-NS5G antigen (amino acids 2480-2729) prior to induction and lanes 2 and 3 after 2 and 4 hours post induction, respectively.
  • pHCV-50 expresses the HCV CKS-NS5H antigen under control of the lac promoter.
  • the HCV CKS-NS5H antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 140 amino acids from the HCV NS5 region (amino acids 2728-2867).
  • Figure 29 presents a schematic representation of the recombinant antigen expressed by pHCV-50. SEQ.ID.NO.
  • 16 and 17 presents the DNA and amino acid sequence of the HCV CKS-NS5H recombinant antigen produced by pHCV-50.
  • Figure 30 presents the expression of pHCV-50 proteins in E.coli.
  • Lane 1 contained the E.coli lysate containing pHCV-50
  • HCV-49 Six individual oligonucleotides representing amino acids 2866-3011 of the HCV genome were ligated together and cloned as a 460 base pair EcoRI-BamHI fragment into the CKS fusion vector pJ0200.
  • the resulting plasmid designated pHCV-49 (SEQ.NO.ID.NO. 12), expresses the HCV CKS-NS5I antigen under control of the lac promoter.
  • the HCV CKS-NS5I antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 146 amino acids from the HCV NS5 region (amino acids 2866-3011).
  • Figure 31 presents a schematic representation of the recombinant antigen expressed by pHCV-49.
  • SEQ.ID.NO. 18 and 19 presents the DNA and amino acid sequence of the HCV CKS-NS5I recombinant antigen produced by pHCV-49.
  • Figure 32 presents the expression of pHCV-49 proteins in E.coli.
  • Lane 1 contained the E.coli lysate containing pHCV-49 expressing HCV CKS-NS5I antigen (amino acids 2866-3011) prior to induction and lanes 2 and 3 after 2 and 4 hours post induction, respectively.
  • These results show that the pHCV-49 fusion protein has an apparent mobility corresponding to a molecular size of 42,000 daltons. This compares acceptably to the predicted molecular mass of 43,497 daltons.
  • F Immunoblot of HCV CKS-NS5 Antigens
  • Induced E.coli lysates containing pHCV-23, pHCV-45, pHCV-48, pHCV-51, pHCV-50, or pHCV-49 were individually run on preparative SDS/PAGE gels to separate the various HCV CKS-NS5 or HCV CKS-BCD recombinant antigens assay from the majority of other E.coli proteins.
  • Gel slices containing the separated individual HCV CKS-NS5 or HCV CKS-BCD recombinant antigens were then electropheretically transferred to nitrocellulose, and the nitrocellulose sheet cut into strips.
  • Figure 40 presents the results of a Western Blot analysis of various serum or plasma samples using these nitrocellulose strips.
  • HCV CKS-NS5F pHCV-51
  • HCV-50 HCV CKS-NS5H
  • pHCV-49 HCV CKS-NS5I
  • Panel A contained five normal human plasma
  • panel B contained five normal human sera
  • panel C contained twenty human sera positive in the Abbott HCV EIA test
  • panel D contained two mouse sera directed against CKS
  • panel E contained two normal mouse sera.
  • Both the HCV CKS-NS5E antigen expressed by pHCV-45 and the HCV CKS-NS5F antigen expressed by pHCV-48 were immunoreactive when screened with human serum samples containing HCV antibodies.
  • the HCV CKS-c100 antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, 363 amino acids from the HCV NS4 region (amino acids 1569-1931) and 10 additional amino acids contributed by linker DNA sequences.
  • the HCV CKS-c100 antigen was expressed at very low levels by pHCV-24.
  • pHCV-58 SEQ.ID.NO. 22 and 23
  • HCV-58 contains a 21 amino acid deletion (HCV amino acids 1600-1620) and was constructed by deleting a 63 base pair NlalV-Haelll restriction fragment.
  • Figure 34 presents a schematic representation of the recombinant antigens expressed by pHCV-24, pHCV-57, and pHCV-58.
  • SEQ.ID. NO. 13 presents the DNA and amino acid sequence of the HCV-C100D1 recombinant antigen produced by pHCV-57.
  • SEQ.ID.NO. 14 presents the DNA and amino acid sequence of the HCV- C100D2 recombinant antigen produced by pHCV-58.
  • Figure 35 presents the expression of pHCV-24, pHCV-57, and pHCV-58 proteins in E.coli.
  • Lane 1 contained the E.coli lysate containing pHCV-24 expressing the HCV CKS-c100 antigen (amino acids 1569-1931) prior to induction and lanes 2 and 3 after 2 and 4 hours post induction, respectively.
  • Lane 4 contained the E.coli lysate containing pHCV-57 expressing the HCV-CKS-C100D1 antigen (amino acids 1569-1574 and 1598-1931) prior to induction and lanes 5 and 6 after 2 and 4 hours induction, respectively.
  • Lane 7 contained the E.coli lysate containing pHCV-58 expressing the HCV CKS-C100D2 antigen (amino acids 1569-1599 and 1621 -1931) prior to induction, and lanes 8 and 9 after 2 and 4 hours induction, respectively.
  • HCV-105 expresses the HCV CKS-NS3 antigen under control of the ]ac promoter.
  • the HCV CKS-NS3 antigen consists of 239 amino acids of CKS, 12 amino acids contributed by linker DNA sequences, 157 amino acids from the HCV NS3 region (amino acids 1473-1629), and 9 additional amino acids contributed by linker DNA sequences.
  • Figure 36 presents a schematic representation of the pHCV-105 antigen.
  • SEQ.ID.NO. 24 and 25 presents the DNA and amino acid sequence of the HCV CKS-NS3 recombinant antigen produced by pHCV-105.
  • Figure 37 presents the expression of pHCV-105 proteins in E.coli.
  • Lane 1 contained the E.coli lysate containing pHCV-105 expressing the HCV CKS-NS3 antigen (amino acids 1472-1629) prior to induction and lanes 2 and 3 after 2 and 4 hours induction, respectively.
  • These results show that the pHCV-105 fusion protein has an apparent mobility corresponding to a molecular mass of 43,000 daltons. This compares acceptably to the predicted molecular mass of 46,454 daltons.
  • a 489 base pair DNA fragment from the putative envelope region of HCV was generated by PCR.
  • This fragment represents the HCV amino acids 1 14-276 and was cloned into the CKS expression vector pJ0202 using EcoRI-BamHI restriction sites.
  • the resulting clone designated pHCV-103 (SEQ.ID.NO. 26 and 27), expresses the HCV CKS-5'ENV antigen under control of the lac promoter.
  • the HCV CKS-5 ⁇ NV antigen consists of 239 amino acids of CKS, 7 amino acids contributed by linker DNA sequences, 163 amino acids from the HCV envelope region (amin ⁇ acids 1 14-276), and 16 additional amino acids contributed by linker DNA sequences.
  • FIG 38 presents a schematic representation of the pHCV-103 antigen.
  • SEQ.ID.NO. 26 and 27 presents the DNA and amino acid sequence of the HCV CKS-5'ENV recombinant antigen produced by pHCV-103.
  • Figure 37 presents the expression of pHCV-103 proteins in E.coli.
  • Lane 1 contained the E.coli lysate containing pHCV-103 expressing the HCV CKS- 5 ⁇ NV antigen (amino acids 1 14-276) prior to induction and lanes 5 and 6 after 2 and 4 hours induction, respectively.
  • These results show that the pHCV-103 fusion protein has an apparent mobility corresponding to a molecular mass of 47,000 daltons. This compares acceptably to the predicted molecular mass of 46,091 daltons.
  • HCV CKS-3 ⁇ NV antigen expresses the HCV CKS-3'ENV antigen under control of the lac promoter.
  • the HCV CKS-3 ⁇ NV antigen consists of 239 amino acids of CKS, 7 amino acids contributed by linker DNA sequences, 207 amino acids from the HCV envelope region (amino acids 263-469), and 15 additional amino acids contributed by linker DNA sequences.
  • Figure 39 presents a schematic representation of the pHCV-101 antigen.
  • SEQ.ID.NO. 28 and 29 presents the DNA and amino acid sequence of the HCV CKS-3 ⁇ NV recombinant antigen produced by pHCV-101.
  • FIG 37 presents the expression of pHCV-101 proteins in E.coli Lane 7 contained the E.coli lysate containing pHCV-101 expressing the HCV CKS-3'E NV antigen (amino acids 263-469) prior to induction and lanes 8 and 9 after 2 and 4 hours induction, respectively. These resulting show that the pHCV-101 fusion protein has an apparent mobility corresponding to a molecular mass of 47,000 daltons. This compares acceptably to the predicted molecular mass of 51 ,181 daltons.
  • a 636 base pair DNA fragment from the putative NS2 region of HCV was generated by PCR. This fragment represents the HCV amino acids 994-1205 and was cloned into the CKS expression vector pJ0201 using EcoRI restriction sites. The resulting clone, designated pHCV-102, expresses the HCV CKS-NS2 antigen under control of the lac promoter.
  • the HCV CKS-NS2 antigen consists of 239 amino acids of CKS, 7 amino acids contributed by linker DNA sequences, 212 amino acids from the HCV NS2 region (amino acids 994- 1205), and 16 additional amino acids contributed by linker DNA sequences.
  • Figure 40 presents a schematic representation of the pHCV-102 antigen.
  • SEQ.ID.NO. 30 and 31 presents the DNA and amino acid sequence of the HCV CKS-NS2 recombinant antigen produced by pHCV-102.
  • Figure 41 presents the expression of pHCV-102 proteins in E.coli.
  • Lane 1 contained the E.coli lysate containing pHCV-102 expressing the HCV CKS-NS2 antigen (amino acids 994-1205) prior to induction and lanes 2 and 3 after 2 and 4 hours induction, respectively.
  • These results show that the pHCV-102 fusion protein has an apparent mobility corresponding to a molecular mass of 53,000 daltons. This compares acceptably to the predicted molecular mass of 51,213 daltons.
  • HCV-107 expresses the HCV CKS-NS1 antigen under control of the Jac promoter.
  • the HCV CKS-NS1 antigen consists of 239 amino acids of CKS, 10 amino acids contributed by linker DNA sequences, and 218 amino acids from the HCV NS1 region (amino acids 617-834).
  • Figure 42 presents a schematic representation of the pHCV-107 antigen.
  • SEQ.ID.NO. 32 and 33 presents the DNA and amino acid sequence of the HCV CKS-NS1 recombinant antigen produced by pHCV-107.
  • HCV-104 expresses the HCV CKS-ENV antigen under control of the lac promoter.
  • the HCV CKS-ENV antigen consists of 239 amino acids of CKS, 7 amino acids contributed by linker DNA sequences, 356 amino acids from the HCV envelope region (amino acids 114- 469), and 15 additional amino acids contributed by linker DNA sequences.
  • Figure 43 presents a schematic representation of the pHCV-104 antigen.
  • SEQ.ID.NO. 34 and 35 presents the DNA and amino acid sequence of the HCV CKS-ENV recombinant antigen produced by pHCV-104.
  • the amino acid sequence of this antigen is designated as pHCV-77 (SEQ. ID. NO. 1).
  • the resultant fusion protein HCV CKS-NS1S1 consists of 239 amino acids of CKS, seven amino acids contributed by linked DNA sequences, and 215 amino acids from the NS1 region of the HCV genome.
  • pHCV-77 was transformed into E.coli K-12 strain XL-1 (recA1 , endA1 , gyrA96, thi-1 , hsdRl 7, SupE44, relA1 , Iac/f1 , p10AB, lacl1ADM15, TN10) cells.
  • Expression analysis and characterization of the recombinant protein was done using polyacrylamide gel electrophoresis as described in Example 1.
  • the apparent molecular weight of the pHCV-77 antigen was the same as the expected molecular weight of 50,228 as visualized on a coumassie stained gel.
  • FIGURE 47A presents the expression of pHCV-77 in E. coli.
  • FIGURE 47B presents an immunoblot of the pHCV-77 antigen expressed in E. coli.
  • Lane 1 contained the E. coli lysate containing pHCV-77 expressing the HCV CKS-NS1S1 antigen prior to induction and Lanes 2 and 3 are 2 and 4 hours post-induction, respectfully.
  • EXAMPLE 11 HCV CKS-NS1S2
  • the resultant fusion protein HCV CKS-NS1S2 consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 167 amino acids from the NS1 region of the HCV genome.
  • pHCV-65 was transformed into E.coli K-12 strain XL-1 (recA1 , endA1 , gyrA96, thi-1 , hsdR17, SupE44, relAI , lac/f 1 , p10AB, laclqAMD15, TN10) cells.
  • Expression analysis and characterization of the recombinant protein was done using polyacrylamide gel electrophoresis as described in Example 1.
  • the apparent molecular weight of the pHCV-65 antigen was the same as the expected molecular weight of 46,223 as visualized on a coumassie stained gel.
  • FIGURE 48A presents the expression of pHCV-65 in E. coli.
  • FIGURE 48B presents an immunoblot of the pHCV-65 antigen expressed in E. coli.
  • Lane 1 contained the E. coli lysate containing pHCV-65 expressing the HCV CKS-NS1S2 antigen prior to induction and Lanes 2 and 3 are 2 and 4 hours post-induction, respectively.
  • EXAMPLE 12. CKS-NS1S3
  • the resultant fusion protein HCV CKS-NS1S3 consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 131 amino acids from the NS1 region of the HCV genome.
  • pHCV-78 was transformed into E.coli K-12 strain XL-1 (recA1 , endA1 , gyrA96, thi-1 , hsdR17, SupE44, relAI , lac/f 1 , p10AB, laclqADM15, TN10) cells.
  • Expression analysis and characterization of the recombinant protein was done using polyacrylamide gel electrophoresis as described in Example 1. Analysis of the coumassie stained gel indicated very low levels of expression of the protein with an expected molecular weight of 42,1141. Western blot analysis also failed to show any immunoreactivity and we are continuing to identify human sera that is specific to this region of NS1.
  • the resultant HCV gene represents amino acids 365-731 of the HCV genome. This resulted in a 1101 base pair EcoRI/BamHI fragment of HCV cloned into the CKS fusion vector pJO200. The complete amino acid sequence of this antigen is designated as pHCV-80 (SEQ. ID. NO. 4).
  • the resultant fusion protein HCV CKS NS1S1-NS1S2 consists of 239 amino acids of CKS, seven amino acids contributed by linker DNA sequences, and 367 amino acids from the NS1 region of the HCV genome.
  • HCV-NS1S1-NS1S2 pHCV-80 was transformed into E.coli K-12 strain XL-1 (recA1, endA1, gyrA96, thi-1 , hsdR17, SupE44, relAI , lac/f 1 , p10AB, laclqADM15, TN10) cells.
  • FIGURE 49A presents the expression of pHCV-80 in E. coli.
  • FIGURE 49B presents an immunoblot of pHCV- 80 antigen expressed in E. coli.
  • Lane 1 contained the E. coli lysate containing pHCV- 80 expressing the HCV CKS-NS1S1-NS1S2 antigen prior to induction and Lanes 2 and 3 are 2 and 4 hours post-induction, respectively.
  • pHCV-92 SEQ. ID. NO. 5
  • NS1 full length NS1
  • the resultant fusion protein HCV CKS-full length NS1 consists of 239 amino acids of CKS, seven amino acids contributed by linker DNA sequences, and 483 amino acids from the NS1 region of the HCV genome.
  • pHCV-92 was transformed into E.coli K-12 strain XL-1 (recA1 , endA1 , gyrA96, thi-1, hsdR17, SupE44, relAI , lac/f 1 , plOAB, laclqADM15, TN10) cells.
  • Expression analysis and characterization of the recombinant protein was done using polyacrylameide gel electrophoresis as described in Example 1. The expression levels as seen by counassie stained gel were virtually undectable and the Western blot indicated no immunoreactivity. We are still in the process of identifying sera that will recognize this region of HCV NS1.
  • the present invention thus provides unique recombinant antigens
  • the NS1 protein is considered to be a rron-structural membrane glycoprotei ⁇ and to be able to elicit a protective immune response of the host against lethal viral infection.
  • recombinant antigens either alone or in combination, can be used in the assay formats provided herein and exemplified in the Examples. It also is contemplated that these recombinant antigens can be used to develop specific inhibitors of viral replication and used for therapeutic purposes, such as for vaccines. Other applications and modifications of the use of these antigens and the specific embodiments of this inventions as set forth herein, will be apparent to those skilled in the art. Accordingly, the invention is intended to be limited only in accordance with the appended claims.
  • NAME POREMBSKI, PRISCILLA E.
  • MOLECULE TYPE DNA (genomic)
  • AAAGC GGA TA CGG CGTT GTG GGCTTTGTATGACAGCCAGG GAAACCCAATGCGTTAATG 1677
  • MOLECULE TYPE DNA (genomic)
  • GGT CTG CTG CAG ACC
  • GCT TCT CGT CAG
  • GCT GAA GTT
  • ATC GCT CCG
  • GCT 1896 Gly Leu Leu Gln Thr Ala Ser Arg Gln Ala Glu Val lle Ala Pro Ala
  • GCT CTG GTT GCT TTC AAA ATC ATG TCT GGT GAA GTT CCG TCT ACC GAA 2280 Ala Leu Val Ala Phe Lys lle Met Ser Gly Glu Val Pro Ser Thr Glu
  • CAGGGAAACC CAATGCCGTT AATGG CAAGAAGCTTAGCCCGCCTAATGAGCGGGCTTTTT 2832
  • GTCCGCATC TCCAGCAGCC GCACGCGGCG CATCTCGGGC AGCGTTGGGT CCTGGCCACG 3312 GGTGCGCATG ATCGTGCTCC TGTCG TTGAG GACCCGGCTA GGCTGGCGGG GTTGCCTTAC 3372
  • GAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCV GAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCV.GTTACCTTCGGAAAAAGAGTTG 4272 GTAGCTCTTGATCCGGCAAA CAAACC ACCGCTGGTAGCGGTGGT T T T T T T GTTTGCAAGC 4332 AGCAGATT ACGCAGAAAA AAAGGATCTCAAGAAGATCC TTT GATCTTT TCTACGGGGT 4392 CTGACGCTCAGTGGAACGAA AACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAA 4452
  • CTCCAGATTT ATCAG CAATAAACC AGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTG 4752
  • MOLECULE TYPE DNA (genomic)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides unique recombinant antigens representing distinct antigenic regions of the NS1 region of the HCV genome which can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to hepatitis C virus (HCV). The present invention also provides an assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with the recombinant antigens. Preferred assay formats include a screening assay, a confirmatory assay, a competition or neutralization assay and an immunodot assay.

Description

HEPATITIS C ASSAY UTILIZING RECOMBINANT ANTIGENS TO NS1
This is a continuation-in-part application of U.S. Serial No. 07/572,822, filed August 24, 1990 and U.S. Serial No. 07,614,069, filed November 7, 1990, which enjoy common ownership and are incorporated herein by reference. This application also is related to co-filed patent applications entitled "HEPATITIS C ASSAY UTILIZING RECOMBINANT ANTIGENS FROM NS5 REGION"(U. S. Serial No. 748,565) and "HEPATITIS C ASSAY UTILIZING RECOMBINANT ANTIGENS TO C-100 REGION"(U. S. Serial No. 748,566) which enjoy common ownership and are incorporated herein by reference.
This invention relates generally to an assay for identifying the presence in a sample of an antibody which is immunologically reactive with a hepatitis C virus antigen and specifically to an assay for detecting a complex of an antibody and recombinant antigens representing distinct regions of the HCV genome. Recombinant antigens derived from the molecular cloning and expression in a heterologous expression system of the synthetic DNA sequences representing distinct antigenic regions of the HCV genome can be used as reagents for the detection of antibodies and antigen in body fluids from individuals exposed to hepatitis C virus (HCV). BACKGROUND OF THE INVENTION
Acute viral hepatitis is clinically diagnosed by a well-defined set of patient symptoms, including jaundice, hepatic tenderness, and an increase in the serum levels of alanine am inotransf erase (ALT) and aspartate aminotransferase.
Additional serologic immunoassays are generally performed to diagnose the specific type of viral causative agent. Historically, patients presenting clinical hepatitis symptoms and not otherwise infected by hepatitis A, hepatitis B, Epstein-Barr or cytomegalovirus were clinically diagnosed as having non-A non-B hepatitis
(NANBH) by default. The disease may result in chronic liver damage.
Each of the well-known, immunologically characterized hepatitis-inducing viruses, hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis D virus
(HDV) belongs to a separate family of viruses and has a distinctive viral
organization, protein structure, and mode of replication.
Attempts to identify the NANBH virus by virtue of genomic similarity to one of the known hepatitis viruses have failed, suggesting that NANBH has a distinct organization and structure. [Fowler, et al., J. Med. Virol., 12:205-213 (1983) and Weiner, et al., J. Med. Virol., 21 :239-247 (1987)].
Progress in developing assays to detect antibodies specific for NANBH has been particularly hampered by difficulties in correctly identifying antigens associated with NANBH. See, for example, Wands, J., et al., U.S. Patent 4,870,076, Wands, et al., Proc, Nat' I, Acad, Sci., 83:6608-6612 (1986), Ohori, et al., J. Med. Virol., 12:161 -178 (1983), Bradley, et al., Proc. Nat'I, Acad, Sci., 84:6277- 6281 , (1987), Akatsuka, T., et al., J. Med, Virol, 20:43-56 (1986), Seto, B., et al. , U.S. Patent Application Number 07/234,641 (available from U.S. Department of Commerce National Technical Information Service, Springfield, Virginia, No. 89138168), Takahashi, K., et al., European Patent Application No. 0 293 274, published November 30, 1988, and Seelig, R., et al., in PCT Application
PCT/EP88/00123.
Recently, another hepatitis-inducing virus has been unequivocally identified as hepatitis C virus (HCV) by Houghton, M., et al., European Patent Application publication number 0 318 216, May 31 , 1989. Related papers describing this virus include Kuo, G., et al., Science, 244:359-361 (1989) and Choo, Q., et. al, Science, 244:362-364 (1989). Houghton, M., et al. reported isolating cDNA sequences from HCV which encode antigens which react immunologically with antibodies present in patients infected with NANBH, thus establishing that HCV is one of the viral agents causing NANBH. The cDNA sequences associated with HCV were isolated from a cDNA library prepared from the RNA obtained from pooled serum from a chimpanzee with chronic HCV infection. The cDNA library contained cDNA sequences of approximate mean size of about 200 base pairs. The cDNA library was screened for encoded epitopes expressed in clones that could bind to antibodies in sera from patients who had previously experienced NANBH.
In the European Patent Application, Houghton, M., et al. also described the preparation of several superoxide dismutase fusion polypeptides (SOD) and the use of these SOD fusion poiypeptides to develop an HCV screening assay. The most complex SOD fusion polypeptide described in the European Patent Application, designated c100-3, was described as containing 154 amino acids of human SOD at the aminoterminus, 5 amino acid residues derived from the expression of a synthetic DNA adapter containing a restriction site, EcoRI, 363 amino acids derived from the expression of a cloned HCV cDNA fragment, and 5 carboxyl terminal amino acids derived from an MS2 cloning vector nucleotide sequence. The DNA sequence encoding this polypeptide was transformed into yeast cells using a plasmid. The transformed cells were cultured and expressed a 54,000 molecular weight polypeptide which was purified to about 80% purity by differential extraction.
Other SOD fusion poiypeptides designated SOD-NANB5-1-1 and SOD- NANB81 were expressed in recombinant bacteria. The E.coli fusion poiypeptides were purified by differential extraction and by chromatography using anion and cation exchange columns. The purification procedures were able to produce SOD- NANB5- 1 -1 as about 80% pure and SOD-NAN38, as about 50% pure.
The recombinant SOD fusion poiypeptides described by Houghton, M., et al, were coated on microtiter wells or polystyrene beads and used to assay serum samples. Briefly, coated microtiter wells were incubated with a sample in a diluent. After incubation, the microtiter wells were washed and then developed using either a radioactively labelled sheep anti-human antibody or a mouse antihuman IgG-HRP (horseradish peroxidase) conjugate. These assays were used to detect both post acute phase and chronic phase HCV infection.
Due to the preparative methods, assay specificity required adding yeast or E.coli extracts to the samples in order to prevent undesired immunological reactions with any yeast or E.coli antibodies present in samples.
Ortho Diagnostic Systems Inc. have developed a immunoenzyme assay to detect antibodies to HCV antigens. The Ortho assay procedure is a three-stage test for serum/plasma carried out in a microwell coated with the recombinant yeast/hepatitis C virus SOD fusion polypeptide c100-3.
In the first stage, a test specimen is diluted directly in the test well and incubated for a specified length of time. If antibodies to HCV antigens are present in the specimen, antigen-antibody complexes will be formed on the microwell surface.
If no antibodies are present, complexes will not be formed and the unbound serum or plasma proteins will be removed in a washing step.
In the second stage, anti-human IgG murine monoclonal antibody horseradish peroxidase conjugate is added to the microwell. The conjugate binds specifically to the antibody portion of the antigen-antibody complexes. If antigen-antibody complexes are not present, the unbound conjugate will also be removed by a washing step.
In the third stage, an enzyme detection system composed of o- phenyienediamine 2HCI (OPD) and hydrogen peroxide is added to the test well. If bound conjugate is present, the OPD will be oxidized, resulting in a colored end product. After formation of the colored end product, dilute sulfuric acid is added to the microwell to stop the color-forming detection reaction.
The intensity of the colored end product is measured with a microwell reader. The assay may be used to screen patient serum and plasma.
It is established that HCV may be transmitted by contaminated blood and blood products. In transfused patients, as many as 10% will suffer from post- transfusion hepatitis. Of these, approximately 90% are the result of infections diagnosed as HCV. The prevention of transmission of HCV by blood and blood products requires reliable, sensitive and specific diagnosis and prognostic tools to identify HCV carriers as well as contaminated blood and blood products. Thus, there exists a need for an HCV assay which uses reliable and efficient reagents and methods to accurately detect the presence of HCV antibodies in samples.
SUMMARY OF THE INVENTION
The present invention provides an improved assay for detecting the presence of an antibody to an HCV antigen in a sample by contacting the sample with at least one recombinant protein representing a distinct antigenic region of the HCV genome.
Recombinant antigens which are derived from the molecular cloning and expression of synthetic DNA sequences in heterologous hosts are provided. Briefly, synthetic DNA sequences which encode the desired proteins representing distinct antigenic regions of the HCV genome are optimized for expression in E.coli by specific codon selection. Specifically, recombinant proteins representing five distinct antigenic regions of NS1 of the HCV genome are described. The proteins are expressed as chimeric fusions with E.coli CMP-KDO synthetase (CKS) gene. The first protein, expressed by plasmid pHCV-77 (identified as SEQ. ID. NO. 1) represents amino acids 365-579 of the HCV sequence of NS1 and, based on analogy to the genomic organization of other flaviviruses, has been named HCV CKS-NS1S1.
Note that the term pHCV-77 will also refer to the fusion protein itself and that pHCV-77' will be the designation for a polypeptide representing the NS1 region from about amino acids 365-579 of the HCV sequence prepared using other recombinant or synthetic methodologies. Other recombinant methodologies would include the preparation of pHCV-77', utilizing different expression systems. The methodology for the preparation of synthetic peptides of HCV is described in U.S. Serial No. 456,162, filed December 22, 1989, and U.S. Serial No. 610,180, filed November 7, 1990, which enjoy common ownership and are incorporated herein by reference. The next protein is expressed by plasmid pHCV-65, identified as SEQ. ID. NO. 2, and represents amino acids 565-731 of the NS1 region of the HCV genome, pHCV-65 has been named HCV CKS-NS1S2 and is expressed by the plasmid pHCV-65. The fusion protein itself will also be referred to as pHCV-65 and pHCV- 65' shall be the designation for a polypeptide from the NS-1 region representing from about amino acids 565-731 of the HCV sequence prepared using other recombinant or synthetic methodologies. The next recombinant antigen represents amino acids 717-847 of the NS1 region of the HCV sequence, and is expressed by the plasmid pHCV-78 (identified by SEQ. ID. NO. 3). The fusion protein will be referred to as pHCV-78 and pHCV-78' shall be the designation for a polypeptide from the NS1 region representing from about amino acids 717-847 of the HCV sequence prepared using other recombinant or synthetic methodologies. It has been designated clone HCV CKS-NS1S3 based on the strategy used in its construction. Figure 44 illustrates the position of pHCV-77, pHCV-65 and pHCV-78 in the NS1 region of the HCV genome. The recombinant antigen produced by pHCV-80 is identified as SEQ. ID. NO.4 and is designated HCV CKS-NS1S1-NS1S2. The fusion protein is also designated by pHCV-80 and pHCV-80' refers to the polypeptide located in the NS1 region of HCV, representing amino acids 365-731 of the HCV genome prepared using different recombinant methodologies. Figure 45 illustrates the position of pHCV-80 within the HCV genome. HCV CKS-Full Length NS1 is the designation for the recombinant protein pHCV-92 (SEQ. ID. NO. 5). It represents amino acids 365-847 of the HCV genome. The fusion proteins will be referred to as pHCV-92 and pHCV 92' shall be the designation for the polypeptide from the NS1 region representing amino acids 365-847 of the HCV sequence prepared using other recombinant or synthetic methodologies. Figure 46 illustrates the position of pHCV-92 in the HCV genome. These antigens are used in the inventive
immunoassays to detect the presence of HCV antibodies in samples.
One assay format according to the invention provides a screening assay for identifying the presence of an antibody that is immunologically reactive with an HCV antigen. Briefly, a fluid sample is incubated with a solid support containing the commonly bound recombinant proteins. Finally, the antibody-antigen complex is detected. In a modification of the screening assay the solid support additionally contains recombinant polypeptide c100-3.
Another assay format provides a confirmatory assay for unequivocally identifying the presence of an antibody that is immunologically reactive with an HCV antigen. The confirmatory assay includes synthetic peptides or recombinant antigens representing the epitopes contained within the NS1 region of the HCV genome, which are the same regions represented by the recombinant proteins described in the screening assay. These are pHCV-77, pHCV-65, pHCV-78, pHCV-
80 and pHCV-92. Recombinant proteins used in the confirmatory assay should have a heterologous source of antigen to that used in the primary screening assay (i.e. should not be an E.coli-derived recombinant antigen nor a recombinant antigen composed in part, of CKS sequences). Briefly, specimens repeatedly reactive in the primary screening assay are retested in the confirmatory assay. Aliquots containing identical amounts of specimen are contacted with a synthetic peptide or recombinant antigen individually coated onto a solid support. Finally, the antibody antigen complex is detected. The poiypeptides or recombinant proteins can be utilized as indicated or combined with other poiypeptides and recombinant proteins a described herein and also described in U.S. Serial No. 456,162 entitled "Hepatitis C Assay", filed December 22, 1989, which enjoys common ownership and is incorporated herein by reference.
Another assay format provides a competition assay or neutralization assay directed to the confirmation that positive results are not false by identifying the presence of an antibody that is immunologically reactive with an HCV antigen in a fluid sample where the sample is used to prepare first and second immunologically equivalent aliquots. The first aliquot is contacted with solid support containing a bound polypeptide which contains at least one epitope of an HCV antigen under conditions suitable for complexing with the antibody to form a detectable antibodypolypeptide complex and the second aliquot is first contacted with the same solid support containing bound polypeptide. The preferred recombinant poiypeptides include pHCV-77, pHCV-65, pHCV-78, pHCV-80 and pHCV-92.
Another assay format provides an immunodot assay for identifying the presence of an antibody that is immunologically reactive with an HCV antigen by concurrently contacting a sample with recombinant poiypeptides each containing distinct epitopes of an HCV antigen under conditions suitable for complexing the antibody with at least one of the poiypeptides and detecting the antibodypolypeptide complex by reacting the complex with colorproducing reagents. The preferred recombinant poiypeptides employed include those recombinant poiypeptides derived from pHCV-77, pHCV-65, pHCV-78, pHCV-80, as well as pHCV-92.
In all of the assays, the sample is preferably diluted before contacting the polypeptide absorbed on a solid support. Samples may be obtained from different biological samples such as whole blood, serum, plasma, cerebral spinal fluid, and lymphocyte or cell culture supernatants. Solid support materials may include cellulose materials, such as paper and nitrocellulose, natural and synthetic polymeric materials, such as poiyacrylamide, polystyrene, and cotton, porous gels such as silica gel, agarose, dextran and gelatin, and inorganic materials such as deactivated alumina, magnesium sulfate and glass. Suitable solid support materials may be used in assays in a variety of well known physical configurations, including microtiter wells, test tubes, beads, strips, membranes, and microparticles. A preferred solid support for a non-immunodot assay is a polystyrene bead. A preferred solid support for an immunodot assay is nitrocellulose.
Suitable methods and reagents for detecting an antibody-antigen complex in an assay of the present invention are commercially available or known in the relevant art. Representative methods may employ detection reagents such as enzymatic, radioisotopic, fluorescent, luminescent, or chemiluminescent reagents. These reagents may be used to prepare hapten-labelled antihapten detection systems according to known procedures, for example, a biotin-labelled antibiotin system may be used to detect an antibody-antigen complex.
The present invention also encompasses assay kits including poiypeptides which contain at least one epitope of an HCV antigen bound to a solid support as well as needed sample preparation reagents, wash reagents, detection reagents and signal producing reagents.
Other aspects and advantages of the invention will be apparent to those skilled in the art upon consideration of the following detailed description which provides illustrations of the invention in its presently preferred embodiments.
E.coli strains containing plasmids useful for constructs of the invention have been deposited at the American Type Culture Collection, Rockville, Maryland on August 10, 1990, under the accession Nos. ATCC 68380 (pHCV-23), ATCC 68381 (pHCV-29), ATCC 68382 (pHCV-31), ATCC 68383 (pHCV-34) and on November 6, 1990 for E.coli strains containing plasmids useful for constructs under the accession Nos. ATCC 68458 (pHCV-50), ATCC 68459 (pHCV-57), ATCC 68460 (pHCV-103), ATCC 68461 (pHCV-102), ATCC 68462 (pHCV-51), ATCC 68463 (pHCV-105), ATCC 68464 (pHCV-107), ATCC 68465 (pHCV-104), ATCC 68466 (pHCV-45), ATCC 68467 (pHCV-48),ATCC 68468 (pHCV-49), ATCC 68469 (pHCV-58) and ATCC 68470 (pHCV-101). E. coli strains containing plasmids useful for constructs of the invention have been deposited at the A.T.C.C. on
September 26, 1991 under deposit numbers ATCC 68690 (pHCV-77), ATCC 68696 (pHCV-65), ATCC 68689 (pHCV-78), ATCC 68688 (pHCV-80) and ATCC 68695 (pHCV-92).
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1 illustrates the HCV genome.
FIGURE 2 illustrates the use of recombinant poiypeptides to identify the presence of antibodies in a chimpanzee inoculated with HCV.
FIGURE 3 illustrates the sensitivity and specificity increase in using the screening assay using pHCV-34 and pHCV-31 antigens.
FIGURE 4 illustrates the construction of plasmid pHCV-34.
FIGURE 5 illustrates fusion protein pHCV-34.
FIGURE 6 illustrates the expression of pHCV-34 proteins in E.coli,
FIGURE 7 illustrates the construction of plasmid pHCV-23. FIGURE 8 illustrates the construction of plasmid pHCV-29.
FIGURE 9 illustrates the construction of plasmid pHCV-31.
FIGURE 10 illustrates the fusion protein pHCV-31.
FIGURE 11 illustrates the expression of pHCV-29 in E.coli.
FIGURE 12 illustrates the expression of pHCV-23 in E.coli.
FIGURE 13 illustrates the expression of pHCV-31 in E.coli.
FIGURE 14 illustrates the increased sensitivity using the screening assay utilizing the pHCV-34.
FIGURE 15 illustrates the increased specificity with the screening assay utilizing pHCV-34 and pHCV-31.
FIGURE 16 illustrates the results in hemodialysis patients using the screening and confirmatory assays.
FIGURE 17 illustrates earlier detection of HCV in a hemodialysis patient using the screening assay.
FIGURE 18 illustrates the results of the screening assay utilizing pHCV-34 and pHCV-31 on samples from individuals with acute NANBH.
FIGURE 19 illustrates the results of the confirmatory assay of the same population group as in Figure 18.
FIGURE 20 illustrates the results of the screening and confirmatory assays on individuals infected with chronic NANBH.
FIGURE 21 illustrates preferred buffers, pH conditions, and spotting concentrations for the HCV immunodot assay.
FIGURE 22 illustrates the results of the HCV immunodot assay.
FIGURE 23 illustrates the fusion protein pHCV-45.
FIGURE 24 illustrates the expression of pHCV-45 in E.coli.
FIGURE 25 illustrates the fusion protein pHCV-48.
FIGURE 26 illustrates the expression of pHCV-48 in E.coli.
FIGURE 27 illustrates the fusion protein pHCV-51.
FIGURE 28 illustrates the expression of pHCV-51 in E.coli.
FIGURE 29 illustrates the fusion protein pHCV-50.
FIGURE 30 illustrates the expression of pHCV-50 in E.coli.
FIGURE 31 illustrates the fusion protein pHCV-49.
FIGURE 32 illustrates the expression of pHCV-49 in E.coli.
FIGURE 33 illustrates an immunoblot of pHCV-23, pHCV-45, pHCV-48, pHCV-51 , pHCV-50 and pHCV-49.
FIGURE 34 illustrates the fusion proteins pHCV-24, pHCV-57, pHCV-58.
FIGURE 35 illustrates the expression of pHCV-24, pHCV-57, and pHCV-58 in E.coli.
FIGURE 36 illustrates the fusion protein pHCV-105.
FIGURE 37 illustrates the expression of pHCV-105 in E.coli.
FIGURE 38 illustrates the fusion protein pHCV-103.
FIGURE 39 illustrates the fusion protein pHCV-101.
FIGURE 40 illustrates the fusion protein pHCV-102.
FIGURE 41 illustrates the expression of pHCV-102 in E.coli.
FIGURE 42 illustrates the fusion protein pHCV-107.
FIGURE 43 illustrates the fusion protein pHCV-104.
FIGURE 44 illustrates the NS1 region of the HCV genome, and in particular, the locations of pHCV-77, pHCV-65 and pHCV-78.
FIGURE 45 illustrates the NS1 region of the HCV genome, and in particular, the location of pHCV-80.
FIGURE 46 illustrates the NS1 region of the HCV genome, and in particlar, the location of pHCV-92.
FIGURE 47A ilustrates the expression of pHCV-77 in E. coli: and FIGURE 47B illustrates an immunblot of pHCV-77 in E. coli.
FIGURE 48A illustrates the expression of pHCV-65 in E. coli and FIGURE 48B illustrates an immunoblot of pHCV-65 in E. coli.
FIGURE 49A illustrates the expression of pHCV-80 in E. coli and FIGURE
49B illustrates an immunoblot of pHCV-80 in E. coli.
PETAILEP DESCRIPTION OF THE INVENTION
The present invention is directed to an assay to detect an antibody to an HCV antigen in a sample. Human serum or plasma is preferably diluted in a sample diluent and incubated with a polystyrene bead coated with a recombinant polypeptide that represents a distinct antigenic region of the HCV genome. If antibodies are present in the sample they will form a complex with the antigenic polypeptide and become affixed to the polystyrene bead. After the complex has formed, unbound materials and reagents are removed by washing the bead and the bead-antigen- antibody complex is reacted with a solution containing horseradish peroxidase labeled goat antibodies directed against human antibodies. This peroxidase enzyme then binds to the antigen-antibody complex already fixed to the bead. In a final reaction the horseradish peroxidase is contacted with o-phenylenediamine and hydrogen peroxide which results in a yellow-orange color. The intensity of the color is proportional to the amount of antibody which initially binds to the antigen fixed to the bead. The preferred recombinant poiypeptides having HCV antigenic epitopes were selected from portions of the HCV genome which encoded poiypeptides which possessed amino acid sequences similar to other known immunologically reactive agents and which were identified as having some immunological reactivity. (The immunological reactivity of a polypeptide was initially identified by reacting the cellular extract of E.coli clones which had been transformed with cDNA fragments of the HCV genome with HCV infected serum. Poiypeptides expressed by clone containing the incorporated cDNA were immunologically reactive with serum known to contain antibody to HCV antigens.) An analysis of a given amino acid sequence, however, only provides rough guides to predicting immunological reactivity. There is no invariably predictable way to ensure immunological activity short of preparing a given amino acid sequence and testing the suspected sequence in an assay.
The use of recombinant poiypeptides representing distinct antigenic regions of the HCV genome to detect the presence of an antibody to an HCV antigen is illustrated in Figure 2. The course of HCV infection in the chimpanzee, Pan, was followed with one assay using recombinant c100-3 polypeptide and with another improved assay, using the two recombinant antigens CKS-Core (pHCV-34)
(SEQ.ID.NO 6 and 7) and pHCV-33c-BCD (pHCV-31) (SEQ.ID.NO 8 and 9) expressed by the plasmids pHCV-34 and pHCV-31, respectively. The assay utilizing the recombinant pHCV-34 and pHCV-31 proteins detected plasma antibody three weeks prior to detection of antibody by the assay using c100-3.
A summary of the results of a study which followed the course of HCV infection in Pan and six other chimpanzees using the two assays described above is summarized in Figure 3. Both assays gave negative results before inoculation and both assays detected the presence of antibodies after the animal had been infected with HCV. However, in the comparison of the two assays, the improved screening assay using pHCV-34 and pHCV-31 detected seroconversion to HCV antigens at an earlier or equivalent bleed date in six of the seven chimpanzees. Data from these chimpanzee studies clearly demonstrate that overall detection of HCV antibodies is greatly increased with the assay utilizing the pHCV-34 and pHCV-31 proteins.
This test is sufficiently sensitive to detect seroconversion during the acute phase of this disease, as defined as an elevation in ALT levels, in most animals. Equally important is the high degree of specificity of the test as no pre-inoculation specimens were reactive.
The poiypeptides useful in the practice of this invention are produced using recombinant technologies. The DNA sequences which encode the desired poiypeptides are preferably assembled from fragments of the total desired sequence. Synthetic DNA fragments of the HCV genome can be synthesized based on their corresponding amino acid sequences. Once the amino acid sequence is chosen, this is then reverse translated to determine the complementary DNA sequence using codons optimized to facilitate expression in the chosen system. The fragments are generally prepared using well known automated processes and apparatus. After the complete sequence has been prepared the desired sequence is incorporated into an expression vector which is transformed into a host cell. The DNA sequence is then expressed by the host cell to give the desired polypeptide which is harvested from the host cell or from the medium in which the host cell is cultured. When smaller peptides are to be made using recombinant technologies it may be advantageous to prepare a single DNA sequence which encodes several copies of the desired polypeptide in a connected chain. The long chain is then isolated and the chain is cleaved into the shorter, desired sequences.
The methodology of polymerase chain reaction (PCR) may also be employed to develop PCR amplified genes from any portion of the HCV genome, which in turn may then be cloned and expressed in a manner similar to the synthetic genes.
Vector systems which can be used include plant, bacterial, yeast, insect, and mammalian expression systems. It is preferred that the codons are optimized for expression in the system used.
A preferred expression system utilizes a carrier gene for a fusion system where the recombinant HCV proteins are expressed as a fusion protein of an E.coli enzyme, CKS (CTP:CMP-3-deoxy-mann o -octulosonate cytidylyl transferase or CMP-KDO synthetase). The CKS method of protein synthesis is disclosed in U.S. Patent Applications Serial Nos. 167,067 and 276,263 filed March 11 , 1988 and
November 23, 1988, respectively, by Boiling (EPO 891029282) which enjoy common ownership and are incorporated herein by reference.
Other expression systems may be utilized including the lambda PL vector system whose features include a strong lambda pL promoter, a strong three-frame translation terminator rrnBtl, and translation starting at an ATG codon.
In the present invention, the amino acid sequences encoding for the recombinant HCV antigens of interest were reverse translated using codons optimized to facilitate high level expression in E.coli. Individual oligonucleotides were synthesized by the method of oligonucleotide directed double-stranded break repair disclosed in U.S. Patent Application Serial No. 883,242, filed July 8, 1986 by Mandecki (EPO 87109357.1) which enjoys common ownership and is incorporated herein by reference. Alternatively, the individual oligonucleotides may be synthesized on the Applied Biosystem 380A DNA synthesizer using methods and reagents recommended by the manufacturer. The DNA sequences of the individual oligonucleotides were confirmed using the Sanger dideoxy chain termination method (Sanger et al., J. Mole. Biol., 162:729 (1982)). These individual gene fragments were then annealed and ligated together and cloned as EcoRI-BamHI subfragments in the CKS fusion vector pJO200. After subsequent DNA sequence confirmation by the Sanger dideoxy chain termination method, the subfragments were digested with appropriate restriction enzymes, gel purified, ligated and cloned again as an EcoRI-BamHI fragment in the CKS fusion vector pJO2OO. The resulting clones were mapped to identify a hybrid gene consisting of the EcoRI-BamHI HCV fragment inserted at the 3' end of the CKS (CMP-KDO synthetase) gene. The resultant fusion proteins, under control of the la c promoter, consist of 239 amino acids of the CKS protein fused to the various regions of HCV.
The synthesis, cloning, and characterization of the recombinant poiypeptides as well as the preferred formats for assays using these poiypeptides are provided in the following examples. Examples 1 and 2 describe the synthesis and cloning of CKS-Core and CKS-33-BCD, respectively. Example 3 describes a screening assay. Example 4 describes a confirmatory assay. Example 5 describes a competition assay. Example 6 describes an immunodot assay. Example 7 describes the synthesis and cloning of HCV CKS-NS5E, CKS-NS5F, CKS-NS5G, CKS-NS5H and CKS-NS5I. Example 8 describes the preparation of HCV CKS-C100 vectors.
Example 9 describes the preparation of HCV PCR derived expression vectors.
Example 10 describes the synthesis and characterization of pHCV-77 of NS1.
Example 11 describes the synthesis and characterization of pHCV-65 of NS1.
Example 12 describes the synthesis and characterization of pHCV-78 of NS1.
Example 13 describes the synthesis and characterization of pHCV-80 of NS1.
Example 14 describes the synthesis and characterization of pHCV-92 of NS1.
REAGENTSAND ENZYMES
Media such as Luria-Bertani (LB) and Superbroth II (Dri Form) were obtained from Gibco Laboratories Life Technologies, Inc., Madison Wisconsin.
Restriction enzymes, Klenow fragment of DNA polymerase I, T4 DNA ligase, T4 polynucleotide kinase, nucleic acid molecular weight standards, M13 sequencing system, X-gal (5-bromo-4-chloro-3-indonyl-β-D-galactoside), IPTG
(isopropyl-β-D-thiogalactoside), glycerol, Dithiothreitol, 4-chloro-1 -naphthol were purchased from Boehringer Mannheim Biochemicals, Indianapolis, Indiana; or New England Biolabs, Inc., Beverly, Massachusetts; or Bethesda Research Laboratories Life Technologies, Inc., Gaithersburg, Maryland. Prestained protein molecular weight standards, acrylamide (crystallized, electrophoretic grade >99%); N-N'-Methylene-bis-acrylamide (BIS); N,N,N',N',- Tetramethylethylenediamine (TEMED) and sodium dodecylsulfate (SDS) were purchased from BioRad Laboratories, Richmond, California. Lysozyme and ampiciliin were obtained from Sigma Chemical Co., St. Louis, Missouri.
Horseradish peroxidase (HRPO) labeled secondary antibodies were obtained from Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Maryland. Seaplaque® agarose (low melting agarose) was purchased from FMC Bioproducts, Rockland, Maine.
T50E10 contained 50mM Tris, pH 8.0, 10mM EDTA; 1X TG contained 100mM Tris, pH 7.5 and 10% glycerol; 2X SDS/PAGE loading buffer consisted of 15% glycerol, 5% SDS, 100mM Tris base, 1 M β-mercaptoethanol and 0.8%
Bromophenol blue dye; TBS container 50 mM Tris, pH 8.0, and 150 mM sodium chloride; Blocking solution consisted of 5% Carnation nonfat dry milk in TBS.
HOSTCELL CULTURES. DNA SOURCES AND VECTORS
E,coli JM103 cells, pUC8, pUC18, pUC19 and M13 cloning vectors were purchased from Pharmacia LKB Biotechnology, Inc., Piscataway, New Jersey;
Competent Epicurean™ coli stains XL1 -Blue and JM109 were purchased from
Stratagene Cloning Systems, LaJolla, California. RR1 cells were obtained from Coli Genetic Stock Center, Yale University, New Haven, Connecticut; and E.coli CAG456 cells from Dr. Carol Gross, University of Wisconsin, Madison, Wisconsin. Vector pRK248.clts was obtained from Dr. Donald R. Helinski, University of California, San Diego, California.
GENERAL METHODS
All restriction enzyme digestion were performed according to suppliers' instructions. At least 5 units of enzyme were used per microgram of DNA, and sufficient incubation was allowed to complete digestion of DNA. Standard procedures were used for minicell lysate DNA preparation, phenol-chloroform extraction, ethanol precipitation of DNA, restriction analysis of DNA on agarose, and low melting agarose gel purification of DNA fragments (Maniatis et al., Molecular Cloning. A Laboratory Manual [New York: Cold Spring Harbor, 1982]). Plasmid isolations from E.coli strains used the alkali lysis procedure and cesium chlorideethidium bromide density gradient method (Maniatis et al., supra). Standard buffers were used for T4 DNA ligase and T4 poly nucleotide kinase (Maniatis et al., supra) .
EXAMPLE 1. CKS-CORE
A. Construction of the Plasmid pJ0200
The cloning vector pJO200 allows the fusion of recombinant proteins to the
CKS protein. The plasmid consists of the plasmid pBR322 with a modified Jac promoter fused to a KdsB gene fragment (encoding the first 239 of the entire 248 amino acids of the E.coli CMP-KDO synthetase of CKS protein), and a synthetic linker fused to the end of the KdsB gene fragment. The cloning vector pJO200 is a modification of vector pTB210. The synthetic linker includes: multiple restriction sites for insertion of genes; translational stop signals, and the trpA rho- independent transcriptional terminator. The CKS method of protein synthesis as well as CKS vectors including pTB210 are disclosed in U.S. Patent Application Serial Nos. 167,067 and 276,263, filed March 11 , 1988 and November 23, 1988, respectively, by Boiling (EPO 891029282) which enjoy common ownership, and are herein incorporated by reference.
B. Preparation of HCV CKS-Core Expression Vector
Six individual nucleotides representing amino acids 1-150 of the HCV genome were ligated together and cloned as a 466 base pair EcoRI-BamHI fragment into the CKS fusion vector pJO200 as presented in Figure 4. The complete DNA sequence of this plasmid, designated pHCV-34, and the entire amino acid sequence of the pHCV-34 recombinant antigen produced is presented in SEQ.ID.NO 6 and 7. The resultant fusion protein HCV CKS-Core, consists of 239 amino acids of CKS, seven amino acids contributed by linker DNA sequences, and the first 150 amino acids of
HCV as illustrated in Figure 5.
The pHCV-34 plasmid and the CKS plasmid pTB210 were transformed into E.coli K-12 strain xL-1 (recAI, endAI, gyrA96, thi-1 , hsdRI7, supE44, relAI, lac/F', proAB, laclqZDMl 5, TN10) cells made competent by the calcium chloride method. In these constructions the expression of the CKS fusion proteins was under the control of the lac promoter and was induced by the addition of IPTG. These plasmids replicated as independent elements, were nonmobilizable and were maintained at approximately 10-30 copies per cell. C. Characterization of Recombinant HCV-Core
In order to establish that clone pHCV-34 expressed the unique HCV-CKS Core protein, the pHCV-34/XL-1 culture was grown overnight at 37°C in growth media consisting of yeast extract, trytone, phosphate salts, glucose, and ampicillin. When the culture reached an OD600 of 1.0, IPTG was added to a final concentration of 1 mM to induce expression. Samples (1.5 ml) were removed at 1 hour intervals, and cells were pelleted and resuspended to an OD600 of 1.0 in 2X SDS/PAGE loading buffer. Aliquots (15ul) of the prepared samples were separated on duplicate 12.5% SDS/PAGE gels.
One gel was fixed in a solution of 50% methanol and 10% acetic acid for 20 minutes at room temperature, and then stained with 0.25% Coomassie blue dye in a solution of 50% methanol and 10% acetic acid for 30 minutes. Destaining was carried out using a solution of 10% methanol and 7% acetic acid for 3-4 hours, or until a clear background was obtained.
Figure 6 presents the expression of pHCV-34 proteins in E.coli. Molecular weight standards were run in Lane M. Lane 1 contains the plasmid pJ0200-the CKS vector without the HCV sequence. The arrows on the left indicate the mobilities of the molecular weight markers from top to bottom: 110,000; 84,000; 47,000; 33,000; 24,000; and 16,000 daltons. The arrows on the right indicate the mobilities of the recombinant HCV proteins. Lane 2 contains the E.coli lysate containing pHCV-34 expressing CKS-Core (amino acids 1 to 150) prior to induction; and Lane 3 after 3 hours of induction. The results show that the recombinant protein pHCV-34 has an apparent mobility corresponding to a molecular size of 48,000 daltons. This compares acceptably with the predicted molecular mass of 43,750 daltons.
Proteins from the second 12.5% SDS/PAGE gel were electrophoretically transferred to nitrocellulose for immunoblotting. The nitrocellulose sheet containing the transferred proteins was incubated with Blocking Solution for one hour and incubated overnight at 4°C with HCV patients' sera diluted in TBS containing E.coli K-12 strain XL-I lysate. The nitrocellulose sheet was washed three times in TBS, then incubated with HRPO-labeled goat anti-human IgG, diluted in TBS containing 10% fetal calf sera. The nitrocellulose was washed three times with TBS and the color was developed in TBS containing 2 mg/ml 4-chloro-1- napthol, 0.02% hydrogen peroxide and 17% methanol. Clone HCV-34 demonstrated a strong immu no reactive band at 48,000 daltons with the HCV patients' sera. Thus, the major protein in the Coomassie stained protein gel was immunoreactive.
Normal human serum did not react with any component of pHCV-34.
EXAMPLE 2. HCV CKS-33C-BCD
A. Preparation of HCV CKS-33c-BCD Expression Vector The construction of this recombinant clone expressing the HCV CKS-33-BCD antigen was carried out in three steps described below. First, a clone expressing the HCV CKS-BCD antigen was constructed, designated pHCV-23. Second, a clone expressing the HCV CKS-33 antigen was constructed, designated pHCV-29. Lastly, the HCV BCD region was excised from pHCV-23 and inserted into pHCV-29 to construct a clone expressing the HCV CKS-33-BCD antigen, designated pHCV-31 (SEQ.ID.NO. 8 and 9).
To construct the plasmid pHCV-23, thirteen individual oligonucleotides representing amino acids 1676-1931 of the HCV genome were ligated together and cloned as three separate EcoRI-BamHI subfragments into the CKS fusion vector pJO200. After subsequent DNA sequence confirmation, the three subfragments, designated B, C, and D respectively, were digested with the appropriate restriction enzymes, gel purified, ligated together, and cloned as a 781 base pair EcoRI-BamHI fragment in the CKS fusion vector pJO200, as illustrated in Figure 7. The resulting plasmid, designated pHCV-23, expresses the HCV CKS-BCD antigen under control of the jac promoter. The HCV CKS-BCD antigen consists of 239 amino acids of CKS, seven amino acids contributed by linker DNA sequences, 256 amino acids from the HCV NS4 region (amino acids 1676-1931 , and 10 additional amino acids contributed by linker DNA sequences.
To construct the plasmid pHCV-29 twelve individual oligonucleotides representing amino acids 1 192-1457 of the HCV genome were ligated together and cloned as two separate EcoRI-BamHI subfragments in the CKS fusion vector pJO200. After subsequent DNA sequence confirmation, the two subfragments were digested with the appropriate restriction enzymes, gel purified, ligated together and cloned again as an 816 base pair EcoRI-BamHI fragment in the CKS fusion vector pJO200, as illustrated in Figure 8. The resulting plasmid, designated pHCV-29, expresses the CKS-33 antigen under control of the jac promoter. The HCV CKS-33 antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 266 amino acids from the HCV NS3 region (amino acids 1192- 1 457) .
To construct the plasmid pHCV-31 , the 781 base pair EcoRI-BamHI fragment from pHCV-23 representing the HCV-BCD region was linker-adapted to produce a Cla1-BamHl fragment which was then gel purified and ligated into pHCV- 29 at the Cla1-BamHl sites as illustrated in Figure 9. The resulting plasmid, designated pHCV-31 , expresses the pHCV-31 antigen under control of the lac
promoter. The complete DNA sequence of pHCV-31 and the entire amino acid sequence of the HCV CKS-33-BCD recombinant antigen produced is presented in SEQ.ID.NO. 8 and 9. The HCV CKS-33-BCD antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, 266 amino acids of the HCV NS3 region (amino acids 1192-1457), 2 amino acids contributed by linker DNA sequences, 256 amino acids of the HCV NS4 region (amino acids 1676-1931), and 10 additional amino acids contributed by linker DNA sequences. Figure 12 presents a schematic representation of the pHCV-31 antigen.
The pHCV-31 plasmid was transformed into E.coli K-12 strain XL-I in a manner similar to the pHCV-34 and CKS-pTB210 plasmids of Example 1. B. Characterization of Recombinant HCV CKS-33-BCD
Characterization of pHCV CKS-33-BCD was carried out in a manner similar to pHCV CKS-Core of Example 1. pHCV-23, pHCV SDS/PAGE gels were run for E.coli lysates containing the plasmids pHCV-29 (Figure 11), pHCV-23 (Figure 12), and pHCV-31 (Figure 13) expressing the recombinant fusion proteins CKS- 33c, CKS-BCD, and CKS-33-BCD, respectively. For all three figures, molecular weight standards were run in Lane M, with the arrows on the left indicating mobilities of the molecular weight markers the from top to bottom: 110,000;
84,000; 47,000; 33,000; 24,000; and 16,000 daltons. In Figure 11 , Lane 1 contained the E.coli lysate containing pHCV-29 expressing HCV CKS-33c (amino acids 1192 to 1457) prior to induction and lane 2 after 4 hours induction. These results show that the recombinant pHCV-29 fusion protein has an apparent mobility corresponding to a molecular size of 60,000 daltons. This compares acceptably to the predicted molecular mass of 54,911.
In Figure 12, Lane 1 contained the E.coli lysate containing pJO200- the CKS vector without the HCV sequence. Lane 2, contained pHCV-20 expressing the
HCV CKS-B (amino acids 1676 to 1790). Lane 3, contained the fusion protein pHCV-23 (amino acids 1676-1931). These results show that the recombinant pHCV-23 fusion protein has an apparent mobility corresponding to a molecular size of 55,000 daltons. This compares acceptably to the predicted molecular mass of 55,070 daltons.
In Figure 13, Lane 1 contained the E.coli lysate containing pJO200 the CKS vector without the HCV sequences. Lane 2 contained pHCV-31 expressing the CKS- 33C-BCD fusion protein (amino acids 1192 to 1447 and 1676 to 1931) prior to induction and lane 3 after 2 hours induction. These results show that the
recombinant pHCV-31 (CKS-33c-BCD) fusion protein has an apparent mobility corresponding to a molecular size of 90,000 daltons. This compares acceptably to the predicted molecular mass of 82,995 daltons. An immunoblot was also run on one of the SDS/PAGE gels derived from the PHCV-31/X1-1 culture. Human serum from an HCV exposed individual reacted strongly with the major pHCV-31 band at 90,000 daltons. Normal human serum did not react with any component of the pHCV-31 (CKS-33-BCD) preparations.
EXAMPLE 3. SCREENING ASSAY
The use of recombinant poiypeptides which contain epitopes within c100-3 as well as epitopes from other antigenic regions from the HCV genome, provide immunological assays which have increased sensitivity and may be more specific than HCV immunological assays using epitopes within c100-3 alone.
In the presently preferred screening assay, the procedure uses two E.coli expressed recombinant proteins, CKS-Core (pHCV-34) and CKS-33-BCD (pHCV- 31), representing three distinct regions of the HCV genome. These recombinant poiypeptides were prepared following procedures described above. In the screening assay, both recombinant antigens are coated onto the same polystyrene bead. In a modification of the screening assay the polystyrene bead may also be coated with the SOD-fusion polypeptide c100-3.
The polystyrene beads are first washed with distilled water and propanol and then incubated with a solution containing recombinant pHCV-31 diluted to 0.5 to 2.0 ug/ml and pHCV-34 diluted to 0.1 to 0.5 ug/ml in 0.1 M NaH2PO4 ·H2O with
0.4M NaC1 and 0.0022% Triton X-100, pH 6.5. The beads are incubated in the antigen solution for 2 hours (plus or minus 10 minutes) at 38-42°C, washed in PBS and soaked in 0.1% (w/v) Triton X-100 in PBS for 60 minutes at 38-42°C. The beads are then washed two times in phosphate buffered saline (PBS), overcoated with a solution of 5.0% (w/v) bovine serum albumin (BSA) in PBS for 60 minutes at 38-42°C and washed one time in PBS. Finally, the beads are overcoated with 5% (w/v) sucrose in PBS, and dried under nitrogen or air.
The polystyrene beads coated with pHCV-31 and pHCV-34 are used in an antibody capture format. Ten microliters of sample are added to the wells of the reaction tray along with 400 ul of a sample diluent and the recombinant coated bead.
The sample diluent consists of 10% (v/v) bovine serum and 20% (v/v) goat serum in 20 mM Tris phosphate buffer containing 0.15% (v/v) Triton X-100, 1%(w/v) BSA, 1% E.coli lysate and 500 ug/ml or less CKS lysate. When the recombinant yeast d 00-3 polypeptide is used, antibodies to yeast antigens which may be present in a sample are reacted with yeast extracts which are added to the sample diluent (typically about 200 ug/ml). The addition of yeast extracts to the sample diluent is used to prevent false positive results. The final material is sterile filtered and filled in plastic bottles, and preserved with 0.1% sodium azide.
After one hour of incubation at 40°C, the beads are washed and 200 ul of conjugate is added to the wells of the reaction tray.
The preferred conjugate is goat anti-human IgG horseradish peroxidase conjugate. Concentrated conjugate is titered to determine a working concentration. A twenty-fold concentrate of the working conjugate solution is then prepared by diluting the concentrate in diluent. The 20X concentrate is sterile filtered and stored in plastic bottles.
The conjugate diluent includes 10% (v/v) bovine serum, 10% (v/v) goat serum and 0.15% Triton-X100 in 20 mM Tris buffer, pH 7.5 with 0.01% gentamicin sulfate, 0.01% thimerosal and red dye. The conjugate is sterile filtered and filled in plastic bottles.
Anti-HCV positive control is prepared from plasma units positive for antibodies to HCV. The pool of units used includes plasma with antibodies reactive to pHCV-31 and pHCV-34. The units are recalcified and heat inactivated at 59-61°C for 12 hours with constant stirring. The pool is aliquoted and stored at -20°C or at 2-8°C. For each lot of positive control, the stock solution is diluted with negative control containing 0.1% sodium azide as a preservative. The final material is sterile filtered and filled in plastic bottles.
Anti-HCV negative control is prepared from recalcified human plasma, negative for antibodies to pHCV-31 and pHCV-34 proteins of HCV. The plasma is also negative for antibodies to human immunodeficiency virus (HIV) and negative for hepatitis B surface antigen (HBsAg). The units are pooled, and 0.1% sodium azide is added as a preservative. The final material is sterile filtered and filled in plastic bottles.
After one hour of incubation with the conjugate at 40°C, the beads are washed, exposed to the OPD substrate for thirty minutes at room temperature and the reaction terminated by the addition of 1 N H2SO4. The absorbance is read at
492 nm.
In order to maintain acceptable specificity, the cutoff for the assay should be at least 5-7 standard deviations above the absorbance value of the normal population mean. In addition, it has generally been observed that acceptable specificity is obtained when the population mean runs at a sample to cutoff (S/CO) value of 0.25 or less. Consistent with these criteria, a "preclinical" cutoff for the screening assay was selected which clearly separated most of the presumed "true negative" from "true positive" specimens. The cutoff value was calculated as the sum of the positive control mean absorbance value multiplied by 0.25 and the negative control mean absorbance value. The cutoff may be expressed algebraically as:
Cutoff value=0.25 PCx + NCx.
Testing may be performed by two methods which differ primarily in the degree of automation and the mechanism for reading the resulting color development in the assay. One method is referred to as the manual or Quantum™ method because Quantum or Quantumatic is used to read absorbance at 492 nm. It is also called the manual method because sample pipetting, washing and reagent additions are generally done manually by the technician, using appropriately calibrated pipettes, dispensers and wash instruments. The second method is referred to as the PPC method and utilizes the automated Abbott Commander® system. This system employs a pipetting device referred to as the Sample Management Center (SMC) and a wash/dispense/read device referred to as the Parallel Processing Center (PPC) disclosed in E.P.O. Publication No. 91114072.1. The optical reader used in the PPC has dual wavelength capabilities that can measure differential absorbencies (peak band and side band) from the sample wells. These readings are converted into results by the processor's Control Center.
Screening Assay Performance
1. Serum/Plasma From Inoculated Chimpanzees
As previously described, Table I summarizes the results of a study which followed the course of HCV infection in seven chimpanzees using a screening assay which utilized the c100-3 polypeptide, and the screening assay which utilized pHCV-31 and pHCV-34. Both assays gave negative results before inoculation and both assays detected the presence of antibodies after the animal had been infected with HCV. However, in the comparison of the two assays, the assay utilizing pHCV- 31 and pHCV-34 detected seroconversion to HCV antigens at an earlier or equivalent bleed date in six of the seven chimpanzees. Data from these chimpanzee studies clearly demonstrate that overall detection of HCV antibodies is greatly increased with the assay utilizing the pHCV-31 and pHCV-34 proteins. This test is
sufficiently sensitive to detect seroconversion during the acute phase of this disease, as defined as an elevation in ALT levels, in most animals. Equally important is the high degree of specificity of the test as no pre-inoculation specimens were reactive.
Non-A. Non-B Panel II (Η. Alter. NIH)
A panel of highly pedigreed human sera from Dr. H. Alter, NIH, Bethesda, MD., containing infectious HCV sera, negative sera and other disease controls were tested. A total of 44 specimens were present in the panel.
Six of seven sera which were "proven infectious" in chimpanzees were positive in both the screening assay using c100-3 as well as in the screening assay utilizing the recombinant proteins pHCV-31 and pHCV-34. These six reactive specimens were obtained from individuals with chronic hepatitis. All six of the reactive specimens were confirmed positive using synthetic peptide sp67. One specimen obtained during the acute phase of NANB post-transfusion hepatitis was non-reactive in both screening assays.
In the group labeled "probable infectious" were three samples taken from the same post transfusion hepatitis patient. The first two acute phase samples were negative in both assays, but the third sample was reactive in both assay. The disease control samples and pedigreed negative controls were uniformly negative.
All sixteen specimens detected as positive by both screening assays were confirmed by the spll7 confirmatory assay (Figure 14). In addition, specimens 10 and 29 were newly detected in the screening assay utilizing the recombinant pHCV- 31 and pHCV-34 antigens and were reactive by the sp75 confirmatory assay.
Specimen 39 was initially reactive in the screening test utilizing pHCV-34 and pHCV-31 , but upon retesting was negative and could not be confirmed by the confirmatory assays.
In summary, both screening tests identified 6 of 6 chronic NANBH carriers and 1 of 4 acute NANBH samples. Paired specimens from an implicated donor were non-reactive in the screening test utilizing c100-3 but were reactive in the screening test with pHCV-31 and pHCV-34. Thus, the screening test utilizing the recombinant antigens pHCV-31 and pHCV-34 appears to be more sensitive than the screening assay utilizing c100-3. None of the disease control specimens or pedigreed negative control specimens were reactive in either screening assay.
3. CBER Reference Panel
A reference panel for antibody to Hepatitis C was received from the Center for Biologies Evaluation and Research (CBER). This 10 member panel consists of eight reactive samples diluted in normal human sera negative for antibody to HCV and two sera that contain no detectable antibody to HCV. This panel was run on the Ortho first generation HCV EIA assay, the screening assay utilizing d 00-3 and the screening assay utilizing pHCV-31 and pHCV-34. The assay results are presented in Figure 15.
The screening assay utilizing pHCV-31 and pHCV-34 detected all six of the HCV positive or borderline sample dilutions. The two non-reactive sample dilutions (709 and 710) appear to be diluted well beyond endpoint of antibody detectabiiity for both screening assays. A marked increase was observed in the sample to cutoff values for three of the members on the screening assay utilizing pHCV-31 and pHCV-34 compared to the screening assay utilizing c100-3 or the Ortho first generation test. All repeatably reactive specimens were confirmed.
EXAMPLE 4. CONFIRMATORY ASSAY
The confirmatory assay provides a means for unequivocally identifying the presence of an antibody that is immunologically reactive with an HCV antigen. The confirmatory assay includes synthetic peptides or recombinant antigens
representing major epitopes contained within the three distinct regions of the HCV genome, which are the same regions represented by the two recombinant antigens described in the screening assay. Recombinant proteins used in the confirmatory assay should have a heterologous source of antigen to that used in the primary screening assay (i.e. should not be an E.coli-derived recombinant antigen nor a recombinant antigen composed in part, of CKS sequences). Specimens repeatedly reactive in the primary screening assay are retested in the confirmatory assay. Aliquots containing identical amounts of specimen are contacted with a synthetic peptide or recombinant antigen individually coated onto a polystyrene bead.
Sero reactivity for epitopes within the c100-3 region of the HCV genome are confirmed by use of the synthetic peptides sp67 and sp65. The synthetic peptide sp117 can also be used to confirm seroreactivity with the c100-3 region.
Seroreactivity for HCV epitopes within the putative core region of HCV are confirmed by the use of the synthetic peptide sp75. In order to confirm
seroreactivity for HCV epitopes within the 33c region of HCV, a recombinant antigen expressed as a chimeric protein with superoxide dismutase (SOD) in yeast is used. Finally, the antibody-antigen complex is detected.
The assay protocols were similar to those described in Example 3 above. The peptides are each individually coated onto polystyrene beads and used in an antibody capture format similar to that described for the screening assay. Ten microliters of specimen are added to the wells of a reaction tray along with 400 ul of a specimen diluent and a peptide coated bead. After one hour of incubation at 40°C, the beads are washed and 200 ul of conjugate (identical to that described in Example 3) is added to the wells of the reaction tray. After one hour of incubation at 40°C, the beads are washed, exposed to the OPD substrate for 30 minutes at room temperature and the reaction terminated by the addition of 1 N H2SO4. The absorbance is read at 492 nm. The cutoff value for the peptide assay is 4 times the mean of the negative control absorbance value.
1. Panels containing Specimens "At Risk" for HCV Infection.
A group of 233 specimens representing 23 hemodialysis patients all with clinically diagnosed NANBH were supplied by Gary Gitnick, M.D. at the University of California, Los Angeles Center for the Health Sciences. These samples which were tested in by the screening assay utilizing d 00-3 were subsequently tested in the screening assay which uses pHCV-31 and pHCV-34. A total of 7/23 patients (30.44%) were reactive in the c100-3 screening assay, with a total of 36 repeat reactive specimens. Ten of 23 patients (43.48%) were reactive by the screening assay utilizing pHCV-31 and pHCV-34, with a total of 70 repeatable reactives among the available specimens (Figure 16). Two specimens were unavailable for testing. All of the 36 repeatedly reactive specimens detected in the c100-3 screening assay were confirmed by synthetic peptide confirmatory assays. A total of 34 of these 36 were repeatedly reactive on HCV EIA utilizing pHCV-34 and pHCV-31 ; two specimens were not available for testing. Of the 36 specimens additionally detected by the screening assay utilizing pHCV-34 and pHCV-31 , 9 were confirmed by the core peptide confirmatory assay (sp75) and 27 were confirmed by the SOD-33C confirmatory assay.
In summary these data indicate that detection of anti-HCV by the screening assay utilizing pHCV-31 and pHCV-34 may occur at an equivalent bleed date or as many as 9 months earlier, when compared to the d 00-3 screening assay. Figure 17 depicts earlier detection by the screening assay utilizing pHCV-34 and pHCV-31 in a hemodialysis patient.
5. Acute/Chronic Non-A. Non-B Hepatitis
A population of specimens was identified from individuals diagnosed as having acute or chronic NANBH. Specimens from individuals with acute cases of NANBH were received from Gary Gitnick, M.D. at the University of California, Los
Angeles Center for Health Sciences. The diagnosis of acute hepatitis was based on the presence of a cytolytic syndrome (ALT levels greater than 2X the upper normal limit) on at least 2 serum samples for a duration of less than 6 months with or without other biological abnormalities and clinical symptoms. All specimens were also negative for IgM antibodies to Hepatitis A Virus (HAV) and were negative for Hepatitis B surface Ag when tested with commercially available tests. Specimens from cases of chronic NANBH were obtained from two clinical sites. Individuals were diagnosed as having chronic NANBH based on the following criteria:
persistently elevated ALT levels, liver biopsy results, and/or the absence of detectable HBsAg. Specimens with biopsy results were further categorized as either chronic active NANBH, chronic persistent NANBH, or chronic NANBH with cirrhosis.
These specimens were tested by both the c100-3 screening assay and the screening assay utilizing pHCV-34 and pHCV-31. The latter testing was performed in replicates of two by both the Quantum and PPC methods.
Community Acquired NANBH (Acute)
The c100-3 screening assay detected 2 of 10 specimens (20.00%) as repeatedly reactive, both of which were confirmed. The screening assay utilizing pHCV-34 and pHCV-31 detected both of these specimens plus and additional 2 specimens (Figure 18). These 2 specimens were confirmed by sp75 (see Figure 1 9) .
Acute Post-Transfusion NANBH
The c100-3 assay detected 4 of 32 specimens (12.50%) as repeatedly reactive, all of which was confirmed. The screening assay utilizing pHCV-34 and pHCV-31 detected 3 out of these 4 specimens (75%) as reactive. The one sample that was missed had an S/CO of 0.95 by the latter screening test. This sample was confirmed by the sp67 peptide (Figure 18). In addition, the screening assay utilizing pHCV-34 and pHCV-31 detected 11 specimens not reactive in the c100-3 screening assay. Of the 9 specimens available for confirmation, 8 were confirmed by sp75 and 1 could not be confirmed but had an S/CO of 0.90 in the sp65
confirmatory test, (see Figure 19).
Chronic NANBH
A summary of the results on these populations is shown in Figure 20.
Overall, 155 of 164 (94.5%) chronic NANBH samples were detected by the screening test utilizing pHCV-31 and pHCV-34 using either Quantum or PPC. The 155 reactive samples were all confirmed in alternate assays using synthetic peptides based on sequences from either the c100, 33c or core regions of the HCV genome. In contrast, only 138 of 164 (84.1%) specimens were positive by the c100-3 assay. All but one of the 138 c100-3 samples were detected as positive by the screening assay utilizing pHCV-31 and pHCV-34. The one discordant specimen was not confirmed by either synthetic or neutralization assays. Conversely, there were 17 confirmed specimens which were positive only by the screening assay utilizing pHCV-34 and pHCV-31.
The results indicate that the screening assay utilizing pHCV-34 and pHCV- 31 is more sensitive than the current test in detecting HCV positive individuals within chronically infected NANBH populations.
EXAMPLE 5, Competition ASSAY
The recombinant poiypeptides containing antigenic HCV epitopes are useful for competition assays. To perform a neutralization assay, a recombinant polypeptide representing epitopes within the c100-3 region such as CKS-BCD (pHCV-23) is solubilized and mixed with a sample diluent to a final concentration of 0.5-50 ug/ml. Ten microliters of specimen or diluted specimen is added to a reaction well followed by 400 ul of the sample diluent containing the recombinant polypeptide and if desired, the mixture may be preincubated for about fifteen minutes to two hours. A bead coated with c100-3 antigen is then added to the reaction well and incubated for one hour at 40°C. After washing, 200 ul of a peroxidase labeled goat anti-human IgG in conjugate diluent is added and incubated for one hour at 40°C. After washing, OPD substrate is added and incubated at room temperature for thirty minutes. The reaction is terminated by the addition of 1 N sulfuric acid and the absorbance read at 492 nm.
Samples containing antibodies to the c1 00-3 antigen generate a reduced signal caused by the competitive binding of the peptides to these antibodies in solution. The percentage of competitive binding may be calculated by comparing the absorbance value of the sample in the presence of a recombinant polypeptide to the absorbance value of the sample assayed in the absence of a recombinant polypeptide at the same dilution. EXAMPLE 6. IMMUNODOT ASSAY
The immunodot assay system uses a panel of purified recombinant poiypeptides placed in an array on a nitrocellulose solid support. The prepared solid support is contacted with a sample and captures specific antibodies to HCV antigens. The captured antibodies are detected by a conjugate-specific reaction. Preferably, the conjugate specific reaction is quantified using a reflectance optics assembly within an instrument which has been described in U.S. Patent Applications Serial No. 07/227,408 filed August 2, 1988. The related U.S. Patent Applications Serial Nos. 07/227,272, 07/227,586 and 07/227,590 further describe specific methods and apparatus useful to perform an immunodot assay. The assay has also been described in U.S. Application Serial No. 07/532,489 filed June 6, 1990. Briefly, a nitrocellulose-base test cartridge is treated with multiple antigenic poiypeptides. Each polypeptide is contained within a specific reaction zone on the test cartridge. After all the antigenic poiypeptides have been placed on the nitrocellulose, excess binding sites on the nitrocellulose are blocked. The test cartridge is then contacted with a sample such that each antigenic polypeptide in each reaction zone will react if the sample contains the appropriate antibody. After reaction, the test cartridge is washed and any antigen-antibody reactions are identified using suitable well known reagents.
As described in the patent applications listed above, the entire process is amenable to automation. The specifications of these applications related to the method and apparatus for performing an immunodot assay are incorporated by reference herein.
In a preferred immunodot assay, the recombinant poiypeptides pHCV-23, pHCV-29, pHCV-34, and c100-3 were diluted in the preferred buffers, pH conditions, and spotting concentrations as summarized in Figure 21 and applied to a preassembled nitrocellulose test cartridge. After drying the cartridge overnight at room temperature 37°C, the non-specific binding capacity of the nitro-cellulose phase was blocked. The blocking solution contained 1% porcine gelatin, 1% casein enzymatic hydrolysate, 5% Tween-20, 0.1% sodium azide, 0.5 M sodium chloride and 20 mM Tris, pH 7.5.
Forty normal donors were assayed by following the method described above. The mean reflectance density value then was determined for each of the recombinant proteins. A cutoff value was calculated as the negative mean plus six standard deviations. Test cartridges were incubated with samples A00642 and 423 (see Figure 22). Sample A00642 was from a convalescent non-A, non-B hepatitis patient, diluted in negative human plasma from 1 :100 to 1 :12800. The other sample, 423, was from a paid plasma donor which tested positive in an assay using a recombinant c100-3 polypeptide, diluted in negative human plasma from 1 :40 to 1 :2560. After sample incubation, sequential incubations with a biotin-conjugated goat anti-human immunoglobulin-specific antibody, an alkaline phosphatase- conjugated rabbit anti-biotin specific antibody, and 5-bromo-4-chloro-3-indolyl phosphate produced a colored product at the site of the reaction. Sample to cutoff values (S/CO) were determined for all HCV recombinant proteins. Those S/CO values greater than or equal to 1.0 were considered reactive. The limiting dilution was defined as the lowest dilution at which the S/CO was greater than or equal to 1.0. As seen in Figure 22, each sample tested positive for all HCV recombinant proteins. The data demonstrate that reactivity for sample A00642 was greatest with pHCV-29, and decreased for the remaining antigens pHCV-23, c100-3, and pHCV-34. Sample 423 most strongly reacted with the recombinant proteiss expressing pHCV-29 and pHCV-34, and to a lesser extent with pHCV-23 and c100- 3.
EXAMPLE 7. HCV CKS-NS5 EXPRESSION VECTORS
A. Preparation of HCV CKS-NS5E
Eight individual oligonucleotides representing amino acids 1932-2191 of the HCV genome were ligated together and cloned as a 793 base pair EcoRI-BamHI fragment into the CKS fusion vector pJ0200. The resulting plasmid, designated pHCV-45 (SEQ.ID.NO 8), expresses the HCV CKS-NS5E antigen under control of the ]ac promoter. The HCV CKS-NS5E antigen consists of 239 amino acids of CKS, nine amino acids contributed by linker DNA sequences, and 260 amino acids from the HCV NS4/NS5 region (amino acids 1932-2191). Figure 23 presents a schematic representation of the recombinant antigen expressed by pHCV-45. SEQ.ID.NO. 10 and 11 presents the DNA and amino acid sequence of the HCV CKS-NS5E recombinant antigen produced by pHCV-45. Figure 24 presents the expression of pHCV-45 proteins in E.coli. Lane 1 contained the E.coli lysate containing pHCV-45
expressing the HCV CKS-NS5E antigen (amino acids 1932-2191) prior to induction and lanes 2 and 3 after 2 and 4 hours post induction, respectively. These results show that the pHCV-45 fusion protein has an apparent mobility
corresponding to a molecular size of 55,000 daltons. This compares acceptably to the predicted molecular mass of 57,597 daltons.
B. Preparation of HCV CKS-NS5F
Eleven individual oligonucleotides representing amino acids 2188-2481 of the HCV genome were ligated together and cloned as a 895 base pair EcoRI-BamHI fragment into the CKS fusion vector pJ0200. The resulting plasmid, designated pHCV-48 , expresses the HCV CKS-NS5F antigen under control of the lac promoter. The HCV CKS-NS5F antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 294 amino acids from the HCV NS5 region (amino acids 2188-2481). Figure 25 presents a schematic representation of the recombinant antigen expressed by pHCV-48. SEQ.ID.NO. 12 and 13 presents the DNA and amino acid sequence of the HCV CKS-NS5F recombinant antigen produced by pHCV-48. Figure 26 presents the expression of pHCV-48 proteins in E.coli. Lane 1 contained the E.coli lysate containing pHCV-48 expressing the HCV CKS-NS5F antigen (amino acids 2188-2481) prior to induction and lanes 2 and 3 after 2 and 4 hours post induction, respectively. These results show that the pHCV-48 fusion protein has an apparent mobility corresponding to a molecular size of 65,000 daltons. This compares acceptably to the predicted molecular mass of 58,985 daltons.
C. Preparation of HCV CKS-NS5G
Seven individual oligonucleotides representing amino acids 2480-2729 of the HCV genome were ligated together and cloned as a 769 base pair EcoRI-BamHI fragment into the CKS fusion vector pJ0200. The resulting plasmid, designated pHCV-51 (SEQ.ID.NO. 10), expresses the HCV CKS-NS5G antigen under control of the lac promoter. The HCV CKS-NS5G antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 250 amino acids from the HCV NS5 region (amino acids 2480-2729). Figure 27 presents a schematic representation of the recombinant antigen expressed by pHCV-51. SEQ.NO.ID NO.14 and 15 presents the DNA and amino acid sequence of the HCV CKS-NS5G recombinant antigen produced by pHCV-51. Figure 28 presents the expression of pHCV-51 proteins in E.coli. Lane 1 contained the E.coli lysate containing pHCV-51 expressing the HCV CKS-NS5G antigen (amino acids 2480-2729) prior to induction and lanes 2 and 3 after 2 and 4 hours post induction, respectively. These results show that the pHCV-51 fusion protein has an apparent mobility
corresponding to a molecular size of 55,000 daltons. This compares acceptably to the predicted molecular mass of 54,720 daltons.
P. Preparation of HCV CKS-NS5H
Six individual oligonucleotides representing amino acids 2728-2867 of the HCV genome were ligated together and cloned as a 439 base pair EcoRI-BamHI fragment into the CKS fusion vector pJ0200. The resulting plasmid, designated pHCV-50 (SEQ.NO.ID.11) expresses the HCV CKS-NS5H antigen under control of the lac promoter. The HCV CKS-NS5H antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 140 amino acids from the HCV NS5 region (amino acids 2728-2867). Figure 29 presents a schematic representation of the recombinant antigen expressed by pHCV-50. SEQ.ID.NO. 16 and 17 presents the DNA and amino acid sequence of the HCV CKS-NS5H recombinant antigen produced by pHCV-50. Figure 30 presents the expression of pHCV-50 proteins in E.coli. Lane 1 contained the E.coli lysate containing pHCV-50
expressing the HCV CKS-NS5H antigen (amino acids 2728-2867) prior to induction and lanes 2 and 3 after 2 and 4 hours post induction, respectively. These results show that the pHCV-50 fusion protein has an apparent mobility
corresponding to a molecular size of 45,000 daltons. This compares acceptably to the predicted molecular mass of 42,783 daltons.
E. Preparation of HCV CKS-NS5I
Six individual oligonucleotides representing amino acids 2866-3011 of the HCV genome were ligated together and cloned as a 460 base pair EcoRI-BamHI fragment into the CKS fusion vector pJ0200. The resulting plasmid, designated pHCV-49 (SEQ.NO.ID.NO. 12), expresses the HCV CKS-NS5I antigen under control of the lac promoter. The HCV CKS-NS5I antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 146 amino acids from the HCV NS5 region (amino acids 2866-3011). Figure 31 presents a schematic representation of the recombinant antigen expressed by pHCV-49. SEQ.ID.NO. 18 and 19 presents the DNA and amino acid sequence of the HCV CKS-NS5I recombinant antigen produced by pHCV-49. Figure 32 presents the expression of pHCV-49 proteins in E.coli. Lane 1 contained the E.coli lysate containing pHCV-49 expressing HCV CKS-NS5I antigen (amino acids 2866-3011) prior to induction and lanes 2 and 3 after 2 and 4 hours post induction, respectively. These results show that the pHCV-49 fusion protein has an apparent mobility corresponding to a molecular size of 42,000 daltons. This compares acceptably to the predicted molecular mass of 43,497 daltons. F. Immunoblot of HCV CKS-NS5 Antigens
Induced E.coli lysates containing pHCV-23, pHCV-45, pHCV-48, pHCV-51, pHCV-50, or pHCV-49 were individually run on preparative SDS/PAGE gels to separate the various HCV CKS-NS5 or HCV CKS-BCD recombinant antigens assay from the majority of other E.coli proteins. Gel slices containing the separated individual HCV CKS-NS5 or HCV CKS-BCD recombinant antigens were then electropheretically transferred to nitrocellulose, and the nitrocellulose sheet cut into strips. Figure 40 presents the results of a Western Blot analysis of various serum or plasma samples using these nitrocellulose strips. The arrows on the right indicate the position of each HCV CKS-BCD or HCV CKS-NS5 recombinant antigen, from top to bottom pHCV-23 (HCV CKS-BCD), pHCV-45 (HCV CKS-NS5E), pHCV-
48 (HCV CKS-NS5F), pHCV-51 (HCV CKS-NS5G), pHCV-50 (HCV CKS-NS5H), pHCV-49 (HCV CKS-NS5I), and pJO200 (CKS). Panel A contained five normal human plasma, panel B contained five normal human sera, panel C contained twenty human sera positive in the Abbott HCV EIA test, panel D contained two mouse sera directed against CKS, and panel E contained two normal mouse sera. Both the HCV CKS-NS5E antigen expressed by pHCV-45 and the HCV CKS-NS5F antigen expressed by pHCV-48 were immunoreactive when screened with human serum samples containing HCV antibodies.
EXAMPLE 8. HCV CKS-C100
A. Preparation of HCV CKS-C100 Vectors
Eighteen individual oligonucleotides representing amino acids 1569-1931 of the HCV genome were ligated together and cloned as four separate EcoRI-BamHI subfragments into the CKS fusion vector pJ0200. After subsequent DNA sequences confirmation, the four subfragments were digested with the appropriate restriction enzymes, gel purified, ligated together, and cloned as an 1 102 base pair EcoRI- BamHI fragment in the CKS fusion vector pJ0200. The resulting plasmid, designated pHCV-24, expresses the HCV CKS-C100 antigen under control of the lac promoter. The HCV CKS-c100 antigen consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, 363 amino acids from the HCV NS4 region (amino acids 1569-1931) and 10 additional amino acids contributed by linker DNA sequences. The HCV CKS-c100 antigen was expressed at very low levels by pHCV-24.
Poor expression levels of this HCV CKS-c100 recombinant antigen were overcome by constructing two additional clones containing deletions in the extreme amino terminal portion of the HCV c100 region. The first of these clones, designated pHCV-57 (SEQ.ID.NO. 20 and 21), contains a 23 amino acid deletion
(HCV amino acids 1575-1597) and was constructed by deleting a 69 base pair Ddel restriction fragment. The second of these clones, designated pHCV-58 (SEQ.ID.NO. 22 and 23), contains a 21 amino acid deletion (HCV amino acids 1600-1620) and was constructed by deleting a 63 base pair NlalV-Haelll restriction fragment.
Figure 34 presents a schematic representation of the recombinant antigens expressed by pHCV-24, pHCV-57, and pHCV-58. SEQ.ID. NO. 13 presents the DNA and amino acid sequence of the HCV-C100D1 recombinant antigen produced by pHCV-57. SEQ.ID.NO. 14 presents the DNA and amino acid sequence of the HCV- C100D2 recombinant antigen produced by pHCV-58. Figure 35 presents the expression of pHCV-24, pHCV-57, and pHCV-58 proteins in E.coli. Lane 1 contained the E.coli lysate containing pHCV-24 expressing the HCV CKS-c100 antigen (amino acids 1569-1931) prior to induction and lanes 2 and 3 after 2 and 4 hours post induction, respectively. Lane 4 contained the E.coli lysate containing pHCV-57 expressing the HCV-CKS-C100D1 antigen (amino acids 1569-1574 and 1598-1931) prior to induction and lanes 5 and 6 after 2 and 4 hours induction, respectively. Lane 7 contained the E.coli lysate containing pHCV-58 expressing the HCV CKS-C100D2 antigen (amino acids 1569-1599 and 1621 -1931) prior to induction, and lanes 8 and 9 after 2 and 4 hours induction, respectively. These results show that both the pHCV-57 and pHCV-58 fusion proteins express at significantly higher levels than the pHCV-24 fusion protein and that both the pHCV-57 and pHCV-58 fusion proteins have an apparent mobility corresponding to a molecular size of 65,000 daltons. This compares acceptably to the predicted molecular mass of 64,450 daltons for pHCV-57 and 64,458 daltons for pHCV-58.
EXAMPLE 9. HCV PCR DERIVED EXPRESSION VECTORS
A. Preparation of HCV DNA Fragments
RNA was extracted from the serum of various chimpanzees or humans infected with HCV by first subjecting the samples to digestion with Proteinase K and SDS for 1 hour at 37° centigrade followed by numerous phenol:chloroform extractions. The RNA was then concentrated by several ethanol precipitations and resuspended in water. RNA samples were then reverse transcribed according to supplier's instructions using a specific primer. A second primer was then added and PCR amplification was performed according to supplier's instructions. An aliquot of this PCR reaction was then subjected to an additional round of PCR using nested primers located internal to the first set of primers. In general, these primers also contained restriction endonuclease recognition sequences to be used for subsequent cloning. An aliquot of this second round nested PCR reaction was then subjected to agarose gel electrophoresis and Southern blot analysis to confirm the specificity of the PCR reaction. The remainder of the PCR reaction was then digested with the appropriate restriction enzymes, the HCV DNA fragment of interest gel purified, and ligated to an appropriate cloning vector. This ligation was then transformed into E.coli and single colonies were isolated and plasmid DNA prepared for DNA sequences analysis. The DNA sequences was then evaluated to confirm that the specific HCV coding region of interest was intact. HCV DNA fragments obtained in this manner were then cloned into appropriate vectors for expression analysis.
B. Preparation of HCV CKS-NS3
Using the methods detailed above, a 474 base pair DNA fragment from the putative NS3 region of HCV was generated by PCR. This fragment represents HCV amino acids #1473-1629 and was cloned into the CKS expression vector pJ0201 by blunt-end ligation. The resulting clone, designated pHCV-105, expresses the HCV CKS-NS3 antigen under control of the ]ac promoter. The HCV CKS-NS3 antigen consists of 239 amino acids of CKS, 12 amino acids contributed by linker DNA sequences, 157 amino acids from the HCV NS3 region (amino acids 1473-1629), and 9 additional amino acids contributed by linker DNA sequences. Figure 36 presents a schematic representation of the pHCV-105 antigen. SEQ.ID.NO. 24 and 25 presents the DNA and amino acid sequence of the HCV CKS-NS3 recombinant antigen produced by pHCV-105. Figure 37 presents the expression of pHCV-105 proteins in E.coli. Lane 1 contained the E.coli lysate containing pHCV-105 expressing the HCV CKS-NS3 antigen (amino acids 1472-1629) prior to induction and lanes 2 and 3 after 2 and 4 hours induction, respectively. These results show that the pHCV-105 fusion protein has an apparent mobility corresponding to a molecular mass of 43,000 daltons. This compares acceptably to the predicted molecular mass of 46,454 daltons.
C. Preparation of HCV CKS-5'ENV
Using the methods detailed above, a 489 base pair DNA fragment from the putative envelope region of HCV was generated by PCR. This fragment represents the HCV amino acids 1 14-276 and was cloned into the CKS expression vector pJ0202 using EcoRI-BamHI restriction sites. The resulting clone, designated pHCV-103 (SEQ.ID.NO. 26 and 27), expresses the HCV CKS-5'ENV antigen under control of the lac promoter. The HCV CKS-5ΕNV antigen consists of 239 amino acids of CKS, 7 amino acids contributed by linker DNA sequences, 163 amino acids from the HCV envelope region (aminό acids 1 14-276), and 16 additional amino acids contributed by linker DNA sequences. Figure 38 presents a schematic representation of the pHCV-103 antigen. SEQ.ID.NO. 26 and 27 presents the DNA and amino acid sequence of the HCV CKS-5'ENV recombinant antigen produced by pHCV-103. Figure 37 presents the expression of pHCV-103 proteins in E.coli. Lane 1 contained the E.coli lysate containing pHCV-103 expressing the HCV CKS- 5ΕNV antigen (amino acids 1 14-276) prior to induction and lanes 5 and 6 after 2 and 4 hours induction, respectively. These results show that the pHCV-103 fusion protein has an apparent mobility corresponding to a molecular mass of 47,000 daltons. This compares acceptably to the predicted molecular mass of 46,091 daltons.
P. Preparation of HCV CKS-3'ENV
Using the methods detailed above, a 621 base pair DNA fragment form the putative envelope region of HCV was generated by PCR. This fragment represents HCV amino acids 263-469 and was cloned into the CKS expression vector pJ0202 using EcoRI restriction sites. The resulting clone, designated pHCV-101
(SEQ.ID.NO. 17), expresses the HCV CKS-3'ENV antigen under control of the lac promoter. The HCV CKS-3ΕNV antigen consists of 239 amino acids of CKS, 7 amino acids contributed by linker DNA sequences, 207 amino acids from the HCV envelope region (amino acids 263-469), and 15 additional amino acids contributed by linker DNA sequences. Figure 39 presents a schematic representation of the pHCV-101 antigen. SEQ.ID.NO. 28 and 29 presents the DNA and amino acid sequence of the HCV CKS-3ΕNV recombinant antigen produced by pHCV-101. Figure 37 presents the expression of pHCV-101 proteins in E.coli Lane 7 contained the E.coli lysate containing pHCV-101 expressing the HCV CKS-3'E NV antigen (amino acids 263-469) prior to induction and lanes 8 and 9 after 2 and 4 hours induction, respectively. These resulting show that the pHCV-101 fusion protein has an apparent mobility corresponding to a molecular mass of 47,000 daltons. This compares acceptably to the predicted molecular mass of 51 ,181 daltons.
E. Preparation of HCV CKS-NS2
Using the methods detailed above, a 636 base pair DNA fragment from the putative NS2 region of HCV was generated by PCR. This fragment represents the HCV amino acids 994-1205 and was cloned into the CKS expression vector pJ0201 using EcoRI restriction sites. The resulting clone, designated pHCV-102, expresses the HCV CKS-NS2 antigen under control of the lac promoter. The HCV CKS-NS2 antigen consists of 239 amino acids of CKS, 7 amino acids contributed by linker DNA sequences, 212 amino acids from the HCV NS2 region (amino acids 994- 1205), and 16 additional amino acids contributed by linker DNA sequences. Figure 40 presents a schematic representation of the pHCV-102 antigen. SEQ.ID.NO. 30 and 31 presents the DNA and amino acid sequence of the HCV CKS-NS2 recombinant antigen produced by pHCV-102. Figure 41 presents the expression of pHCV-102 proteins in E.coli. Lane 1 contained the E.coli lysate containing pHCV-102 expressing the HCV CKS-NS2 antigen (amino acids 994-1205) prior to induction and lanes 2 and 3 after 2 and 4 hours induction, respectively. These results show that the pHCV-102 fusion protein has an apparent mobility corresponding to a molecular mass of 53,000 daltons. This compares acceptably to the predicted molecular mass of 51,213 daltons.
F. Preparation of HCV CKS-NS1
Using the methods detailed above, a 654 base pair DNA fragment from the putative NS1 region of HCV was generated by PCR. This fragment represents HCV amino acids 617-834 and was cloned into the CKS expression vector pJ0200 using EcoRI-BamHI restriction sites. The resulting clone, designated pHCV-107, expresses the HCV CKS-NS1 antigen under control of the Jac promoter. The HCV CKS-NS1 antigen consists of 239 amino acids of CKS, 10 amino acids contributed by linker DNA sequences, and 218 amino acids from the HCV NS1 region (amino acids 617-834). Figure 42 presents a schematic representation of the pHCV-107 antigen. SEQ.ID.NO. 32 and 33 presents the DNA and amino acid sequence of the HCV CKS-NS1 recombinant antigen produced by pHCV-107.
G. Preparation of HCV CKS-ENV
Using the methods detailed above, a 1068 base pair DNA fragment from the putative envelope region of HCV was generated by PCR. This fragment represents HCV amino acids #114-469 and was cloned into the CKS expression vector pJ0202 using EcoRI restriction sites. The resulting clone, designated pHCV-104, expresses the HCV CKS-ENV antigen under control of the lac promoter. The HCV CKS-ENV antigen consists of 239 amino acids of CKS, 7 amino acids contributed by linker DNA sequences, 356 amino acids from the HCV envelope region (amino acids 114- 469), and 15 additional amino acids contributed by linker DNA sequences. Figure 43 presents a schematic representation of the pHCV-104 antigen. SEQ.ID.NO. 34 and 35 presents the DNA and amino acid sequence of the HCV CKS-ENV recombinant antigen produced by pHCV-104.
EXAMPLE 10. HCV CKS-NS1S1
A. Construction of the HCV CKS-NS1S1 Expression Vector
Eight individual oligonucleotides representing amino acids 365-579 of the HCV genome were ligated together and cloned as a 645 base pair EcoRI/BamHI fragment into the CKS fusion vector pJO200. The amino acid sequence of this antigen is designated as pHCV-77 (SEQ. ID. NO. 1). The resultant fusion protein HCV CKS-NS1S1 consists of 239 amino acids of CKS, seven amino acids contributed by linked DNA sequences, and 215 amino acids from the NS1 region of the HCV genome.
B. Production and Characterization of the Recombinant Antigen HCV-NS1S1
pHCV-77 was transformed into E.coli K-12 strain XL-1 (recA1 , endA1 , gyrA96, thi-1 , hsdRl 7, SupE44, relA1 , Iac/f1 , p10AB, lacl1ADM15, TN10) cells. Expression analysis and characterization of the recombinant protein was done using polyacrylamide gel electrophoresis as described in Example 1. The apparent molecular weight of the pHCV-77 antigen was the same as the expected molecular weight of 50,228 as visualized on a coumassie stained gel. The immunoreactivity as determined by Western blot analysis using human sera indicated that this
recombinant antigen was indeed immunoreactive. FIGURE 47A presents the expression of pHCV-77 in E. coli. FIGURE 47B presents an immunoblot of the pHCV-77 antigen expressed in E. coli. Lane 1 contained the E. coli lysate containing pHCV-77 expressing the HCV CKS-NS1S1 antigen prior to induction and Lanes 2 and 3 are 2 and 4 hours post-induction, respectfully. EXAMPLE 11. HCV CKS-NS1S2
A. Construction of the HCV CKS-NS1S2 Expression Vector
Six individual oligonucleotides representing amino acids 565-731 of the HCV genome was ligated together and cloned as a 501 base pair EcoRI/BamHI fragment into the CKS fusion vector pJO200. The complete amino acid sequence of this antigen is designated as pHCV-65 (SEQ. ID. NO. 2). The resultant fusion protein HCV CKS-NS1S2 consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 167 amino acids from the NS1 region of the HCV genome.
B. Production and Characterization of the Recombinant Antigen HCV-NS1S2
pHCV-65 was transformed into E.coli K-12 strain XL-1 (recA1 , endA1 , gyrA96, thi-1 , hsdR17, SupE44, relAI , lac/f 1 , p10AB, laclqAMD15, TN10) cells. Expression analysis and characterization of the recombinant protein was done using polyacrylamide gel electrophoresis as described in Example 1. The apparent molecular weight of the pHCV-65 antigen was the same as the expected molecular weight of 46,223 as visualized on a coumassie stained gel. The immunoreactivity as determined by Western blot analyis using human sera indicated that this
recombinant antigen was indeed immunoreactive. FIGURE 48A presents the expression of pHCV-65 in E. coli. FIGURE 48B presents an immunoblot of the pHCV-65 antigen expressed in E. coli. Lane 1 contained the E. coli lysate containing pHCV-65 expressing the HCV CKS-NS1S2 antigen prior to induction and Lanes 2 and 3 are 2 and 4 hours post-induction, respectively. EXAMPLE 12. CKS-NS1S3
A. Construction of the HCV CKS-NS1S3 Expression Vector
Six individual oligonucleotides representing amino acids 717-847 of the HCV genome were ligated together and cloned as a 393 base pair EcoRI/BamHI fragment into the CKS fusion vector pJO200. The complete amino acid sequence of this antigen is designated as pHCV-78 (SEQ. ID. NO. 3). The resultant fusion protein HCV CKS-NS1S3 consists of 239 amino acids of CKS, eight amino acids contributed by linker DNA sequences, and 131 amino acids from the NS1 region of the HCV genome.
B. Production and Characterization of the Recombiant Antigen HCV-NS1S3
pHCV-78 was transformed into E.coli K-12 strain XL-1 (recA1 , endA1 , gyrA96, thi-1 , hsdR17, SupE44, relAI , lac/f 1 , p10AB, laclqADM15, TN10) cells. Expression analysis and characterization of the recombinant protein was done using polyacrylamide gel electrophoresis as described in Example 1. Analysis of the coumassie stained gel indicated very low levels of expression of the protein with an expected molecular weight of 42,1141. Western blot analysis also failed to show any immunoreactivity and we are continuing to identify human sera that is specific to this region of NS1.
EXAMPLE 13. CKS-NS1S1-NS1S2
A. Construction of the HCV CKS-NS1S1-NS1S2 Expression Vector
The construction of pHCV-80 (NS1S1-NS1S2) involved using the
SACI/BamHI insert from pHCV-65 and ligating that into the Sacl/BamHI vector backbone of pHCV-77. The resultant HCV gene represents amino acids 365-731 of the HCV genome. This resulted in a 1101 base pair EcoRI/BamHI fragment of HCV cloned into the CKS fusion vector pJO200. The complete amino acid sequence of this antigen is designated as pHCV-80 (SEQ. ID. NO. 4). The resultant fusion protein HCV CKS NS1S1-NS1S2 consists of 239 amino acids of CKS, seven amino acids contributed by linker DNA sequences, and 367 amino acids from the NS1 region of the HCV genome.
B. Production and Characterization of the Recombinant Antigen HCV-NS1S1-NS1S2 pHCV-80 was transformed into E.coli K-12 strain XL-1 (recA1, endA1, gyrA96, thi-1 , hsdR17, SupE44, relAI , lac/f 1 , p10AB, laclqADM15, TN10) cells.
Expression analysis and characterization of the recombinant protein was done using polyacrylamide gel electrophoresis as described in Example 1. The apparent molecular weight of the pHCV-80 antigen was the same as the expected molecular weight of 68,454 as visualized on a coumassie stained gel. The immunoreactivity as determined by Western blot analysis using human sera indicated that this
recombinant antigen was very immunoreactive. FIGURE 49A presents the expression of pHCV-80 in E. coli. FIGURE 49B presents an immunoblot of pHCV- 80 antigen expressed in E. coli. Lane 1 contained the E. coli lysate containing pHCV- 80 expressing the HCV CKS-NS1S1-NS1S2 antigen prior to induction and Lanes 2 and 3 are 2 and 4 hours post-induction, respectively.
EXAMPLE 14. HCV CKS-FULL LENGTH NS1
A. Construction of the HCV CKS-full length NS1 Expression Vector
The construction of pHCV-92 (SEQ. ID. NO. 5) full length NS1) involved using the Xhol/BamHI insert from pHCV-78 (SEQ. ID. NO. 3) and ligating that into the Xhol/BamHI vector backbone of pHCV-80 (SEQ. ID. NO. 4). The resultant HCV gene represents amino acids 365-847 of the HCV genome. This resulted in a 1449 base pair EcoRI/BamHI fragment of HCV cloned into CKS fusion vector pJO200. The complete amino acid sequence of this antigen is designated as pHCV-92 (SEQ. ID. NO. 5). The resultant fusion protein HCV CKS-full length NS1 consists of 239 amino acids of CKS, seven amino acids contributed by linker DNA sequences, and 483 amino acids from the NS1 region of the HCV genome.
B. Production and Characterization of the Recombinant Antigen pHCV-92
pHCV-92 was transformed into E.coli K-12 strain XL-1 (recA1 , endA1 , gyrA96, thi-1, hsdR17, SupE44, relAI , lac/f 1 , plOAB, laclqADM15, TN10) cells. Expression analysis and characterization of the recombinant protein was done using polyacrylameide gel electrophoresis as described in Example 1. The expression levels as seen by counassie stained gel were virtually undectable and the Western blot indicated no immunoreactivity. We are still in the process of identifying sera that will recognize this region of HCV NS1. The present invention thus provides unique recombinant antigens
representing distinct antigenic regions of the HCV genome which can be used as reagents for the detection and/or confirmation of antibodies and antigens in test samples from individuals exposed to HCV. The NS1 protein is considered to be a rron-structural membrane glycoproteiή and to be able to elicit a protective immune response of the host against lethal viral infection.
The recombinant antigens, either alone or in combination, can be used in the assay formats provided herein and exemplified in the Examples. It also is contemplated that these recombinant antigens can be used to develop specific inhibitors of viral replication and used for therapeutic purposes, such as for vaccines. Other applications and modifications of the use of these antigens and the specific embodiments of this inventions as set forth herein, will be apparent to those skilled in the art. Accordingly, the invention is intended to be limited only in accordance with the appended claims. SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: DEVARE, S.
DESAI, S.
DAI LEY, S.
(ii) TITLE OF INVENTION: HCV SYNTHETIC PEPTIDE FROM NS1 REGION
(iii) NUMBER OF SEQUENCES: 35
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: ABBOTT LABORATORIES
(B) STREET: ONE ABBOTT PARK ROAD
(C) CITY: ABBOTT PARK
(D) STATE: ILLINOIS
(E) COUNTRY: U.S.
(F) ZIP: 60065-3500
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentin Release #1.0, Version #1.25
(vi) CURRENT APPUCATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: POREMBSKI, PRISCILLA E.
(B) REGISTRATION NUMBER: 33,207
(C) REFERENCE/DOCKET NUMBER: 4834PC.02
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 708-937-6365
(B) TELEFAX: 708-937-9556
(2) INFORMATION FOR SEQ IP NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 463 amino acids
(B) TYPE: amino acid
(C) STRANOEPNESS: single
(P) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 :
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu 1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Thr Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Thr Met Val Gly Asn Trp Ala Lys Val Leu
245 250 255
Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu Thr His Val Thr
260 265 270
Gly Gly Ser Ala Gly His Thr Val Ser Gly Phe Val Ser Leu Leu Ala 275 280 285
Pro Gly Ala Lys Gln Asn Val Gln Leu lle Asn Thr Asn Gly Ser Trp 290 295 300 His Leu Asn Ser Thr Ala Leu Asn Cys Asn Asp Ser Leu Asn Thr Gly 305 310 315 320
Trp Leu Ala Gly Leu Phe Tyr His His Lys Phe Asn Ser Ser Gly Cys
325 330 335
Pro Glu Arg Leu Ala Ser Cys Arg Pro Leu Thr Asp Phe Asp Gln Gly
340 345 350
Trp Gly Gln lle Ser Tyr Ala Asn Gly Ser Gly Pro Asp Gln Arg Pro 355 360 365
Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly lle Val Pro Ala Lys 370 375 380
Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val Val 385 390 395 400
Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr Tyr Ser Trp Gly Glu Asn
405 410 415
Asp Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro Pro Leu Gly Asn
420 425 430
Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe Thr Lys Val Cys 435 440 445
Gly Ala Pro Pro Cys Val lle Gly Gly Ala Gly Asn Asn Thr Leu
450 455 460
(2) INFORMATION FOR SEQ ID N02:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 414 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID N02:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu 1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Thr Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Met Gly Ala Pro Pro Cys Val lle Gly Gly
245 250 255
Ala Gly Asn Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His
260 265 270
Pro Asp Ala Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp lle Thr Pro 275 280 285
Arg Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Thr Pro Cys Thr 290 295 300
lle Asn Thr Thr lle Phe Lys lle Arg Met Tyr Val Gly Gly Val Glu 305 310 315 320
His Arg Leu Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp
325 330 335
Leu Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Thr Thr
340 345 350 Thr Gln Trp Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu 355 360 365
Ser Thr Gly Leu lle His Leu Gly Gln Asn lle Val Asp Val Gln Tyr 370 375 380
Leu Tyr Gly Val Gly Ser Ser lle Ala Ser Trp Ala lle Lys Trp Glu 385 390 395 400
Tyr Val Val Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val
405 410
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 378 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
Met Ser Phe Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu Pro 1 5 10 15
Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His Val
20 25 30
Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala Thr 35 40 45
Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu Val 50 55 60
Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala Glu 65 70 75 80
Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn Val
85 90 95
Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val Ala
100 105 110
Asp Asn Leu Ala Gln Arg Gln Val Gly Met Thr Thr Leu Ala Val Pro 115 120 125
lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val Val 130 135 140
Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle Pro 145 150 155 160 Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp Asn 165 170 175
Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle Arg
180 185 190
Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met Leu 195 200 205
Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala Val 210 215 220
Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu Asp 225 230 235 240
Pro Ser Thr Asn Ser Thr Met Glu Tyr Val Val Leu Leu Phe Leu Leu
245 250 255
Leu Ala Asp Ala Arg Val Cys Ser Cys Leu Trp Met Met Leu Leu lle
260 265 270
Ser Gln Ala Glu Ala Ala Leu Glu Asn Leu Val lle Leu Asn Ala Ala 275 280 285
Ser Leu Ala Gly Thr His Gly Leu Val Ser Phe Leu Val Phe Phe Cys 290 295 300
Phe Ala Trp Tyr Leu Lys Gly Lys Trp Val Pro Gly Ala Val Tyr Thr 305 310 315 320
Phe Tyr Gly Met Trp Pro Leu Leu Leu Leu Leu Leu Ala Leu Pro Gln
325 330 335
Arg Ala Tyr Ala Leu Asp Thr Glu Val Ala Ala Ser Cys Gly Gly Val
340 345 350
Val Leu Val Gly Leu Met Ala Leu Thr Leu Ser Pro Tyr Tyr Lys Arg 355 360 365
Tyr lle Ser Trp Cys Leu Trp Trp Leu Gln
370 375
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 622 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu 1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Thr Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Thr Met Val Gly Asn Trp Ala Lys Val Leu
245 250 255
Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu Thr His Val Thr
260 265 270
Gly Gly Ser Ala Gly His Thr Val Ser Gly Phe Val Ser Leu Leu Ala 275 280 285
Pro Gly Ala Lys Gln Asn Val Gln Leu lle Asn Thr Asn Gly Ser Trp 290 295 300
His Leu Asn Ser Thr Ala Leu Asn Cys Asn Asp Ser Leu Asn Thr Gly 305 310 315 320 Trp Leu Ala Gly Leu Phe Tyr His His Lys Phe Asn Ser Ser Gly Cys
325 330 335
Pro Glu Arg Leu Ala Ser Cys Arg Pro Leu Thr Asp Phe Asp Gln Gly
340 345 350 Trp Gly Gln lle Ser Tyr Ala Asn Gly Ser Gly Pro Asp Gln Arg Pro 355 360 365
Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly lle Val Pro Ala Lys 370 375 380
Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val Val 385 390 395 400
Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr Tyr Ser Trp Gly Glu Asn
405 410 415
Asp Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro Pro Leu Gly Asn
420 425 430 Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe Thr Lys Val Cys 435 440 445
Gly Ala Pro Pro Cys Val lle Gly Pro Pro Cys Val lle Gly Gly Ala 450 455 460
Gly Asn Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro 465 470 475 480
Asp Ala Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp lle Thr Pro Arg
485 490 495
Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr lle
500 505 510
Asn Tyr Thr lle Phe Lys lle Arg Met Tyr Val Gly Gly Val Glu His 515 520 525
Arg Leu Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu 530 535 540
Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Thr Thr Thr 545 550 555 560 Gln Trp Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser
565 570 575
Thr Gly Leu lle His Leu His Gln Asn lle Val Asp Val Gln Tyr Leu
580 585 590 Tyr Gly Val Gly Ser Ser lle Ala Ser Trp Ala lle Lys Trp Glu Tyr 595 600 605
Val Val Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Xaa
610 615 620
(2) INFORMATION FOR SEQ ID NOS:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 738 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NOS:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu 1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Thr Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Thr Met Val Gly Asn Trp Ala Lys Val Leu
245 250 255
Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu Thr His Val Thr
260 265 270
Gly Gly Ser Ala Gly His Thr Val Ser Gly Phe Val Ser Leu Leu Ala 275 280 285
Pro Gly Ala Lys Gln Asn Val Gln Leu lle Asn Thr Asn Gly Ser Trp 290 295 300
His Leu Asn Ser Thr Ala Leu Asn Cys Asn Asp Ser Leu Asn Thr Gly 305 310 315 320 Trp Leu Ala Gly Leu Phe Tyr His His Lys Phe Asn Ser Ser Gly Cys
325 330 335
Pro Glu Arg Leu Ala Ser Cys Arg Pro Leu Thr Asp Phe Asp Gln Gly
340 345 350 Trp Gly Gln lle Ser Tyr Ala Asn Gly Ser Gly Pro Asp Gln Arg Pro 355 360 365
Tyr Cys Trp His Tyr Pro Pro Lys Pro Cys Gly lle Val Pro Ala Lys 370 375 380
Ser Val Cys Gly Pro Val Tyr Cys Phe Thr Pro Ser Pro Val Val Val 385 390 395 400
Gly Thr Thr Asp Arg Ser Gly Ala Pro Thr Tyr Ser Trp Gly Glu Asn
405 410 415
Asp Thr Asp Val Phe Val Leu Asn Asn Thr Arg Pro Pro Leu Gly Asn
420 425 430 Trp Phe Gly Cys Thr Trp Met Asn Ser Thr Gly Phe Thr Lys Val Cys 435 440 445
Gly Ala Pro Pro Cys Val lle Gly Pro Pro Cys Val lle Gly Gly Ala 450 455 460
Gly Asn Asn Thr Leu His Cys Pro Thr Asp Cys Phe Arg Lys His Pro 465 470 475 480 Asp Ala Thr Tyr Ser Arg Cys Gly Ser Gly Pro Trp lle Thr Pro Arg 485 490 495
Cys Leu Val Asp Tyr Pro Tyr Arg Leu Trp His Tyr Pro Cys Thr lle
500 505 510
Asn Tyr Thr lle Phe Lys lle Arg Met Tyr Val Gly Gly Val Glu His 515 520 525
Arg Leu Glu Ala Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu 530 535 540
Glu Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Thr Thr Thr 545 550 555 560 Gln Trp Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Ser
565 570 575
Thr Gly Leu lle His Leu His Gln Asn lle Val Asp Val Gln Tyr Leu
580 585 590
Tyr Gly Val Gly Ser Ser lle Ala Ser Trp Ala lle Lys Trp Glu Tyr 595 600 605
Val Val Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg Val Cys Ser Cys 610 615 620
Leu Trp Met Met Leu Leu lle Ser Gln Ala Glu Ala Ala Leu Glu Asn 625 630 635 640
Leu Val lle Leu Asn Ala Ala Ser Leu Ala Gly Thr His Gly Leu Val
645 650 655
Ser Phe Leu Val Phe Phe Cys Phe Ala Trp Tyr Leu Lys Gly Lys Trp
660 665 670
Val Pro Gly Ala Val Tyr Thr Phe Tyr Gly Met Trp Pro Leu Leu Leu 675 680 685
Leu Leu Leu Ala Leu Pro Gln Arg Ala Tyr Ala Leu Asp Thr Glu Val 690 695 700
Ala Ala Ser Cys Gly Gly Val Val Leu Val Gly Leu Met Ala Leu Thr 705 710 715 720
Leu Ser Pro Tyr Tyr Lys Arg Tyr lle Ser Trp Cys Leu Trp Trp Leu
725 730 735 Gln Xaa
(2) INFORMATION FOR SEQ IP NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 4481 base pairs (B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 130..1317
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
GAA TTAATTC CCATTAATGT GAGTTAG CTC ACTCATTAGG CACCCCAGGC TTT ACACTTT 60
ATGTT CCG GC TCGTATTTTG TGTGGAATTG TGAGCGGATA ACAATT GGGC ATCCAGTAAG 120
GAGGTTT AA ATGAGTTTT GTG GTCATT ATT CCC GCG CGC TAC GCG TCG 168
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser
1 5 10
ACG CGT CTG CCC GGT AAA CCA TT G GTT GAT ATT AAC GGC AAA CCC ATG 216 Thr Arg Leu Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met
15 20 25
ATT GTT CAT GTT CTT GAA CGC GCG CGT GAATCA GGT GCC GAG CGC ATC 264 lle Val His Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle
30 35 40 45
ATC GTG GCA ACC GAT CAT GAG GAT GTT GCC CGC GCC GTT GAA GCC GCT 312 lle Val Ala Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala
50 55 60
GGC GGT GAA GTA TGT ATG ACG CGC GCC GAT CAT CAG TCA GGA ACA GAA 360 Gly Gly Glu Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu
65 70 75
CGT CTG GCG GAA GTT GTC GAA AAA TGC GCA TTC AGC GAC GAC ACG GTG 408 Arg Leu Ala Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val
80 85 90
ATC GTT AAT GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT 456 lle Val Asn Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle
95 100 105
CGT CAG GTT GCT GAT AAC CTC GCT CAG CGT CAG GTG GGT ATG GCG ACT 504 Arg Gln Val Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr
110 115 120 125
CTG GCG GTG CCA ATC CAC AAT GCG GAA GAA GCG TTT AAC CCG AAT GCG 552 Leu Ala Val Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala
130 135 140
GTG AAA GTG GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TTC TCT CGC 600 Val Lys Val Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg
145 150 155 GCC ACC ATT CCT TGG GAT CGT GAT CGT TTT GCA GAA GGC CTT GAA ACC 648 Ala Thr lle Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr
160 165 170
GTT GGC GAT AAC TTC CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA 696 Val Gly Asp Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala
175 180 185
GGC TTT ATC CGT CGT TAC GTC AAC TGG CAG CCA AGT CCG TTA GAA CAC 744 Gly Phe lle Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His
190 195 200 205
ATC GAA ATG TTA GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC 792 lle Glu Met Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle
210 215 220
CAT GTT GCT GTT GCT CAG GAA GTT CCT GGC ACA GGT GTG GAT ACC CCT 840 His Val Ala Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro
225 230 235
GAA GAT CTC GAC CCG TCG ACG AAT TCC ATG TCT ACC AAC CCG AAA CCG 888 Glu Asp Leu Asp Pro Ser Thr Asn Ser Met Ser Thr Asn Pro Lys Pro
240 245 250
CAG AAA AAA AAC AAA CGT AAC ACC AAC CGT CGT CCG CAG GAC GTT AAA 936 Gln Lys Lys Asn Lys Arg Asn Thr Asn Arg Arg Pro Gln Asp Val Lys
255 260 265
TTC CCG GGT GGT GGT CAG ATC GTT GGT GGT GTT TAC CTG CTG CCG CGT 984 Phe Pro Gly Gly Gly Gln lle Val Gly Gly Val Tyr Leu Leu Pro Arg
270 275 280 285
CGT GGT CCG CGT CTG GGT GTT C GT GCT ACG CGT AA ACC TCT GAA CGT 1032 Arg Gly Pro Arg Leu Gly Val Arg Ala Thr Arg Lys Thr Ser Glu Arg
290 295 300
TCT CAG CCG CGT GGG CGT CGT CAG CCG ATC CCG AAA GCT CGT CGT CCG 1080 Ser Gln Pro Arg Gly Arg Arg Gln Pro lle Pro Lys Ala Arg Arg Pro
305 310 315
GAA GGT CGT ACC TGG GCT CAG CCG GGT TAC CCG TGG CCG CTG TAC GGT 1128 Glu Gly Arg Thr Trp Ala Gln Pro Gly Tyr Pro Trp Pro Leu Tyr Gly
320 325 330
AAC GAA GGT TGC GGT TGG GCT GGT TGG CTG CTG TCT CCG CGT GGA TCT 1176 Asn Glu Gly Cys Gly Trp Ala Gly Trp Leu Leu Ser Pro Arg Gly Ser
335 340 345
CGT CCG TCT TGG GGT CCG ACC GAC CCG CGT CGT CGT TCT CGT AAC CTT 1224 Arg Pro Ser Trp Gly Pro Thr Asp Pro Arg Arg Arg Ser Arg Asn Leu
350 355 360 365
GGTAAAGTTATCGAT ACC CTG ACC TGC GGT TTC GCT GAC CTG ATG GGT 1272 Gly Lys Val lle Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met Gly 370 375 380
TAC ATA CCG CTG GTT GGA GCT CCG CTG GGT GGT GCT GCT CGT GCT 1317
Tyr lle Pro Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg Ala
385 390 395
TAACC CATGG ATCCTCTAGA CTGCAGGCAT GCTAAGTAAG TAGATCTTG AGCGCGTTCGC 1377
GCTGAAATGC GCTAATTTCA CTCT ACGACACTCAGCCAA TTTTGGGAGG AGTGTCGTAC 1437
CGTTACGATT TTCCTC AATT TTTCTTTTCA ACAATTGATC TCATTCAGGT GAC ATCTTTT 1497
ATATTGGCGC TCATTATGAA AGCAGTAGCT TTTATGAGGG TAATCTGAAT GGAACAGCTG 1557 CGTGCCGAAT TAAGCCATTT ACTGGGCGAAAAACTCAGTCGTATTGAGTGCGTCAATGAA 1617
AAAGC GGA TA CGG CGTT GTG GGCTTTGTATGACAGCCAGG GAAACCCAATGCGTTAATG 1677
GCAAGAAGCT TAGCCCGCCT AATGAGCGGGCT T T T T T T TCGACGCGAGGCTGGATGGCCT 1737
TCCCCATTAT GATTCTTCTC GCTTCCGGCGGCATCGGGATGCCCGCGTTGCAGGCCATGC 1797
TGTCCAGGCA GGTAGATGAC GACCATCAGG GACAGCTTCA AGGATCGCTC GCGGCTCTTA 1857
CCAGCCTAAC TTCGATCA CT GGACCGCTGATCGTCACGGCGATTTATGCCGCCTCGGCGA 1917
GCACATGGAA CGGGTT GGCA TGGATT GTAGGCGCCGCCCT ATACCTTGTCTGCCTCCCCG 1977
CGTT GCGTCG CGGTGCATGG AGCCGGGC CACCTCGACCTGAATGGAAGCC GGCGGCACCT 2037
CGCTAACGGA TT CACCACTC CAAGAATT GG AGCC AATCAATTCTTGCGGAGAACTGTGAA 2097
TGCGCAAACC AACCCTTGGC AGAACATATC CATCGCGTCCGCCATCTCCAGCAGCCGCAC 2157
GCGGCGCATC TCGGGCAGCG TT GGGTCCTGGCCACGGCTGCGCATGATCGTGCTCCTGTC 2217
GTTGAGGA CC CGGCTAGGCT GGCGGGGTTGCCTTACTGGTTAGCAGAATGAATCACCGAT 2277
ACGCGAGCGA ACGTGAAGC G ACTGCTGCTG CAAAACGTCTGCGACCTGAGCAACAACATG 2337 AATGGTCTTC GGTTTCCGTG TTTCGTAAAGTCTGGAAACG CGGAAGTCAGCGCCCTGCAC 2397
CATT ATGTTC C GGATCTGCA TC GCAGGATGCTGCTGGCTACCCTGTGGAA 2457
TGTATT AACG AAGCGCTTCTTCCGCTT CCTCGCTCACTGA CTCGCTGCGC TCGGTCGTTC 2517 GGCTGCGGC G AGCGGTATCA GCTCACTCAA AGGCGGTAA TACGGTTATCC ACAGAATCAG 2577
GGGATAACGC AGGAAAGAAC ATGTGAGC AA AAGGCCA GCA AAAGGCCAGG AACCGTAAAA 2637
AG GCCGC GTT GCTGGCGTTT TT CC TAGGCTCCGCCCCCC TGACGAGCAT CACAAAAATC 2697
GACGCTCAAG TCAGAGGTGG CGAAA CCCGACAGGACTATA AAGATACCAG GCGTTTCCCC 2757
CTGGAAGCTC CCTCGTGCGC TCTCCTGTT COGACCCTGCC GCTTACCGGA TACCTGTCCG 2817 CCTTTCTCCC TTCGGGAAGC GTGGCGCTTT CTCAATGCTC ACGCTGTAGG TATCTCAGTT 2877 CGGTGTAGGT CGTTCGCTCC AAGCTGGGCT GTGTGCACGA ACCCCCCGTTCAGCCCGACC 2937
GCTGCGCC TT ATCCG GTAAC TATCG TCTT G AGTCCAACCC GGTAAGACACGACTTATCGC 2997
CACTGGCAGC AGCCACTGGT AACAGGATTAGC AGAGCGAG GTATGTAGGCGGTGCTACAG 3057
AGTTCTTGAA GTGGTGGCCT AACTACGGCT ACACTAGAAG GACAGTATTT GGTATCTGCG 3117
CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GA GTTGGTAG CTCTT GATCCGGCAAACAAA 3177
CCACCGCTGG TAGCGGTGGT T T T T T TGT T T GCAAGCAGCAGATTACGCGCAGAAAAAAAG 3237 GATCTCAAGA AGATCCTTTG ATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACT 3297
CACGTTAAGG GATTTTGGTC ATGAGATTAT CAAAAAGGAT CTTCACCTAG ATCCTTTTAA 3357 ATTAAAAATG AAGTTTTAAA TCAATCTAAA GTATATATGA GTAAACTTGG TCTGACAGTT 3417 ACCAATGCTT AATCAGTGAG GCACCTATCT CAGCGATCTGTCTATTTCGTTCATCCATAG 3477 TTGCCTGACT CCCCGTCG TG TAGATAACTA CGATACGGGGAGGGCTTACCATCTGGCCCCA 3537 GTGCTGCAAT GATACCGCGA GACC CACGCT CACCGGCTCCAGATTTATCAGCAATAAACC 3597
AGCCAGCCGG AAGGGCCGAG CGC AGAAGTG GTCCTGCAACTTTATCCGCCTCCATCCAGT 3657
CTATTAATT G TTGCCGGGAA GCTAGAGTAA GTAGTTCGCCAGTTAATAGTTTGCGCAACG 3717 TTGTTTGCCAT TGCTACAGGC ATCGTGGTGT CACGCTCGTC GTTTGGTATG GCTTCATTCA 3777 GCTCCGGTTC CC AACGATCA AGGCGAGTTA CATGATCCCC CATGTTGTGCAAAAAAGCGG 3837
TTAGCTCCTT CGGTCCTCCG ATCGTTGTCA GAAGTAAGTTGGCCGCAGTGTTATCACTCA 3897
TGG TTATGGC AGCACTGCAT AATTCTCTT A CTGTCATGCCATCCG TAAGATGCTTTTCTG 3957 TGACTGGTGA GTACTCAACC AAGTCATTCT GAGAATAGTG TATGCGGCGACCGAGTTGCT 4017 CTTGCCCGGC GTCAACACGG GATAATACCG CGCCACATAGCAGAACTTTAAAAGTGCTCA 4077
TCATTGGAAA ACOTT CTTCG GGGCGAAAAC TCTCAAGGATCTTACCGCTGTTGAGATCCA 4137 GTTCGATGTA ACCC ACTC GT GCACCCAACT GATCTTCAGCATCTTTTACTTTCACCAGCG 4197
TTTCTGGGTG AGCAAAAACA GGAAGGCAAA ATGC CGCAAA AAAGGGAATAAGGGCGACAC 4257
GGAAATGTTG AATACTCATA CTCTTCCTTT TTCAATATTATT GAAGCATTTATCAGGGTT 4317 ATTGTCTCAT GAGCGGATAC ATATTTGAAT GTATTTAGAA AAATAAACAA ATAGGGGTTC 4377 CGCGCACATT TCCCCGAAAA GTGCCACCTG ACGTCTAAGAAACCATTATT ATCATGACAT 4437 TAACCTATAA AAATAGGCGT ATCACGAGGC CCTTTCGTCT TCAA 4481
(2) INFORMATION FOR SEQ ID NO:7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 396 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Met Ser Thr Asn Pro Lys Pro Gln Lys Lys
245 250 255
Asn Lys Arg Asn Thr Asn Arg Arg Pro Gln Asp Val Lys Phe Pro Gly
260 265 270
Gly Gly Gln lle Val Gly Gly Val Tyr Leu Leu Pro Arg Arg Gly Pro
275 280 285
Arg Leu Gly Val Arg Ala Thr Arg Lys Thr Ser Glu Arg Ser Gln Pro
290 295 300
Arg Gly Arg Arg Gln Pro lle Pro Lys Ala Arg Arg Pro Glu Gly Arg
305 310 315 320
Thr Trp Ala Gln Pro Gly Tyr Pro Trp Pro Leu Tyr Gly Asn Glu Gly
325 330 335
Cys Gly Trp Ala Gly Trp Leu Leu Ser Pro Arg Gly Ser Arg Pro Ser
340 345 350
Trp Gly Pro Thr Asp Pro Arg Arg Arg Ser Arg Asn Leu Gly Lys Val
355 360 365
lle Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr lle Pro
370 375 380
Leu Val Gly Ala Pro Leu Gly Gly Ala Ala Arg Ala
385 390 395
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5600 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 130..2472
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:
GAATTAATTC CCATTAATGT GAGTTAGCTC ACTCATTAGG CACCCCAGGC TTTACACTTT 60
ATGTT CCG GCTCGTATTTTG TGTGGAATTGTGAGCGGATAACAATTGGGC ATCCAGTAAG 120 GAGGTTTAAATGAGTTTTGTG GTCATTATTCCCGCGCGCTACGCGTCG 168 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser
1 5 10
ACG CG T CTG CCC G GT AAA CCA TTG GTT GAT ATT AAC GGC AAA CCC ATG 216 Thr Arg Leu Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met
15 20 25
ATT GTT CAT GTT CTT GAA CGC GCG CGT GAA TCA GGT GCC GAG CGC ATC 264 lle Val His Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle
30 35 40 45
ATC GTG GCA ACC GAT CAT GAG GAT GTT GCC CGC GCC GTT GAA GCC GCT 312 lle Val Ala Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala
50 55 60
GGC GGT GAA GTA TGT ATG ACG CGC GCC GAT CAT CAG TCA GGA ACA GAA 360 Gly Gly Glu Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu
65 70 75
CGT CTG GCG GAA GTT GTC GAA AAA TGC GCA TTC AGC GAC GAC ACG GTG 408 Arg Leu Ala Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val
80 85 90
ATC GTT AAT GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT 456 lle Val Asn Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle
95 100 105
CGT CAG GTT GCT GAT AAC CTC GCT CAG CGT CAG GTG GGT ATG GCGA CT 504 Arg Gln Val Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr
110 115 120 125
CTG GCG GTG CCA ATC CAC AAT GCG GAA GAA GCG TTT AAC CCG AAT GCG 552 Leu Ala Val Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala
130 135 140 GTG AAA GTG GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TTC TCT CGC 600 Val Lys Val Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg
145 150 155
GCC ACC ATT CCT TGG GAT CGT GAT CGT TTT GCA GAA GGC CTT GAA ACC 648 Ala Thr lle Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr
160 165 170
GTT GGC GAT AAC TTC CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA 696 Val Gly Asp Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala
175 180 185
GGC TTT ATC CGT CGT TAC GTC AAC TGG CAG CCA AGT CCG TTA GAA CAC 744 Gly Phe lle Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His
190 195 200 205
ATC GAA ATG TTA GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC 792 lle Glu Met Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle
210 215 220 CAT GTT GCT GTT GCT CAG GAA GTT CCT GGC ACA GGT GTG GAT ACC CCT 840 His Val Ala Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro
225 230 235
GAA GAT CTC GAC CCG TC G ACG AAT TCC ATG GCT GTT GAC TTT ATC CCG 888 Glu Asp Leu Asp Pro Ser Thr Asn Ser Met Ala Val Asp Phe lle Pro
240 245 250
GTT GAA AAT CTC GAG ACT ACT ATG CGT TCT CCG GTT TTC ACT GAC AAC 936 Val Glu Asn Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn
255 260 265
TCT TCT CCG CCG GTT GTT CCG CAG TCT TTC CAG GTT GCT CAC CTG CAT 984 Ser Ser Pro Pro Val Val Pro Gln Ser Phe Gln Val Ala His Leu His
270 275 280 285
GCT CCG ACT GGT TCT GGT AAA TCT ACT AAA GTT CCA GCT GCT TAC GCT 1032 Ala Pro Thr Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala
290 295 300
GCT CAG GGTTAC AAA GTT CTG GTT CTG AAC CCG TCT GTT GCT GCT ACT 1080 Ala Gln Gly Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr
305 310 315
CTG GGT TTC GGC GCC TAC ATG TCT AAA GCT CAC GGT ATC GAC CCG AAC 1128 Leu Gly Phe Gly Ala Tyr Met Ser Lys Ala His Gly lle Asp Pro Asn
320 325 330
ATT CGT ACT GGT GTA CGT ACT ATC ACT ACT GGT TCT CCG ATC ACT TAC 1176 lle Arg Thr Gly Val Arg Thr lle Thr Thr Gly Ser Pro lle Thr Tyr
335 340 345
TCT ACT TAC GGT AAA TTC CTG GCT GAC GGT GGT TGC TCT GGT GGT GCT 1224 Ser Thr Tyr Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala
350 355 360 365
TAC GAT ATC ATC ATC TGC GAC GAA TGC CAC TCT ACT GAC GCT ACT TCT 1272 Tyr Asp lle lle lle Cys Asp Glu Cys His Ser Thr Asp Ala Thr Ser
370 375 380
ATC CTG GGT ATC GGT ACC GTT CTG GAC CAG GCT GAA ACT GCA GGT GCT 1320 lle Leu Gly lle Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala
385 390 395
CGT CTG GTT GTT CTG GCT ACT GCT ACT CCG CCG GGTTCT GTT ACT GTT 1368 Arg Leu Val Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val
400 405 410
CCG CAC CCG AAC ATC GAA GAA GTTGCT CTG TCG ACT ACT GGT GAA ATC 1416 Pro His Pro Asn lle Glu Glu Val Ala Leu Ser Thr Thr Gly Glu lle
415 420 425
CCG TT C TAC GGT AAA GCT ATC CCG CTC GAG GTT ATC AAA GGT GGT CGT 1464 Pro Phe Tyr Gly Lys Ala lle Pro Leu Glu Val lle Lys Gly Gly Arg 430 435 440 445
CAC CTG ATT TTC TGC CAC TCT AAA AAA AAA TGC GAC GAA CTG GCT GCT 1512 His Leu lle Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala
450 455 460 AAG CTT GTT GCT CTG GGT ATC AAC GCT GTT GCTTACTAC CGT GGT CTG 1560 Lys Leu Val Ala Leu Gly lle Asn Ala Val Ala Tyr Tyr Arg Gly Leu
465 470 475
GAC GTT TCT GTT ATC CCG ACT TCT GGT GAC GTT GTT GTT GTG GCC ACT 1608 Asp Val Ser Val lle Pro Thr Ser Gly Asp Val Val Val Val Ala Thr
480 485 490
GAC GCT CTG ATG ACT GGTTAC ACT GGT GAC TTC GAC TCT GTT ATC GAT 1656 Asp Ala Leu Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val lle Asp
495 500 505
TGC AAC ACT TGC AAT TCG TCG ACC GGT TGC GTT GTT ATC GTT GGT CGT 1704 Cys Asn Thr Cys Asn Ser Ser Thr Gly Cys Val Val lle Val Gly Arg
510 515 520 525
GTT GTT CTG TCT GGT AAA CCG GCC ATT ATC CCG GAC CGT GAA GTT CTG 1752 Val Val Leu Ser Gly Lys Pro Ala lle lle Pro Asp Arg Glu Val Leu
530 535 540
TAC CGT GAG TTC GAC GAA ATG GAA GAA TGC TCT CAG CAC CTG CCG TAC 1800 Tyr Arg Glu Phe Asp Glu Met Glu Glu Cys Ser Gln His Leu Pro Tyr
545 550 555
ATC GAA CAG GGT ATG ATG CTG GCT GAA CAG TTC AAA CAG AAA GCT CTG 1848 lle Glu Gln Gly Met Met Leu Ala Glu Gln Phe Lys Gln Lys Ala Leu
560 565 570
GGT CTG CTG CAG ACC GCT TCT CGT CAG GCT GAA GTT ATC GCT CCG GCT 1896 Gly Leu Leu Gln Thr Ala Ser Arg Gln Ala Glu Val lle Ala Pro Ala
575 580 585
GTT CAG ACC AAC TGG CAG AAA CTC GAG ACC TTC TGG GCT AAA CAC ATG 1944 Val Gln Thr Asn Trp Gln Lys Leu Glu Thr Phe Trp Ala Lys His Met
590 595 600 605
TGG AAC TTC ATC TCT GGT ATC CAG TAC CTG GCT GGT CTG TCT ACC CTG 1992 Trp Asn Phe lle Ser Gly lle Gln Tyr Leu Ala Gly Leu Ser Thr Leu
610 615 620
CCG GGT AAC CCG GCT ATC GCA AGC TTG ATG GCT TTC ACC GCT GCT GTT 2040 Pro Gly Asn Pro Ala lle Ala Ser Leu Met Ala Phe Thr Ala Ala Val
625 630 635
ACC TCT CCG CTG ACC ACC TCT CAG ACC CTG CTG TTC AAC ATT CTG GGT 2088 Thr Ser Pro Leu Thr Thr Ser Gln Thr Leu Leu Phe Asn lle Leu Gly
640 645 650
GGT TGG GTT GCT GCT CAG CTG GCT GCT CCG GGT GCT GCT ACC GCTTT C 2136 Gly Trp Val Ala Ala Gln Leu Ala Ala Pro Gly Ala Ala Thr Ala Phe
655 660 665
GTT GGT GCT GGT CTG GCT GGT GCT GCT ATC GGT TCT GTA GGC CTG GGT 2184 Val Gly Ala Gly Leu Ala Gly Ala Ala lle Gly Ser Val Gly Leu Gly
670 675 680 685
AAA GTT CTG ATC GAC ATT CTG GCT GGT TAC GGT GCT GGT GTT GCT GGA 2232 Lys Val Leu lle Asp lle Leu Ala Gly Tyr Gly Ala Gly Val Ala Gly
690 695 700
GCT CTG GTT GCT TTC AAA ATC ATG TCT GGT GAA GTT CCG TCT ACC GAA 2280 Ala Leu Val Ala Phe Lys lle Met Ser Gly Glu Val Pro Ser Thr Glu
705 710 715
GAT CTG GTT AAC CTG CTG CCG GCT ATC CTG TCT CCG GGT GCT CTG GTT 2328 Asp Leu Val Asn Leu Leu Pro Ala lle Leu Ser Pro Gly Ala Leu Val
720 725 730
GTT GGT GTT GTT TGC GCT GCT ATC CTG CGT CGT CAC GTT GGC CCG GGT 2376 Val Gly Val Val Cys Ala Ala lle Leu Arg Arg His Val Gly Pro Gly
735 740 745
GAA GGT GCT GTT CAG TGG ATG AAC CGT CTG ATC GCT TTC GCT TCT CGT 2424 Glu Gly Ala Val Gln Trp Met Asn Arg Leu lle Ala Phe Ala Ser Arg
750 755 760 765
GGT AAC CAC GTT TCT CCA TGG GAT CCT CTA GAC TGC AGGCATGCTAAG 2472 Gly Asn His Val Ser Pro Trp Asp Pro Leu Asp Cys Arg His Ala Lys
770 775 780
TAAGTAGATC TTGAGCGCGT TCGCGCTGAA ATGCGCTAAT TTCACTTCAC GACACTTCAG 2532 CCAATTTTGG GAGGAGTGTC GTACCGTTAC GATTTTCCTC AATTTTTCTT TTCAACAATT 2592 GATCTCATTCAGGTGACATCTTTTATATTG GCGCTCATTA TGAAAGCAGT AGCTTTTATG 2652 AGGGTAATCT GAATGGAACAGCTGCGTGCCGAATTAAGCC ATTTACTGGGCGAAAAACTC 2712 AGTCGTATTG AGTGCCGTCAA TGAAAAAGCG GATACGGCGTTGTGGGCTTTGTATGACAGC 2772
CAGGGAAACC CAATGCCGTT AATGG CAAGAAGCTTAGCCCGCCTAATGAGCGGGCTTTTT 2832
TTTCGACGCG AGGCTGGATGGCCTTCCCCATTATGATTCTTCTCGCTTCCGGCGGCATCG 2892
GGATGCCCGC GTTGCAGGCCATGCTGTCCAGGCAGGTAGATGACGACCATCAGGGACAGC 2952
TTCAAGGATC GCTCGCGG CTCTTACCAGCCTAACTTCGATCACTGGACCGCTGATCGTCA 3012
CGGCGATTTA TGCCGCCTCGGCGAGCACATGGAACGGGTTGGCATGGATTGTAGGCGCCG 3072
CCCTATACCT TGTCTGCCTCCCCGCGTT GCGnOGCGGTGCATGGAGCCGGGCCACCTCGA 3132
CCTGAATGGA AGCCGGCGGCACCTCGC TAA CGGATTCACCACTCCAAGAATTGGAGCCAA 3192 TCAATTCTTG CGGAGAACTG TGAATGCGCA AACC AACCC T TGGCAGAACA TATCCATCGC 3252
GTCCGCATC TCCAGCAGCC GCACGCGGCG CATCTCGGGC AGCGTTGGGT CCTGGCCACG 3312 GGTGCGCATG ATCGTGCTCC TGTCG TTGAG GACCCGGCTA GGCTGGCGGG GTTGCCTTAC 3372
TGGTTT AGCAG AATGAATCAC CGATACGCGA GCGAACGTGA AGCGACTGCT GCTGCAAAAC 3432
GTCTGCGACCTGAGCAACAACATGAATGGTCTTCGGTTTCCGTGTTTCGTAAAGTCTGGA 3492
AACGCGGAAGTCAGCCGCCCTGCA CC ATTAT GTTCCGGATCTGCATCGCAGGATGCTGCTG 3552
GCTACCCTGTGGAACACCTACATCTGTATTAACGAAGCGCTTCTTCCGCTTCCTCGCTCA 3612
CTGACTCGCTGCGCTCGGTCGTT CGGCTGCGGCGAG CGGTATCAGCTCACTCAAAGGCGG 3672
TAATACGGTT ATCCACAGAA TCAGGGGATAACGGCAGAAAGAACATGTGAGCAAAAGGCC 3732
AGCAAAAGGCCAGGAACCGTAAAAAGGCC GC GTTGCTGGCGT T T T TCCATAGGCTCCGCC 3792
CCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGAC 3852
TATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCC 3912
TGCCGCT TACCGGATACCTGTCCCGCCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAAT 3972
GCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGT CGTTCGCTCCAAGCTGGGCTGTGTGC 4032
ACGAACCCCCCGTT CAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCA 4092
ACCCGGTAAGACAC GACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAG 4152
CGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTAGACTA 4212
GAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCV.GTTACCTTCGGAAAAAGAGTTG 4272 GTAGCTCTTGATCCGGCAAA CAAACC ACCGCTGGTAGCGGTGGT T T T T T T GTTTGCAAGC 4332 AGCAGATT ACGCGCAGAAAA AAAGGATCTCAAGAAGATCC TTT GATCTTT TCTACGGGGT 4392 CTGACGCTCAGTGGAACGAA AACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAA 4452
GGATCTTCAC CTAGATCCTT TTAAATTAAA AATGAA GTTT TAAATCAATC TAAAGTATAT 4512 ATGAGTAAAC TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA 4572 TCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATAC 4632 GGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGG 4692
CTCCAGATTT ATCAG CAATAAACC AGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTG 4752
CAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTT 4812 CGCCAGTTAA TAGTTTGCGC AACGTTGTTGCCATTGCTAC AGGCATCGTG GTGTCACGCT 4872 CGTCGTT T GG TATGGCTT CA TT CAGCTCCG G TTCCCAACG ATCAAGGCGA GTTACATGAT 4932
CCCCCATGTT GTGCAAAAAA GCGGTT AGCTCCTTCGGTCC TCCGATCGTT GTCAGAAGTA 4992
AGTTGGCCGC AGTGTTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA 5052 TGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTC ATTCTGAGAA T 5112 AGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAACACGGGATAATACCGCGCCAC 5172
ATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTT CTTC GGGGCGAAAACTCTCAA 5232 GGATCTTACCGCTGTT GAGATCCAGTT CGATGTAACCCACTCG TGCACCCAACTGATCTT 5292 CAGCATCTTTTACTTTCACC AGCGTTTCTGGGTGAGCAAA AACAGGAAGGCAAAATGCCG 5352 CAAAAAAGGG AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT 5412 ATTATTGAA G C ATTTATC AG GGTTATTGTC TC ATGAGCGG ATAC ATATTT GAATGTATTT 5472 AGAAAAATAA ACAAATAGGGGTTCCGCGCACATTT CCCCGAAAAGTGCCACCTGA CGTCT 5532 AAGAAACCATTATTATCATG ACATTAACCT ATAAAAATAG GCGTATCACG AGGCCCTTTC 5592 GTCTTCAA 5600
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 781 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn 85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Met Ala Val Asp Phe lle Pro Val Glu Asn
245 250 255
Leu Glu Thr Thr Met Arg Ser Pro Val Phe Thr Asp Asn Ser Ser Pro
260 265 270
Pro Val Val Pro Gln Ser Phe Gln Val Ala His Leu His Ala Pro Thr 275 280 285
Gly Ser Gly Lys Ser Thr Lys Val Pro Ala Ala Tyr Ala Ala Gln Gly 290 295 300
Tyr Lys Val Leu Val Leu Asn Pro Ser Val Ala Ala Thr Leu Gly Phe 305 310 315 320
Gly Ala Tyr Met Ser Lys Ala His Gly lle Asp Pro Asn lle Arg Thr
325 330 335
Gly Val Arg Thr lle Thr Thr Gly Ser Pro lle Thr Tyr Ser Thr Tyr
340 345 350
Gly Lys Phe Leu Ala Asp Gly Gly Cys Ser Gly Gly Ala Tyr Asp lle 355 360 365
lle lle Cys Asp Glu Cys His Ser Thr Asp Ala Thr Ser lle Leu Gly 370 375 380 lle Gly Thr Val Leu Asp Gln Ala Glu Thr Ala Gly Ala Arg Leu Val 385 390 395 400
Val Leu Ala Thr Ala Thr Pro Pro Gly Ser Val Thr Val Pro His Pro
405 410 415
Asn lle Glu Glu Val Ala Leu Ser Thr Thr Gly Glu lle Pro Phe Tyr
420 425 430
Gly Lys Ala lle Pro Leu Glu Val lle Lys Gly Gly Arg His Leu lle 435 440 445
Phe Cys His Ser Lys Lys Lys Cys Asp Glu Leu Ala Ala Lys Leu Val 450 455 460
Ala Leu Gly lle Asn Ala Val Ala Tyr Tyr Arg Gly Leu Asp Val Ser 465 470 475 480
Val lle Pro Thr Ser Gly Asp Val Val Val Val Ala Thr Asp Ala Leu
485 490 495
Met Thr Gly Tyr Thr Gly Asp Phe Asp Ser Val lle Asp Cys Asn Thr
500 505 510
Cys Asn Ser Ser Thr Gly Cys Val Val lle Val Gly Arg Val Val Leu
515 520 525
Ser Gly Lys Pro Ala lle lle Pro Asp Arg Glu Val Leu Tyr Arg Glu 530 535 540
Phe Asp Glu Met Glu Glu Cys Ser Gln His Leu Pro Tyr lle Glu Gln 545 550 555 560
Gly Met Met Leu Ala Glu Gln Phe Lys Gln Lys Ala Leu Gly Leu Leu
565 570 575 Gln Thr Ala Ser Arg Gln Ala Glu Val lle Ala Pro Ala Val Gln Thr
580 585 590
Asn Trp Gln Lys Leu Glu Thr Phe Trp Ala Lys His Met Trp Asn Phe
595 600 605
lle Ser Gly lle Gln Tyr Leu Ala Gly Leu Ser Thr Leu Pro Gly Asn 610 615 620
Pro Ala lle Ala Ser Leu Met Ala Phe Thr Ala Ala Val Thr Ser Pro 625 630 635 640
Leu Thr Thr Ser Gln Thr Leu Leu Phe Asn lle Leu Gly Gly Trp Val
645 650 655
Ala Ala Gln Leu Ala Ala Pro Gly Ala Ala Thr Ala Phe Val Gly Ala
660 665 670 Gly Leu Ala Gly Ala Ala lle Gly Ser Val Gly Leu Gly Lys Val Leu
675 680 685
lle Asp lle Leu Ala Gly Tyr Gly Ala Gly Val Ala Gly Ala Leu Val
690 695 700
Ala Phe Lys lle Met Ser Gly Glu Val Pro Ser Thr Glu Asp Leu Val
705 710 715 720
Asn Leu Leu Pro Ala lle Leu Ser Pro Gly Ala Leu Val Val Gly Val
725 730 735
Val Cys Ala Ala lle Leu Arg Arg His Val Gly Pro Gly Glu Gly Ala
740 745 750
Val Gln Trp Met Asn Arg Leu lle Ala Phe Ala Ser Arg Gly Asn His
755 760 765
Val Ser Pro Trp Asp Pro Leu Asp Cys Arg His Ala Lys
770 775 780
(2) INFORMATION FOR SEQ ID NO:10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1548 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1548
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
ATG AGT TTT GTG GTC ATT ATT CCC GCG CGC TAC GCG TCG ACG CGT CTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCC GGT AAA CCA TTG GTT GAT ATT AAC GGC AAA CCC ATG ATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
GTT CTT GAA CGC GCG CGT GAA TCA GGT GCC GAG CGC ATC ATC GTG GCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
ACC GAT CAT GAG GAT GTT GCC CGC GCC GTT GAA GCC GCT GGC GGT GAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
GTA TGT ATG ACG CGC GCC GAT CAT CAG TCA GGA ACA GAA CGT CTG GCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAA GTT GTC GAA AAA TGC GCA TTC AGC GAC GAC ACG GTG ATC GTT AAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95 GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG AC A ATC ATT CGT CAG GTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
GCT GAT AAC CTC GCT CAG CGT CAG GTG GGT ATG GCG ACT CTG GCG GTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
CCA ATC CAC AAT GCG GAA GAA GCG TTT AAC CCG AAT GCG GTG AAA GTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TTC TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
CCT TGG GAT CGT GAT CGT TTT GCA GAA GGC CTT GAA ACC GTT GGC GAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175 AAC TTC CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA GGC TTT ATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
CGT CGT TAC GTC AAC TGG CAG CCA AGT CCG TTA GAA CAC ATC GAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TTA GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC CAT GTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTT GCT CAG GAA GTT CCT GGC ACA GGT GTG GAT ACC CCT GAA GAT CTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GAC CCG TCG ACG AAT TCC CCA TGG ACC CAC TAC GTT CCG GAA TCT GAC 768 Asp Pro Ser Thr Asn Ser Pro Trp Thr His Tyr Val Pro Glu Ser Asp
245 250 255
GCT GCT GCT CGA GTT ACC GCT ATC CTG TCT TCT CTG ACC GTT ACC CAG 816 Ala Ala Ala Arg Val Thr Ala lle Leu Ser Ser Leu Thr Val Thr Gln
260 265 270
CTT CTG CGT CGT CTG CAC CAG TGG ATC TCT TCT GAA TGC ACC ACC CCG 864 Leu Leu Arg Arg Leu His Gln Trp lle Ser Ser Glu Cys Thr Thr Pro
275 280 285 TGC TCT GGT TCT TGG CTG CGT GAC ATC TGG GAC TGG ATC TGC GAA GTT 912 Cys Ser Gly Ser Trp Leu Arg Asp lle Trp Asp Trp lle Cys Glu Val
290 295 300
CTG TCT GAC TTC AAA ACC TGG CTG AAA GCT AAA CTG ATG CCG CAG CTG 960 Leu Ser Asp Phe Lys Thr Trp Leu Lys Ala Lys Leu Met Pro Gln Leu
305 310 315 320
CCG GGT ATC CCG TTC GTT TCT TGC CAG CGT GGT TAC AAA GGT GTT TGG 1008 Pro Gly lle Pro Phe Val Ser Cys Gln Arg Gly Tyr Lys Gly Val Trp
325 330 335
CGT GTT GAC GGT ATC ATG CAC ACC CGT TGC CAC TGC GGT GCT GAA ATC 1056 Arg Val Asp Gly lle Met His Thr Arg Cys His Cys Gly Ala Glu lle
340 345 350
ACC GGT CAC GTT AAA AAC GGT ACC ATG CGT ATC GTT GGT CCG CGT ACC 1104 Thr Gly His Val Lys Asn Gly Thr Met Arg lle Val Gly Pro Arg Thr
355 360 365
TGC CGT AAC ATG TGG TCT GGC ACC TTC CCG ATC AAC GCTTAC ACC ACC 1152 Cys Arg Asn Met Trp Ser Gly Thr Phe Pro lle Asn Ala Tyr Thr Thr
370 375 380
GGT CCG TGC ACC CCG CTG CCG GCT CCG AAC TAC ACC TTC GCT CTG TGG 1200 Gly Pro Cys Thr Pro Leu Pro Ala Pro Asn Tyr Thr Phe Ala Leu Trp
385 390 395 400
CGT GTT TCTGCTGAA GAA TACGTTGAA ATCCGTCAGGTTGGTGACTTC 1248 Arg Val Ser Ala Glu Glu Tyr Val Glu lle Arg Gln Val Gly Asp Phe
405 410 415
CAC TAC GTT ACC GGT ATG ACC ACC GAC AAC CTG AAA TGC CCG TGC CAG 1296 His Tyr Val Thr Gly Met Thr Thr Asp Asn Leu Lys Cys Pro Cys Gln
420 425 430
GTT CCG TCT CCG GAG TTC TTC ACC GAA CTG GAC GGT GTT CGT CTG CAC 1344 Val Pro Ser Pro Glu Phe Phe Thr Glu Leu Asp Gly Val Arg Leu His
435 440 445
CGT TTC GCT CCG CCG TGC AAA CCG CTG CTG CGT GAA GAA GTT TCT TTC 1392 Arg Phe Ala Pro Pro Cys Lys Pro Leu Leu Arg Glu Glu Val Ser Phe
450 455 460
CGT GTT GGT CTG CAC GAA TAC CCG GTT GGT TCT CAG CTG CCG TGC GAA 1440 Arg Val Gly Leu His Glu Tyr Pro Val Gly Ser Gln Leu Pro Cys Glu
465 470 475 480
CCG GAA CCG GAC GTT GCT GTT CTG ACC TCT ATG CTG ACC GAC CCG TCT 1488 Pro Glu Pro Asp Val Ala Val Leu Thr Ser Met Leu Thr Asp Pro Ser
485 490 495
CAC ATC ACC GCT GAA GCT GCT GGT CGT CGA CTG GAT CCT CTA GAC TGC 1536 His lle Thr Ala Glu Ala Ala Gly Arg Arg Leu Asp Pro Leu Asp Cys
500 505 510 AGG CAT GCT AAG 1548 Arg His Ala Lys
515
(2) INFORMATION FOR SEQ ID NO:11 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 516 amino acids
(B) TYPE: amino acid
(0) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE OESCRIPTION: SEQ ID NO:11 :
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu 1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Pro Trp Thr His Tyr Val Pro Glu Ser Asp
245 250 255
Ala Ala Ala Arg Val Thr Ala lle Leu Ser Ser Leu Thr Val Thr Gln
260 265 270
Leu Leu Arg Arg Leu His Gln Trp lle Ser Ser Glu Cys Thr Thr Pro 275 280 285
Cys Ser Gly Ser Trp Leu Arg Asp lle Trp Asp Trp lle Cys Glu Val 290 295 300
Leu Ser Asp Phe Lys Thr Trp Leu Lys Ala Lys Leu Met Pro Gln Leu 305 310 315 320
Pro Gly lle Pro Phe Val Ser Cys Gln Arg Gly Tyr Lys Gly Val Trp
325 330 335
Arg Val Asp Gly lle Met His Thr Arg Cys His Cys Gly Ala Glu lle
340 345 350
Thr Gly His Val Lys Asn Gly Thr Met Arg lle Val Gly Pro Arg Thr
355 360 365
Cys Arg Asn Met Trp Ser Gly Thr Phe Pro lle Asn Ala Tyr Thr Thr 370 375 380
Gly Pro Cys Thr Pro Leu Pro Ala Pro Asn Tyr Thr Phe Ala Leu Trp 385 390 395 400
Arg Val Ser Ala Glu Glu Tyr Val Glu lle Arg Gln Val Gly Asp Phe
405 410 415
His Tyr Val Thr Gly Met Thr Thr Asp Asn Leu Lys Cys Pro Cys Gln
420 425 430
Val Pro Ser Pro Glu Phe Phe Thr Glu Leu Asp Gly Val Arg Leu His 435 440 445
Arg Phe Ala Pro Pro Cys Lys Pro Leu Leu Arg Glu Glu Val Ser Phe 450 455 460
Arg Val Gly Leu His Glu Tyr Pro Val Gly Ser Gln Leu Pro Cys Glu 465 470 475 480
Pro Glu Pro Asp Val Ala Val Leu Thr Ser Met Leu Thr Asp Pro Ser
485 490 495 His lle Thr Ala Glu Ala Ala Gly Arg Arg Leu Asp Pro Leu Asp Cys
500 505 510
Arg His Ala Lys
515
(2) INFORMATION FOR SEQ ID NO:12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1623 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1 ..1623
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
ATG AGT TTT GTG GTC ATT ATT CCC GCG CGC TAC GCG TCG ACG CGT CTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCC GGT AAA CCA TTG GTT GAT ATT AAC GGC AAA CCC ATG ATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
GTT CTT GAA CGC GCG CGT GAA TCA GGT GCC GAG CGC ATC ATC GTG GCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
ACC GAT C AT GAG GAT GTT GCC CGC GCC GTT GAA GCC GCT GGC GGT GAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
GTA TGT ATG ACG CGC GCC GAT CAT CAG TCA GGA ACA GAA CGT CTG GCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAA GTT GTC GAA AAA TGC GCA TTC AGC GAC GAC ACG GTG ATCGTT AAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT CGT CAG GTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
GCT GAT AAC CTC GCT CAG CGT CAG GTG GGT ATG GCG ACT CTG GCG GTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125 CCAATCCACAATGCGGAA GAA GCGTTTAACCCGAATGCGGTGAAA GTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TTC TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
CCTTGGGATCGTGATCGTTTTGCAGAA GGCCTTGAA ACCGTT GGCGAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175 AAC TTC CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA GGC TTT ATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
CGT CGTTAC GTC AAC TGG CAG CCA AGT CCG TTA GAA CAC ATC GAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TTA GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC CAT GTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTTGCTCAGGAA GTTCCTGGCACAGGTGTG GATACCCCTGAA GATCTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GAC CCGTCG ACGAATTCT ATG CGT CGA CTG GCT CGT GGT TCT CCG CCG 768 Asp Pro Ser Thr Asn Ser Met Arg Arg Leu Ala Arg Gly Ser Pro Pro
245 250 255
TCT GTT GCTTCT TCTTCT GCT TCT CAA CTG TCT GCT CCG TCT CTG AAA 816 Ser Val Ala Ser Ser Ser Ala Ser Gln Leu Ser Ala Pro Ser Leu Lys
260 265 270
GCTACCTGCACCGCTAACCACGACTCTCCGGACGCTGAA CTGATCGAA 864 Ala Thr Cys Thr Ala Asn His Asp Ser Pro Asp Ala Glu Leu lle Glu
275 280 285
GCTAACCTGCTGTGGCGTCAGGAA ATGGGTGGTAACATCACCCGTGTT 912 Ala Asn Leu Leu Trp Arg Gln Glu Met Gly Gly Asn lle Thr Arg Val
290 295 300
GAA TCTGAA AACAAA GTTGTTATCCTGGACTCTTT CGACCCGCTGGTT 960 Glu Ser Glu Asn Lys Val Val lle Leu Asp Ser Phe Asp Pro Leu Val
305 310 315 320
GCTGAA GAA GACGAA CGTGAGATCTCTGTTCCGGCTGAA ATCCTGCGT 1008 Ala Glu Glu Asp Glu Arg Glu lle Ser Val Pro Ala Glu lle Leu Arg
325 330 335
AAA TCTCGTCGTTTC GCT CAG GCT CTG CCG GTT TGG GCT CGT CCG GAC 1056 Lys Ser Arg Arg Phe Ala Gln Ala Leu Pro Val Trp Ala Arg Pro Asp
340 345 350 TACAACCCGCCGCTGGTTGAA ACCTGGAAA AAA CCGGACTACGAA CCG 1104 Tyr Asn Pro Pro Leu Val Glu Thr Trp Lys Lys Pro Asp Tyr Glu Pro
355 360 365
CCGGTT GTT CACGGTTGCCCGCTGCCGCCGCCGpAAATCTCCGCCGGTT 1152
Pro Val Val His Gly Cys Pro Leu Pro Pro Pro Lys Ser Pro Pro Val
370 375 380
CC G CCG CCG CG TAAA AAACGTACC GTTGTTCTGACCGAA TCTACC CTG 1200 Pro Pro Pro Arg Lys Lys Arg Thr Val Val Leu Thr Glu Ser Thr Leu
385 390 395 400
TCT ACC GCT CTG GCT GAA CTG GCT ACC CGT TCT TTC GGT TCT TCT TCT 1248 Ser Thr Ala Leu Ala Glu Leu Ala Thr Arg Ser Phe Gly Ser Ser Ser
405 410 415
ACCTCGGGTATCACCGGTGACAACACCACCACCTCTTCTGAA CCG GCT 1296 Thr Ser Gly lle Thr Gly Asp Asn Thr Thr Thr Ser Ser Glu Pro Ala
420 425 430
CCGTCTGGTTGCCCGCCG GACTCTGACGCTGAA TCTTACTCTTCTATG 1344 Pro Ser Gly Cys Pro Pro Asp Ser Asp Ala Glu Ser Tyr Ser Ser Met
435 440 445
CCG CCG CTG GAA GGT GAA CCG GGT GAC CCG GAT CTG TCT GAC GGTTCT 1392 Pro Pro Leu Glu Gly Glu Pro Gly Asp Pro Asp Leu Ser Asp Gly Ser
450 455 460
TGG TCT ACC GTT TCT TCT GAA GCT AAC GCT GAA GAC GTT GTT TGC TGC 1440 Trp Ser Thr Val Ser Ser Glu Ala Asn Ala Glu Asp Val Val Cys Cys
465 470 475 480
TCT ATG TCT TAC TCT TGG ACC GGT GCT CTG GTT ACT CCG TGC GCT GCT 1488 Ser Met Ser Tyr Ser Trp Thr Gly Ala Leu Val Thr Pro Cys Ala Ala
485 490 495
GAA GAA CAG AAA CTG CCG ATC AAC GCT CTG TCT AAC TCT CTG CTG CGT 1536 Glu Glu Gln Lys Leu Pro lle Asn Ala Leu Ser Asn Ser Leu Leu Arg
500 505 510
CAC CAC AAC CTG GTT TAC TCT ACC ACC TCT CGT TCT GCT TGC CAG CGT 1584 His His Asn Leu Val Tyr Ser Thr Thr Ser Arg Ser Ala Cys Gln Arg
515 520 525
CAG AAA AAA GTT ACC TTC GAC CGT CTG CAA GTT CTA GAC 1623 Gln Lys Lys Val Thr Phe Asp Arg Leu Gln Val Leu Asp
530 535 540
(2) INFORMATION FOR SEQ ID NO:13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 541 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu 1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Met Arg Arg Leu Ala Arg Gly Ser Pro Pro
245 250 255
Ser Val Ala Ser Ser Ser Ala Ser Gln Leu Ser Ala Pro Ser Leu Lys 260 265 270
Ala Thr Cys Thr Ala Asn His Asp Ser Pro Asp Ala Glu Leu lle Glu 275 280 285
Ala Asn Leu Leu Trp Arg Gln Glu Met Gly Gly Asn lle Thr Arg Val 290 295 300
Glu Ser Glu Asn Lys Val Val lle Leu Asp Ser Phe Asp Pro Leu Val 305 310 315 320
Ala Glu Glu Asp Glu Arg Glu lle Ser Val Pro Ala Glu lle Leu Arg
325 330 335
Lys Ser Arg Arg Phe Ala Gln Ala Leu Pro Val Trp Ala Arg Pro Asp
340 345 350
Tyr Asn Pro Pro Leu Val Glu Thr Trp Lys Lys Pro Asp Tyr Glu Pro 355 360 365
Pro Val Val His Gly Cys Pro Leu Pro Pro Pro Lys Ser Pro Pro Val 370 375 380
Pro Pro Pro Arg Lys Lys Arg Thr Val Val Leu Thr Glu Ser Thr Leu 385 390 395 400
Ser Thr Ala Leu Ala Glu Leu Ala Thr Arg Ser Phe Gly Ser Ser Ser
405 410 415
Thr Ser Gly lle Thr Gly Asp Asn Thr Thr Thr Ser Ser Glu Pro Ala
420 425 430
Pro Ser Gly Cys Pro Pro Asp Ser Asp Ala Glu Ser Tyr Ser Ser Met
435 440 445
Pro Pro Leu Glu Gly Glu Pro Gly Asp Pro Asp Leu Ser Asp Gly Ser 450 455 460
Trp Ser Thr Val Ser Ser Glu Ala Asn Ala Glu Asp Val Val Cys Cys 465 470 475 480
Ser Met Ser Tyr Ser Trp Thr Gly Ala Leu Val Thr Pro Cys Ala Ala
485 490 495
Glu Glu Gln Lys Leu Pro lle Asn Ala Leu Ser Asn Ser Leu Leu Arg
500 505 510
His His Asn Leu Val Tyr Ser Thr Thr Ser Arg Ser Ala Cys Gln Arg 515 520 525
Gln Lys Lys Val Thr Phe Asp Arg Leu Gln Val Leu Asp
530 535 540
(2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1488 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1488
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
ATG AGTTTTGTG GTC ATT ATT CCC GCG CGC TAC GCG TCG ACG CGT CTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCC GGT AAA CCA TTG GTT GAT ATT AAC GGC AAA CCC ATG ATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
GTTCTTGAA CGCGCGCGTGAA TCAGGTGCCGAGCGCATCATCGTG GCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
ACCGATCATGAGGATGTTGCC CGCGCCGTTGAA GCC GCTGGCGGTGAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
GTATGTATGACGCGCGCC GATCATCAGTCAGGAACAGAA CGTCTGGCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAA GTTGTC GAA AAA TGC GCA TTC AGC GAC GAC ACG GTG ATCGTTAAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT CGT CAG GTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
GCT GAT AAC CTC GCT CAG CGT CAG GTG GGT ATG GCG ACT CTG GCG GTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
CCAATCCACAATGCGGAA GAA GCGTTTAACCCGAATGCGGTGAAA GTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TTC TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160 CCT TGG GAT CGT GAT CGT TTT GCA GAA GGC CTT GAA ACC GTT GGC GAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
AAC TTC CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA GGC TTT ATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
CGT CGTTAC GTC AAC TGG CAG CCA AGT CCG TTA GAA CAC ATC GAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TTA GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC CAT GTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTTGCTCAGGAA GTTCCTGGCACAGGTGTGGATACCCCTGAA GATCTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GAC CCG TCG ACG AATTCT CTA GAC TCC CAC TAC CAG GAC GTT CTG AAA 768 Asp Pro Ser Thr Asn Ser Leu Asp Ser His Tyr Gln Asp Val Leu Lys
245 250 255
GAA GTT AAA GCT GCT GCT TCT AAA GTT AAA GCT AAC CTG CTG TCT GTT 816 Glu Val Lys Ala Ala Ala Ser Lys Val Lys Ala Asn Leu Leu Ser Val
260 265 270
GAA GAA GCA TGC TCT CTG ACC CCG CCG CAC TCT GCT AAA TCT AAA TTC 864 Glu Glu Ala Cys Ser Leu Thr Pro Pro His Ser Ala Lys Ser Lys Phe
275 280 285
GGT TAC GGT GCT AAA GAC GTT CGT TGC CAC GCT CGT AAA GCT GTT ACC 912 Gly Tyr Gly Ala Lys Asp Val Arg Cys His Ala Arg Lys Ala Val Thr
290 295 300
CAC ATC AAC TCT GTT TGG AAA GAT CTG CTG GAA GAC AAC GTT ACC CCG 960 His lle Asn Ser Val Trp Lys Asp Leu Leu Glu Asp Asn Val Thr Pro
305 310 315 320
ATC GAC ACC ACC ATC ATG GCT AAA AAC GAA GTT TTC TGC GTT CAG CCG 1008 lle Asp Thr Thr lle Met Ala Lys Asn Glu Val Phe Cys Val Gln Pro
325 330 335
GAA AAA GGT GGT CGT AAA CCG GCT CGT CTG ATC GTT TTC CCG GAC CTG 1056 Glu Lys Gly Gly Arg Lys Pro Ala Arg Leu lle Val Phe Pro Asp Leu
340 345 350
GGT GTT CGT GTT TGC GAA AAA ATG GCT CTG TAC GAC GTT GTT ACC AAA 1104 Gly Val Arg Val Cys Glu Lys Met Ala Leu Tyr Asp Val Val Thr Lys
355 360 365
CTG CCG CTG GCT GTT ATG GGT TCT TCT TAC GGT TTC CAG TAC TCT CCG 1152 Leu Pro Leu Ala Val Met Gly Ser Ser Tyr Gly Phe Gln Tyr Ser Pro
370 375 380 GGTCAGCGTGTTGAGTT CCTGGTT CAGGCTTGGAAA TCTAAA AAA ACC 1200 Gly Gln Arg Val Glu Phe Leu Val Gln Ala Trp Lys Ser Lys Lys Thr
385 390 395 400
CCG ATG GGT TTC TCT TAC GAC ACC CGT TGC TTC GAC TCT ACC GTT ACC 1248 Pro Met Gly Phe Ser Tyr Asp Thr Arg Cys Phe Asp Ser Thr Val Thr
405 410 415
GAA TCTGACATT CGTACCGAAGAA GCTATCTACCAGTGCTGCGACCTG 1296 Glu Ser Asp lle Arg Thr Glu Glu Ala lle Tyr Gln Cys Cys Asp Leu
420 425 430
GAC CCG CAG GCT CGT GTT GCT ATC AAA TCT CTG ACC GAA CGT CTG TAC 1344 Asp Pro Gln Ala Arg Val Ala lle Lys Ser Leu Thr Glu Arg Leu Tyr
435 440 445
GTTGGTGGTCCGCTGACCAACTCTCGGGGTGAA AACTGCGGTTACCGT 1392 Val Gly Gly Pro Leu Thr Asn Ser Arg Gly Glu Asn Cys Gly Tyr Arg
450 455 460
CGTTGCCGTGCTTCTGGTGTTCTG ACC ACC TCT TGC GGT AAC ACC CTG 1440 Arg Cys Arg Ala Ser Gly Val Leu Thr Thr Ser Cys Gly Asn Thr Leu
465 470 475 480
ACC TGC TAC ATC AAA GCT CGT GCT GCT TGC CGT GCT GCT GGT CTG CAG 1488 Thr Cys Tyr lle Lys Ala Arg Ala Ala Cys Arg Ala Ala Gly Leu Gln
485 490 495
(2) INFORMATION FOR SEQ ID NO:15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 496 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn 85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val 100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle 180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Leu Asp Ser His Tyr Gln Asp Val Leu Lys
245 250 255
Glu Val Lys Ala Ala Ala Ser Lys Val Lys Ala Asn Leu Leu Ser Val 260 265 270
Glu Glu Ala Cys Ser Leu Thr Pro Pro His Ser Ala Lys Ser Lys Phe 275 280 285
Gly Tyr Gly Ala Lys Asp Val Arg Cys His Ala Arg Lys Ala Val Thr 290 295 300
His lle Asn Ser Val Trp Lys Asp Leu Leu Glu Asp Asn Val Thr Pro 305 310 315 320
lle Asp Thr Thr lle Met Ala Lys Asn Glu Val Phe Cys Val Gln Pro
325 330 335
Glu Lys Gly Gly Arg Lys Pro Ala Arg Leu lle Val Phe Pro Asp Leu 340 345 350
Gly Val Arg Val Cys Glu Lys Met Ala Leu Tyr Asp Val Val Thr Lys 355 360 365 Leu Pro Leu Ala Val Met Gly Ser Ser Tyr Gly Phe Gln Tyr Ser Pro
370 375 380
Gly Gln Arg Val Glu Phe Leu Val Gln Ala Trp Lys Ser Lys Lys Thr
385 390 395 400
Pro Met Gly Phe Ser Tyr Asp Thr Arg Cys Phe Asp Ser Thr Val Thr
405 410 415
Glu Ser Asp lle Arg Thr Glu Glu Ala lle Tyr Gln Cys Cys Asp Leu
420 425 430
Asp Pro Gln Ala Arg Val Ala lle Lys Ser Leu Thr Glu Arg Leu Tyr
435 440 445
Val Gly Gly Pro Leu Thr Asn Ser Arg Gly Glu Asn Cys Gly Tyr Arg
450 455 460
Arg Cys Arg Ala Ser Gly Val Leu Thr Thr Ser Cys Gly Asn Thr Leu
465 470 475 480
Thr Cys Tyr lle Lys Ala Arg Ala Ala Cys Arg Ala Ala Gly Leu Gln
485 490 495
(2) INFORMATION FOR SEQ ID NO:16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1161 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1161
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
ATG AGT TTT GTG GTC ATT ATT CCC GCG CGC TAC GCG TCG ACG CGT CTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCC GGTAAA CCATTG GTT GAT ATT AAC GGC AAA CCC ATG ATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
GTTCTTGAA CGCGCGCGTGAA TCAGGTGCCGAGCGCATCATCGTGGCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
ACCGATCATGAGGATGTTGCC CGCGCCGTTGAA GCC GCTGGCGGTGAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60
GTATGTATGACGCGCGCC GATCATCAGTCAGGAACAGAA CGTCTGGCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAA GTTGTC GAA AAA TGC GCA TTC AGC GAC GAC ACG GTG ATCGTTAAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT CGT CAG GTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
GCTGATAACCTCGCTCAGCGTCAGGTGGGTATGGCGACTCTGGCGGTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
CCA ATC CAC AAT GCG GAA GAA GCG TTT AAC CCG AAT GCG GTG AAA GTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TTC TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
CC TGGGATCGTGATCGTTTTGCAGAA GGCCTTGAA ACCGTTGGCGAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
AAC TTC CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA GGC TTT ATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
CGT CGT TAC GTC AAC TGG CAG CCA AGT CCG TTA GAA CAC ATC GAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TTA GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC CAT GTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTT GCT CAG GAA GTT CCT GGC ACA GGT GTG GAT ACC CCT GAA GAT CTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GAC CCG TCG ACG AATTGC ATG CTG CAG GAC TGC ACC ATG CTG GTTTGC 768 Asp Pro Ser Thr Asn Cys Met Leu Gln Asp Cys Thr Met Leu Val Cys
245 250 255
GGT GAC GAC CTG GTT GTT ATC TGC GAA TCT GCT GGT GTT CAG GAA GAC 816 Gly Asp Asp Leu Val Val lle Cys Glu Ser Ala Gly Val Gln Glu Asp
260 265 270
GCT GCT TCT CTG CGT GCT TT c ACC GAA GCT ATG ACC CGT TAC TCT GCT 864 Ala Ala Ser Leu Arg Ala Phe Thr Glu Ala Met Thr Arg Tyr Ser Ala
275 280 285
CCCCCGGGTGACCCGCCGCAG CC GGAA TACGAC CTGGAA CTGATCACC 912 Pro Pro Gly Asp Pro Pro Gln Pro Glu Tyr Asp Leu Glu Leu lle Thr
290 295 300
TCT TGC TCT TCT AAC GTT TCT GTT GCT CAC GAC GGT GCT GGT AAA CGT 960 Ser Cys Ser Ser Asn Val Ser Val Ala His Asp Gly Ala Gly Lys Arg
305 310 315 320
GTT TACTACCTGACCCGTGACCCGACCACCCCGCTGGCTCGTGCTGCT 1008 Val Tyr Tyr Leu Thr Arg Asp Pro Thr Thr Pro Leu Ala Arg Ala Ala
325 330 335
TGG GAA ACC GCT CGT CAC ACC CCG GTAAACTCTTGG CTG GGT AAC ATC 1056 Trp Glu Thr Ala Arg His Thr Pro Val Asn Ser Trp Leu Gly Asn lle
340 345 350
ATC ATG TT C GCT CCG ACC CTG TGG GCC CGT ATG ATC CTG ATG ACC CAC 1104 lle Met Phe Ala Pro Thr Leu Trp Ala Arg Met lle Leu Met Thr His
355 360 365
TT C TT C TCT GTT CTG ATC GCT CGT GAC CAG CTG GAA CAG GCT CTG GAC 1152
Phe Phe Ser Val Leu lle Ala Arg Asp Gln Leu Glu Gln Ala Leu Asp
370 375 380
TGC GAG ATC 1161
Cys Glu lle
385
(2) INFORMATION FOR SEQ ID NO:17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 387 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val 100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle 180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Cys Met Leu Gln Asp Cys Thr Met Leu Val Cys
245 250 255
Gly Asp Asp Leu Val Val lle Cys Glu Ser Ala Gly Val Gln Glu Asp 260 265 270
Ala Ala Ser Leu Arg Ala Phe Thr Glu Ala Met Thr Arg Tyr Ser Ala 275 280 285
Pro Pro Gly Asp Pro Pro Gln Pro Glu Tyr Asp Leu Glu Leu lle Thr 290 295 300
Ser Cys Ser Ser Asn Val Ser Val Ala His Asp Gly Ala Gly Lys Arg 305 310 315 320
Val Tyr Tyr Leu Thr Arg Asp Pro Thr Thr Pro Leu Ala Arg Ala Ala
325 330 335
Trp Glu Thr Ala Arg His Thr Pro Val Asn Ser Trp Leu Gly Asn lle 340 345 350
lle Met Phe Ala Pro Thr Leu Trp Ala Arg Met lle Leu Met Thr His 355 360 365
Phe Phe Ser Val Leu lle Ala Arg Asp Gln Leu Glu Gln Ala Leu Asp
370 375 380
Cys Glu lle
385
(2) INFORMATION FOR SEQ ID NO:18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1179 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:1 ..1179
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
ATG AGTTTT GTG GTC ATT ATT CCC GCG CGC TAC GCG TCG ACG CGT CTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCCGGTAAA CCATT GGTT GATATT AACGGCAAA CCCATGATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
GTT CTT GAA CGCGCGCGTGAA TCAGGTGCCGAGCGCATCATCGTG GCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
ACCGATCATGAGGATGTT GCC CGCGCCGTT GAA GCC GCTGGCGGTGAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
GTATGTATGACGCGCGCC GATCATCAGTCAGGAACAGAA CGTCTGGCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAA GTT GTCGAA AAA TGCGCATT CAGCGACGACACGGTGATCGTT AAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT CGT CAG GTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
GCTGATAACCTCGCTCAGCGTCAGGTGGGTATGGCGACTCTGGCGGTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val 115 120 125
CCAATCCACAATGCGGAA GAA GCGTTT AACCCGAATGCGGTGAAA GTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TT C TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
CCTTGGGATCGTGATCGTTTT GCAGAA GGCCTT GAA ACCGTT GGCGAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
AAC TT C CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA GGC TTT ATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
CGTCGTTAC GTC AAC TGG CAG CCA AGT CCG TT A GAA CAC ATC GAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TT A GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC CAT GTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTT GCTCAGGAA GTT CCTGGCACAGGTGTGGATACCCCTGAA GATCTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GAC CCG TCG ACG AAT TCC ATG GAG ATC TAC GGT GCT TGC TAC TCT ATC 768 Asp Pro Ser Thr Asn Ser Met Glu lle Tyr Gly Ala Cys Tyr Ser lle
245 250 255
GAA CCGCTGGACCTGCCGCCGATCATT CAGCGTCTGCACGGTCTGTCT 816 Glu Pro Leu Asp Leu Pro Pro lle lle Gln Arg Leu His Gly Leu Ser
260 265 270
GCT TT C TCT CTG CAC TCT TAC TCC CCG GGT GAA ATC AAC CGT GTT GCT 864 Ala Phe Ser Leu His Ser Tyr Ser Pro Gly Glu lle Asn Arg Val Ala
275 280 285
GCTTGC CTG CGT AAA CTG GGT GTT CCG CCG CTG CGTGCTTGG CGT CAC 912 Ala Cys Leu Arg Lys Leu Gly Val Pro Pro Leu Arg Ala Trp Arg His
290 295 300
CGTGCTCGTTCTGTT CGTGCTCGTCTGCTGGCTCGTGGTGGCCGTGCT 960 Arg Ala Arg Ser Val Arg Ala Arg Leu Leu Ala Arg Gly Gly Arg Ala
305 310 315 320
GCT ATC TGC GGT AAA TAC CTG TT CAAC TGG GCT GTT CGT ACC AAA CTG 1008 Ala lle Cys Gly Lys Tyr Leu Phe Asn Trp Ala Val Arg Thr Lys Leu
325 330 335
AAA CTG ACC CCG ATC GCT GCT GCT GGT CAG CTG GAC CTG TCTGGTTGG 1056 Lys Leu Thr Pro lle Ala Ala Ala Gly Gln Leu Asp Leu Ser Gly Trp
340 345 350
TT C ACC GCT GGT TAC TCT GGT GGT GAC ATC TAC CAC TCT GTT TCT CAC 1104 Phe Thr Ala Gly Tyr Ser Gly Gly Asp lle Tyr His Ser Val Ser His
355 360 365
GCT CGT CCG CGTTGG ATC TGG TTC TGC CTG CTG CTG CTG GCT GCT GGT 1152 Ala Arg Pro Arg Trp lle Trp Phe Cys Leu Leu Leu Leu Ala Ala Gly
370 375 380
GTT GGT ATC TAC CTG CTG CCG AAC CGT 1179
Val Gly lle Tyr Leu Leu Pro Asn Arg
385 390
(2) INFORMATION FOR SEQ ID NO:19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 393 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle 180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Met Glu lle Tyr Gly Ala Cys Tyr Ser lle
245 250 255
Glu Pro Leu Asp Leu Pro Pro lle lle Gln Arg Leu His Gly Leu Ser 260 265 270
Ala Phe Ser Leu His Ser Tyr Ser Pro Gly Glu lle Asn Arg Val Ala 275 280 285
Ala Cys Leu Arg Lys Leu Gly Val Pro Pro Leu Arg Ala Trp Arg His 290 295 300
Arg Ala Arg Ser Val Arg Ala Arg Leu Leu Ala Arg Gly Gly Arg Ala 305 310 315 320
Ala lle Cys Gly Lys Tyr Leu Phe Asn Trp Ala Val Arg Thr Lys Leu
325 330 335
Lys Leu Thr Pro lle Ala Ala Ala Gly Gln Leu Asp Leu Ser Gly Trp 340 345 350
Phe Thr Ala Gly Tyr Ser Gly Gly Asp lle Tyr His Ser Val Ser His 355 360 365
Ala Arg Pro Arg Trp lle Trp Phe Cys Leu Leu Leu Leu Ala Ala Gly 370 375 380
Val Gly lle Tyr Leu Leu Pro Asn Arg
385 390
(2) INFORMATION FOR SEQ ID NO:20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1791 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1791
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
ATGAGTTTTGTGGTCATT ATT CCCGCGCGCTACGCGTCGACGCGTCTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCCGGTAAACCATTGGTT GATATT AACGGCAAACCCATGATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
GTT CTT GAACGCGCGCGTGAATCAGGTGCCGAGCGCATCATCGTGGCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
ACCGATCATGAGGATGTT GCCCGCGCCGTT GAAGCCGCTGGCGGTGAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
GTATGTATGACGCGCGCCGATCATCAGTCAGGAACAGAACGTCTGGCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAAGTT GTCGAAAAATGCGCATTCAGCGACGACACGGTGATCGTT AAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT CGT CAG GTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
GCTGATAACCTCGCTCAGCGTCAGGTGGGTATGGCGACTCTGGCGGTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
CCAATCCACAATGCGGAAGAAGCGTTTAACCCGAATGCGGTGAAAGTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TTC TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
CCTTGGGATCGTGATCGTTTT GCAGAAGGCCTT GAAACCGTT GGCGAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
AAC TTC CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA GGC TTT ATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle 180 185 190
CGT CGT TAC GTC AAC TGG CAG CCA AGT CCG TT A GAA CAC ATC GAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TT A GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC CAT GTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTT GCTCAGGAA GTT CCTGGCACAGGTGTGGATACCCCTGAA GATCTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GAC CCG TCG ACG AATTCC ATG GAC GCT CAC TT C CTG TCT CAG GCG CCG 768 Asp Pro Ser Thr Asn Ser Met Asp Ala His Phe Leu Ser Gln Ala Pro
245 250 255
CCGCCGTCTTGGGATCAGATGTGGAAA TGCCTGATCCGTCTGAAA CCG 816 Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu lle Arg Leu Lys Pro
260 265 270
ACCCTGCACGGCCCGACCCCGCTGCTGTACCGTCTGGGTGCTGTT CAG 864 Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln
275 280 285
AAC GAA ATC ACC CTG ACC CAC CCG GTT ACC AAA TAC ATC ATG ACC TGC 912 Asn Glu lle Thr Leu Thr His Pro Val Thr Lys Tyr lle Met Thr Cys
290 295 300
ATG TCT GCT GAT CTA GAA GTT GTT ACC TCT ACC TGG GTT CTG GTT GGT 960 Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp Val Leu Val Gly
305 310 315 320
GCT GTT CTG GCT GCT CTG GCT GCTTAC TGC CTG TCG ACC GGT TGC GTT 1008 Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu Ser Thr Gly Cys Val
325 330 335
GTT ATC GTT GGT CGT GTT GTT CTG TCT GGT AAA CCG GCC ATT ATC CCG 1056 Val lle Val Gly Arg Val Val Leu Ser Gly Lys Pro Ala lle lle Pro
340 345 350
GACCGTGAA GTT CTGTAC CGTGAGTT CGAC GAA ATGGAA GAA TGCTCT 1104 Asp Arg Glu Val Leu Tyr Arg Glu Phe Asp Glu Met Glu Glu Cys Ser
355 360 365
CAG CAC CTG CCG TAC ATC GAA CAG GGT ATG ATG CTG GCT GAA CAG TT C 1152 Gln His Leu Pro Tyr lle Glu Gln Gly Met Met Leu Ala Glu Gln Phe
370 375 380
AAA CAG AAA GCT CTG GGT CTG CTG CAG ACC GCTTCT CGT CAG GCTGAA 1200 Lys Gln Lys Ala Leu Gly Leu Leu Gln Thr Ala Ser Arg Gln Ala Glu
385 390 395 400
GTT ATC GCT CCG GCT GTT CAG ACC AAC TGG CAG AAA CTC GAG ACC TT C 1248 Val lle Ala Pro Ala Val Gln Thr Asn Trp Gln Lys Leu Glu Thr Phe
405 410 415
TGG GCT AAA CAC ATG TGG AAC TT C ATC TCT GGT ATC CAG TAC CTG GCT 1296 Trp Ala Lys His Met Trp Asn Phe lle Ser Gly lle Gln Tyr Leu Ala
420 425 430
GGT CTG TCT ACC CTG CCG GGTAAC CCG GCT ATC GCA AGC TT G ATG GCT 1344 Gly Leu Ser Thr Leu Pro Gly Asn Pro Ala lle Ala Ser Leu Met Ala
435 440 445
TT CACCGCTGCTGTT ACCTCTCCGCTGACCACCTCTCAGACCCTGCTG 1392 Phe Thr Ala Ala Val Thr Ser Pro Leu Thr Thr Ser Gln Thr Leu Leu
450 455 460
TT CAACATT CTGGGTGGTTGGGTT GCTGCTCAGCTGGCTGCTCCGGGT 1440 Phe Asn lle Leu Gly Gly Trp Val Ala Ala Gln Leu Ala Ala Pro Gly
465 470 475 480
GCT GCT ACC GCTTT C GTT GGT GCT GGT CTG GCT GGT GCT GCT ATC GGT 1488 Ala Ala Thr Ala Phe Val Gly Ala Gly Leu Ala Gly Ala Ala lle Gly
485 490 495
TCT GTA GGC CTG GGT AAA GTT CTG ATC GAC ATT CTG GCT GGT TAC GGT 1536 Ser Val Gly Leu Gly Lys Val Leu lle Asp lle Leu Ala Gly Tyr Gly
500 505 510
GCTGGTGTT GCTGGAGCTCTGGTT GCTTT CAAA ATCATGTCTGGTGAA 1584 Ala Gly Val Ala Gly Ala Leu Val Ala Phe Lys lle Met Ser Gly Glu
515 520 525
GTT CCGTCTACCGAA GATCTGGTT AACCTGCTGCCGGCTATCCTGTCT 1632 Val Pro Ser Thr Glu Asp Leu Val Asn Leu Leu Pro Ala lle Leu Ser
530 535 540
CCG GGT GCT CTG GTT GTT GGTGTT GTT TGC GCT GCT ATC CTG CGT CGT 1680 Pro Gly Ala Leu Val Val Gly Val Val Cys Ala Ala lle Leu Arg Arg
545 550 555 560
CACGTT GGCCCGGGTGAA GGTGCTGTT CAGTGGATGAACCGTCTGATC 1728 His Val Gly Pro Gly Glu Gly Ala Val Gln Trp Met Asn Arg Leu lle
565 570 575
GCTTT CGCTTCT CGT GGTAAC CAC GTT TCTCCATGG GAT CCT CTA GAC 1776 Ala Phe Ala Ser Arg Gly Asn His Val Ser Pro Trp Asp Pro Leu Asp
580 585 590
TGC AGG CAT GCT AA G 1791
Cys Arg His Ala Lys
595
(2) INFORMATION FOR SEQ ID NO:21 :
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 597 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21 :
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu 1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His 20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val 100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle 180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Met Asp Ala His Phe Leu Ser Gln Ala Pro
245 250 255 Pro Pro Ser Trp Asp Gln Met Trp Lys Cys Leu lle Arg Leu Lys Pro 260 265 270
Thr Leu His Gly Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala Val Gln 275 280 285
Asn Glu lle Thr Leu Thr His Pro Val Thr Lys Tyr lle Met Thr Cys 290 295 300
Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp Val Leu Val Gly 305 310 315 320
Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu Ser Thr Gly Cys Val
325 330 335
Val lle Val Gly Arg Val Val Leu Ser Gly Lys Pro Ala lle lle Pro 340 345 350
Asp Arg Glu Val Leu Tyr Arg Glu Phe Asp Glu Met Glu Glu Cys Ser 355 360 365
Gln His Leu Pro Tyr lle Glu Gln Gly Met Met Leu Ala Glu Gln Phe 370 375 380
Lys Gln Lys Ala Leu Gly Leu Leu Gln Thr Ala Ser Arg Gln Ala Glu 385 390 395 400
Val lle Ala Pro Ala Val Gln Thr Asn Trp Gln Lys Leu Glu Thr Phe
405 410 415
Trp Ala Lys His Met Trp Asn Phe lle Ser Gly lle Gln Tyr Leu Ala 420 425 430
Gly Leu Ser Thr Leu Pro Gly Asn Pro Ala lle Ala Ser Leu Met Ala 435 440 445
Phe Thr Ala Ala Val Thr Ser Pro Leu Thr Thr Ser Gln Thr Leu Leu 450 455 460
Phe Asn lle Leu Gly Gly Trp Val Ala Ala Gln Leu Ala Ala Pro Gly 465 470 475 480
Ala Ala Thr Ala Phe Val Gly Ala Gly Leu Ala Gly Ala Ala lle Gly
485 490 495
Ser Val Gly Leu Gly Lys Val Leu lle Asp lle Leu Ala Gly Tyr Gly 500 505 510
Ala Gly Val Ala Gly Ala Leu Val Ala Phe Lys lle Met Ser Gly Glu 515 520 525
Val Pro Ser Thr Glu Asp Leu Val Asn Leu Leu Pro Ala lle Leu Ser 530 535 540 Pro Gly Ala Leu Val Val Gly Val Val Cys Ala Ala lle Leu Arg Arg
545 550 555 560
His Val Gly Pro Gly Glu Gly Ala Val Gln Trp Met Asn Arg Leu lle
565 570 575
Ala Phe Ala Ser Arg Gly Asn His Val Ser Pro Trp Asp Pro Leu Asp
580 585 590
Cys Arg His Ala Lys
595
(2) INFORMATION FOR SEQ ID NO:22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1797 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1797
(xi) SEQUENCE DESCRIPTION: SEQ ID N022:
ATG AGTTTT CTG GTC ATT ATT CCC GCG CGC TAC GCG TCG ACG CGT CTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCCGGTAAA CCATT GGTT GATATT AAC GGCAAA CCCATGATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
GTT CTT GAA CGC GCG CGT GAA TCA GCT GCC GAG CGC ATCATCGTGGCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
ACCGATCATGAGGATGTT GCC CGCGCCGTT GAA GCCGCTGGCGGTGAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
GTATGT ATG ACG CGC GCCGATCATCAGTCAGGAACAGAA CGTCTG GCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAA GTT GTC GAA AAA TGC GCATT C AGC GAC GAC ACG CTG ATC GTT AAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT CGT CAG GTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val 100 105 110
GCT GAT AAC CTC GCT CAG CGT CAG CTG GGT ATG GCG ACT CTG GCG GTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
CCA ATC CAC AAT GCG GAA GAA GCG TTT AAC CCG AAT GCG GTG AAA CTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TT C TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
CCT TGG GAT CGT GAT CGT TT TGCA GAA GGC CTT GAA ACC GTT GGC GAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
AACTT CCTGCGT CATCTT GGTATT TATGGCTACCGTGCAGGCTTTATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
CGT CGT TAC GTC AAC TGG CAG CCA AGT CCG TT A GAA CAC ATC GAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TT AGAGCAGCTT CGTGTT CTGTGGTACGGCGAA AAA ATCCATGTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTT GCTCAGGAA GTT CCTGGCACAGGTGTGGATACCCCTGAA GATCTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GAC CCG TCG ACG AAT TCC ATG GAC GCT CAC TT C CTG TCT CAG ACC AAA 768 Asp Pro Ser Thr Asn Ser Met Asp Ala His Phe Leu Ser Gln Thr Lys
245 250 255
CAGTCTGGTGAA AACCTT CCGTACCTGGTT GCTTACCAGGCTACCGTT 816 Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val
260 265 270
TGCGCTCGTGCTCAGGCCCCGACCCCGCTGCTGTACCGTCTGGGTGCT 864 Cys Ala Arg Ala Gln Ala Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala
275 280 285
GTT CAGAACGAA ATCACCCTGACCCACCCGGTT ACC/\AA TACATCATG 912 Val Gln Asn Glu lle Thr Leu Thr His Pro Val Thr Lys Tyr lle Met
290 295 300
ACC TGC ATG TCT GCT GAT CTA GAA GTT GTT ACC TCT ACC TGG GTT CTG 960 Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp Val Leu
305 310 315 320
GTT GGTGGTGTT CTGGCTGCTCTGGCTGCTTACTGCCTGTCGACCGGT 1008 Val Gly Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu Ser Thr Gly
325 330 335
TGCGTT GTT ATCGTT GGTCGTGTT GTT CTGTCTGGTAAA CCG GCC ATT 1056 Cys Val Val lle Val Gly Arg Val Val Leu Ser Gly Lys Pro Ala lle
340 345 350
ATCCCGGACCGTGAA GTT CTGTACCGTGAGTT CGACGAA ATGGAA GAA 1104 lle Pro Asp Arg Glu Val Leu Tyr Arg Glu Phe Asp Glu Met Glu Glu
355 360 365
TGC TCT CAG CAC CTG CCG TAC ATC GAA CAG GGT ATG ATG CTG GCT GAA 1152 Cys Ser Gln His Leu Pro Tyr lle Glu Gln Gly Met Met Leu Ala Glu
370 375 380
CAG TT C AAA CAG AAA GCT CTG GGT CTG CTG CAG ACC GCT TCT CGT CAG 1200 Gln Phe Lys Gln Lys Ala Leu Gly Leu Leu Gln Thr Ala Ser Arg Gln
385 390 395 400
GCTGAA GTT ATCGCTCCGGCTGTT CAGACCAACTGGCAGAAA CTCGAG 1248 Ala Glu Val lle Ala Pro Ala Val Gln Thr Asn Trp Gln Lys Leu Glu
405 410 415
ACC TT C TGG GCT AAA CAC ATG TGG AAC TT C ATC TCT GGT ATC CAG TAC 1296 Thr Phe Trp Ala Lys His Met Trp Asn Phe lle Ser Gly lle Gln Tyr
420 425 430
CTG GCT GGT CTG TCT ACC CTG CCG GGTAAC CCG GCT ATC GCAAGCTT G 1344 Leu Ala Gly Leu Ser Thr Leu Pro Gly Asn Pro Ala lle Ala Ser Leu
435 440 445
ATG GCT TT C ACC GCT GCT GTT ACC TCT CCG CTG ACC ACC TCT CAG ACC 1392 Met Ala Phe Thr Ala Ala Val Thr Ser Pro Leu Thr Thr Ser Gln Thr
450 455 460
CTG CTG TT C AAC ATT CTG GGT GGT TGG GTT GCT GCT CAG CTG GCT GCT 1440 Leu Leu Phe Asn lle Leu Gly Gly Trp Val Ala Ala Gln Leu Ala Ala
465 470 475 480
CCGGCTGCTGCTACCGCTTT CGTT GGTGCTGGTCTGGCTGGTGCTGCT 1488 Pro Gly Ala Ala Thr Ala Phe Val Gly Ala Gly Leu Ala Gly Ala Ala
485 490 495
ATC GCT TCT GTA GGC CTG GCT AAA GTT CTG ATC GAC ATT CTG GCT GGT 1536 lle Gly Ser Val Gly Leu Gly Lys Val Leu lle Asp lle Leu Ala Gly
500 505 510
TAC GGT GCT GGT GTT GCT GGA GCT CTG GTT GCT TT C AAA ATC ATG TCT 1584 Tyr Gly Ala Gly Val Ala Gly Ala Leu Val Ala Phe Lys lle Met Ser
515 520 525
GGT GAA GTT CCG TCT ACC GAA GAT CTG GTTAAC CTG CTG CCG GCT ATC 1632 Gly Glu Val Pro Ser Thr Glu Asp Leu Val Asn Leu Leu Pro Ala lle
530 535 540 CTG TCT CCG GGT GCT CTG GTT GTT GGT GTT GTT TGC GCT GCT ATC CTG 1680 Leu Ser Pro Gly Ala Leu Val Val Gly Val Val Cys Ala Ala lle Leu
545 550 555 560
CGTCGTCACGTT GGCCCGGGTGAA GGTGCTGTT CAGTGGATGAACCGT 1728 Arg Arg His Val Gly Pro Gly Glu Gly Ala Val Gln Trp Met Asn Arg
565 570 575
CTG ATC GCT TT C GCT TCT CGT GGT AAC CAC GTT TCT CCA TGG GAT CCT 1776 Leu lle Ala Phe Ala Ser Arg Gly Asn His Val Ser Pro Trp Asp Pro
580 585 590
CTA GAC TGC AGG CAT GCT AA G 1797
Leu Asp Cys Arg His Ala Lys
595
(2) INFORMATION FOR SEQ ID NO:23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 599 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle 180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Met Asp Ala His Phe Leu Ser Gln Thr Lys
245 250 255
Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr Gln Ala Thr Val 260 265 270
Cys Ala Arg Ala Gln Ala Pro Thr Pro Leu Leu Tyr Arg Leu Gly Ala 275 280 285
Val Gln Asn Glu lle Thr Leu Thr His Pro Val Thr Lys Tyr lle Met 290 295 300
Thr Cys Met Ser Ala Asp Leu Glu Val Val Thr Ser Thr Trp Val Leu 305 310 315 320
Val Gly Gly Val Leu Ala Ala Leu Ala Ala Tyr Cys Leu Ser Thr Gly
325 330 335
Cys Val Val lle Val Gly Arg Val Val Leu Ser Gly Lys Pro Ala lle 340 345 350
lle Pro Asp Arg Glu Val Leu Tyr Arg Glu Phe Asp Glu Met Glu Glu 355 360 365
Cys Ser Gln His Leu Pro Tyr lle Glu Gln Gly Met Met Leu Ala Glu 370 375 380
Gln Phe Lys Gln Lys Ala Leu Gly Leu Leu Gln Thr Ala Ser Arg Gln 385 390 395 400
Ala Glu Val lle Ala Pro Ala Val Gln Thr Asn Trp Gln Lys Leu Glu
405 410 415
Thr Phe Trp Ala Lys His Met Trp Asn Phe lle Ser Gly lle Gln Tyr 420 425 430
Leu Ala Gly Leu Ser Thr Leu Pro Gly Asn Pro Ala lle Ala Ser Leu 435 440 445
Met Ala Phe Thr Ala Ala Val Thr Ser Pro Leu Thr Thr Ser Gln Thr
450 455 460
Leu Leu Phe Asn lle Leu Gly Gly Trp Val Ala Ala Gln Leu Ala Ala
465 470 475 480
Pro Gly Ala Ala Thr Ala Phe Val Gly Ala Gly Leu Ala Gly Ala Ala
485 490 495
lle Gly Ser Val Gly Leu Gly Lys Val Leu lle Asp lle Leu Ala Gly
500 505 510
Tyr Gly Ala Gly Val Ala Gly Ala Leu Val Ala Phe Lys lle Met Ser
515 520 525
Gly Glu Val Pro Ser Thr Glu Asp Leu Val Asn Leu Leu Pro Ala lle
530 535 540
Leu Ser Pro Gly Ala Leu Val Val Gly Val Val Cys Ala Ala lle Leu
545 550 555 560
Arg Arg His Val Gly Pro Gly Glu Gly Ala Val Gln Trp Met Asn Arg
565 570 575
Leu lle Ala Phe Ala Ser Arg Gly Asn His Val Ser Pro Trp Asp Pro
580 585 590
Leu Asp Cys Arg His Ala Lys
595
(2) INFORMATION FOR SEQ ID NO:24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1251 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1251
(xi) SEQUENCE DESCRIPTION: SEQ ID NO24:
ATG AGT TTT GTG GTC ATT ATT CCC GCG CGC TAC GCG TCG ACG CGT CTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCCGGTA AA CCATT GGTT GATATT AACGGCAAA CCCATGATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His 20 25 30
GTT CTT GAA CGCGCGCGTGAA TCAGGTGCCGAGCGCATCATCCTGGCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
ACCGATCATGAGGATGTT GCC CGCGCCGTT GAA GCC GCTGGCGCTGAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
CTATCTATGACGCGCGCC GATCATCAGTCAGGAACAGAA CGTCTGGCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAA GTT GTCGAA AAA TGC GCATT CAGCGACGACACGGTGATCGTT AAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT CGT CAG GTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
GCT GATAAC CTC GCT CAG CGT CAG CTG GGT ATG GCG ACT CTG GCG GTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
CCAATCCACAATGCGGAA GAA GCGTT TAACCCGAATGCGCTGAAA CTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TT C TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
CCT TGG GAT CGT GAT CCT TTT GCA GAA GGC CTT GAA ACC GTT GGC GAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
AAC TT C CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA GGC TTT ATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
CGT CGTTAC GTC AAC TGG CAG CCA AGT CCG TT A GAA CAC ATC GAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TT A GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC CAT GTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTT GCT CAG GAA GTT CCT GGC ACA GGT GTG GAT ACC CCT GAA GAT CTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GACCCGTCGACTCGAATT CGAGCTCGGTACCCTGAGACAATCACGCTT 768 Asp Pro Ser Thr Arg lle Arg Ala Arg Tyr Pro Glu Thr lle Thr Leu
245 250 255
CCCCAGGATGCTGTCTCCCGCACCCAGCGTCGGGGCAGGACTGGCAGG 816 Pro Gln Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg
260 265 270
GGGAAGCCAGGCATCTACAGATTTGTGGCACCGGGGGAGCGCCCTTCC 864 Gly Lys Pro Gly lle Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser
275 280 285
GGCATGTT CGACTCGTCCGTCCTCTGCGAGTGCTATGACGCGGGCTGG 912 Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Trp
290 295 300
CCTTGGTATGAGCTCACACCCGCC GAGACC/VCAGTT AGGCTACGAGCG 960 Pro Trp Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala
305 310 315 320
TAC ATG AAC ACC CCG GGA CTC CCC GTG TGC CAA GAC CAT CFGAATTT 1008 Tyr Met Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe
325 330 335
TGG GAG GGC GTC TT C ACG GCT CTC ACC CAT ATA GAC GCC CAC TTT CTA 1056 Trp Glu Gly Val Phe Thr Gly Leu Thr His lle Asp Ala His Phe Leu
340 345 350
TCCCAGACAAAGCAGAGTGGGGAA AACCTT CCTTACCTGGTAGCGTAC 1104 Ser Gln Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr
355 360 365
CAA GCCACCGTGTGCGCTAGAGCTCAA GCC CCTCCCCCATCGTGGGAC 1152 Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp
370 375 380
CAG ATG TGG AAG TGC TT G ATC CGC CTC AAG CCT ACC CTT CAT GGG CCG 1200 Gln Met Trp Lys Cys Leu lle Arg Leu Lys Pro Thr Leu His Gly Pro
385 390 395 400
ACCCCCCTGCTATACAGACTGGGCGGGGGATCCTCTAGACTGCAGGCA 1248 Thr Pro Leu Leu Tyr Arg Leu Gly Gly Gly Ser Ser Arg Leu Gln Ala
405 410 415
TGC 1251
Cys
(2) INFORMATION FOR SEQ ID NO:25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 417 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu 1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His 20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val 100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle 180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Vai Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Arg lle Arg Ala Arg Tyr Pro Glu Thr lle Thr Leu
245 250 255
Pro Gln Asp Ala Val Ser Arg Thr Gln Arg Arg Gly Arg Thr Gly Arg 260 265 270 Gly Lys Pro Gly lle Tyr Arg Phe Val Ala Pro Gly Glu Arg Pro Ser
275 280 285
Gly Met Phe Asp Ser Ser Val Leu Cys Glu Cys Tyr Asp Ala Gly Trp
290 295 300
Pro Trp Tyr Glu Leu Thr Pro Ala Glu Thr Thr Val Arg Leu Arg Ala
305 310 315 320
Tyr Met Asn Thr Pro Gly Leu Pro Val Cys Gln Asp His Leu Glu Phe
325 330 335
Trp Glu Gly Val Phe Thr Gly Leu Thr His lle Asp Ala His Phe Leu
340 345 350
Ser Gln Thr Lys Gln Ser Gly Glu Asn Leu Pro Tyr Leu Val Ala Tyr
355 360 365
Gln Ala Thr Val Cys Ala Arg Ala Gln Ala Pro Pro Pro Ser Trp Asp
370 375 380
Gln Met Trp Lys Cys Leu lle Arg Leu Lys Pro Thr Leu His Gly Pro
385 390 395 400
Thr Pro Leu Leu Tyr Arg Leu Gly Gly Gly Ser Ser Arg Leu Gln Ala
405 410 415
Cys
(2) INFORMATION FOR SEQ ID NO:26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1275 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1275
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.26:
ATGAGTTTTGTGGTCATT ATT CCCGCGCGCTACGCGTCGACGCGTCTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCCGGTAAA CCATT GGTT GATATT AACGGCAAA CCCATGATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
GTT CTT GAA CGCGCGCGTGAA TCAGGTGCCGAGCGCATCATCGTG GCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
ACCGATCATGAGGATGTT GCCCGCGCCGTT GAA GCC GCTGGCGGTGAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
GTATGT ATG ACG CGC GCC GAT CAT CAG TCA GGA ACA GAA CGT CTG GCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAA GTT GTC GAA AAA TGC GCA TT C AGC GAC GAC ACG CTG ATC GTT AAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT CGT CAG GTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
GCT GAT AAC CTC GCT CAG CGT CAG GTG GGT ATG GCG ACT CTG GCG GTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
CCAATCCACAATGCGGAA GAA GCGTT TAACCCGAATGCGGTGAAA GTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TT C TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
CCT TGG GAT CGT GAT CCT TTT GCA GAA GGC CTT GAA ACC GTT GGC GAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
AAC TT C CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA GGC TTT ATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
CGTCGTTAC GTC AAC TGG CAG CCA AGT CCG TT AGAA CAC ATC GAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TT A GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC CAT GTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTT GCT CAG GAA GTT CCT GGC ACA GGT GTG GAT ACC CCT GAA GAT CTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GACCCGTCGACTCGAATT CGTAGGTCGCGCAATTT GGGTAAGGTCATC 768 Asp Pro Ser Thr Arg lle Arg Arg Ser Arg Asn Leu Gly Lys Val lle
245 250 255 GAC ACC CTC ACG TGC GGC TT C GCC GAC CTC ATG GGG TAT ATT CCG CTC 816 Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr lle Pro Leu
260 265 270
GTCGGCGCCCCTCTT GGAGGCGCTGCCAGGGCCCTGGGCCATGGCGTC 864 Val Gly Ala Pro Leu Gly Gly Ala Ala Arg Ala Leu Gly His Gly Val
275 280 285
CGG GTT CTGGAA GAC GGC GTG AAC TAT GCG ACA GGG AATCTT CCT GCT 912 Arg Val Leu Glu Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly
290 295 300
TGC TCTTT C TCT ATC TT C CTT CTG GCC CTG CTC TCTTGC CTG ACC GTG 960 Cys Ser Phe Ser lle Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val
305 310 315 320
CCCGCATCAGCCTACCAA GTACGCAACTCCTCGGGCCTTTACCATGTC 1008 Pro Ala Ser Ala Tyr Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val
325 330 335
ACCAATGATTGCCCCAACTCGAGTATT GTG TACGAGACGGCC GATGCC 1056 Thr Asn Asp Cys Pro Asn Ser Ser lle Val Tyr Glu Thr Ala Asp Ala
340 345 350
ATCCTGCACACTCCGGGGTGCGTCCCTTGCGTT CGTGAGGGCAACGCC 1104 lle Leu His Thr Pro Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala
355 360 365
TCG A GATGTTGGCTGGCGGTGGCCCCCACA GTGGCCA CCA GGGATGGA 1152 Ser Arg Cys Trp Val Ala Val Ala Pro Thr Val Ala Thr Arg Asp Gly
370 375 380
AAA CTC CCC GCA ACG CAG CTT CGA CGT CAC ATT GAT CTG CTT GTC GGG 1200 Lys Leu Pro Ala Thr Gln Leu Arg Arg His lle Asp Leu Leu Val Gly
385 390 395 400
AGC GCC ACC CTCTGTTCG GCCCTCTACTT A AGG AGCTCG GTACCCGGG 1248 Ser Ala Thr Leu Cys Ser Ala Leu Tyr Leu Arg Ser Ser Val Pro Gly
405 410 415
GAT CCT CTA GAC TGC AGG CAT GCT AA G 1275
Asp Pro Leu Asp Cys Arg His Ala Lys
420 425
(2) INFORMATION FOR SEQ ID NO:27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 425 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu 1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His 20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val 100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle 180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Arg lle Arg Arg Ser Arg Asn Leu Gly Lys Val lle
245 250 255
Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr lle Pro Leu 260 265 270
Val Gly Ala Pro Leu Gly Gly Ala Ala Arg Ala Leu Gly His Gly Val 275 280 285 Arg Val Leu Glu Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly
290 295 300
Cys Ser Phe Ser lle Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val
305 310 315 320
Pro Ala Ser Ala Tyr Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val
325 330 335
Thr Asn Asp Cys Pro Asn Ser Ser lle Val Tyr Glu Thr Ala Asp Ala
340 345 350
lle Leu His Thr Pro Gly Cys Val Pro Cys Val Arg Glu Gly Asn Ala
355 360 365
Ser Arg Cys Trp Val Ala Val Ala Pro Thr Val Ala Thr Arg Asp Gly
370 375 380
Lys Leu Pro Ala Thr Gln Leu Arg Arg His lle Asp Leu Leu Val Gly
385 390 395 400
Ser Ala Thr Leu Cys Ser Ala Leu Tyr Leu Arg Ser Ser Val Pro Gly
405 410 415
Asp Pro Leu Asp Cys Arg His Ala Lys
420 425
(2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1401 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1401
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
ATGAGTTT TGTGGTCATT ATT CCCGCGCGCTACGCGTCGACGCGTCTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCCGGTAAA CCATT GGTT GATATT AACGGCAAA CCCATGATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
GTT CTT GAA CGCGCGCGTGAA TCAGGTGCCGAGCGCATCATCGTG GCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45 ACCGATCA TGAGGATGTT GCCC GCGCCGTT GAA GCC GCTGGCGCTGAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
CTATGTATGACGCGCGCCGATCATCAGTCAGGAACAGAA CGTCTGGCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAA GTT GTCGAA AAA TGCGCATT CAGCGACGACACGCTGATCGTT AAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT CGT CAG GTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
GCT GAT AAC CTC GCT CAG CGT CAG GTG GGT ATG GCG ACT CTG GCG GTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
CCAATCCACAATGCGGAA GAA GCGTTT AACCCGAATGCGGTGAAA CTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TT C TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
CCT TGG GAT CGT GAT CCT TTT GCA GAA GGC CTT GAA ACC GTT GGC GAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
AAC TT C CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA GGC TTT ATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
CGT CGT TAC GTC AAC TGG CAG CC A AGT CCG TT A GAA CAC ATC GAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TT A GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC CAT GTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTT GCTCAGGAA GTT CCTGGCACAGGTGTGGATACCCCTGAA GATCTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GAC CCG TCG ACT CGA ATT CTG CTT GTC GGG AGC GCC ACC CTC TGC TCG 768 Asp Pro Ser Thr Arg lle Leu Leu Val Gly Ser Ala Thr Leu Cys Ser
245 250 255
GCC CTC TAT GTG GGG GAC TT G TGC GGG TCT CTC TTT cTT GTC GGT CAA 816 Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly Gln 260 265 270
CTG TT C ACTTT C TCC CCC AGG CAG CAC TGG ACA ACG CAA GAC TGC AAC 864 Leu Phe Thr Phe Ser Pro Arg Gln His Trp Thr Thr Gln Asp Cys Asn
275 280 285
TGTTCT ATC TAC CCC GGC CAC GTA ACG GGT CAC CGC ATG GCA TGG GAT 912 Cys Ser lle Tyr Pro Gly His Val Thr Gly His Arg Met Ala Trp Asp
290 295 300
ATG ATG ATG AAC TGG TCC CCT ACG ACA GCG CTG CTA GTA GCT CAG CTG 960 Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ala Gln Leu
305 310 315 320
CTC AGG GTC CCG CAA GCC ATC TT G GAC ATG ATC GCT GGT GCC CAC TGG 1008 Leu Arg Val Pro Gln Ala lle Leu Asp Met lle Ala Gly Ala His Trp
325 330 335
GGAGTCCTAGCGGGCATAGCGTATTT CTCCATGGTGGGGAA CTGGGCG 1056 Gly Val Leu Ala Gly lle Ala Tyr Phe Ser Met Val Gly Asn Trp Ala
340 345 350
AAGGTCCTGGTAGTG CTGCTGCTATTT GCC GGCGTT GACGCGGAA ACC 1104 Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu Thr
355 360 365
CACGTCACCGGGGGAAGTGCCGGCCACATT ACGGCTGGGCTT GTT CGT 1152 His Val Thr Gly Gly Ser Ala Gly His lle Thr Ala Gly Leu Val Arg
370 375 380
CTC CTTTCA CCA GGC GCC AAG CAG AAC ATC CAA CTG ATC AAC ACCAAC 1200 Leu Leu Ser Pro Gly Ala Lys Gln Asn lle Gln Leu lle Asn Thr Asn
385 390 395 400
GGCAGTTGGCACATCAATAGCACGGCCTT GAACTGCAATGAA AGCCTT 1248 Gly Ser Trp His lle Asn Ser Thr Ala Leu Asn Cys Asn Glu Ser Leu
405 410 415
AAC ACC GGC TGG TT A GCA GGG CTC TT C TAT CAC CAC AAATTCAAC TCT 1296 Asn Thr Gly Trp Leu Ala Gly Leu Phe Tyr His His Lys Phe Asn Ser
420 425 430
TCAGGCTGTCCTGAGAGGGTT GCC AGCTGCCGTCGCCTT ACCGATTTT 1344 Ser Gly Cys Pro Glu Arg Val Ala Ser Cys Arg Arg Leu Thr Asp Phe
435 440 445
GAC CAG GGC TGG GAA TTC GAG CTC GGT ACC CGG GGA TCC TCT AGACTG 1392 Asp Gln Gly Trp Glu Phe Glu Leu Gly Thr Arg Gly Ser Ser Arg Leu
450 455 460
CAG GCA TGC 1401
Gln Ala Cys
465 (2) INFORMATION FOR SEQ ID N0:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 467 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO.29:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu 1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His 20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val 100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle 180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240 Asp Pro Ser Thr Arg lle Leu Leu Val Gly Ser Ala Thr Leu Cys Ser 245 250 255
Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser Val Phe Leu Val Gly Gln 260 265 270
Leu Phe Thr Phe Ser Pro Arg Gln His Trp Thr Thr Gln Asp Cys Asn 275 280 285
Cys Ser lle Tyr Pro Gly His Val Thr Gly His Arg Met Ala Trp Asp 290 295 300
Met Met Met Asn Trp Ser Pro Thr Thr Ala Leu Val Val Ala Gln Leu 305 310 315 320
Leu Arg Val Pro Gln Ala lle Leu Asp Met lle Ala Gly Ala His Trp
325 330 335
Gly Val Leu Ala Gly lle Ala Tyr Phe Ser Met Val Gly Asn Trp Ala 340 345 350
Lys Val Leu Val Val Leu Leu Leu Phe Ala Gly Val Asp Ala Glu Thr 355 360 365
His Val Thr Gly Gly Ser Ala Gly His lle Thr Ala Gly Leu Val Arg 370 375 380
Leu Leu Ser Pro Gly Ala Lys Gln Asn lle Gln Leu lle Asn Thr Asn 385 390 395 400
Gly Ser Trp His lle Asn Ser Thr Ala Leu Asn Cys Asn Glu Ser Leu
405 410 415
Asn Thr Gly Trp Leu Ala Gly Leu Phe Tyr His His Lys Phe Asn Ser 420 425 430
Ser Gly Cys Pro Glu Arg Val Ala Ser Cys Arg Arg Leu Thr Asp Phe 435 440 445
Asp Gln Gly Trp Glu Phe Glu Leu Gly Thr Arg Gly Ser Ser Arg Leu 450 455 460
Gln Ala Cys
465
(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1422 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular (ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1422
(xi) SEQUENCE DESCRIPTION: SEQ ID NO_30:
ATG AGTTTTGTG GTC ATT ATT CCCGCG CGCTACGCGTCG ACGCCTCTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCCGGTAAA CCATT GGTT GATATT AAC GGCAAA CCCATGATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
GTT cTT GAA CGCGCGCGTGAA TCAGGTGCCGAGCGCATCATCGTGGCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
ACC GAT CAT GAG GAT GTT GCC CGC GCC GTT GAA GCC GCT GGC GCTGAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
GTATCTATGACGCGCGCCGATCATCAGTCAGGAACAGAA CGTCTGGCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAA GTT GTCGAA AAA TGCGCATT CAGCGACGACACGCTGATCGTT AAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT CGT CAG GTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 1 10
GCT GAT AAC CTC GCT CAG CGT CAG GTG GCT ATG GCG ACT CTG GCG CTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
CCA ATC CAC AAT GCG GAA GAA GCG TTT AAC CCG AAT GCG GTG AAA GTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TT C TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
CCT TGG GAT CGT GAT CGT TTT GCA GAA GGC CTT GAA ACC GTT GGC GAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
AAC TT C CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA GGC TTT ATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190 CGT CGT TAC GTC AAC TGG CAG CCA AGT CCG TT A GAA CAC ATC GAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TT A GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC CAT GTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTT GCTCAGGAA GTT CCTGGCACAGGTGTG GATACCCCTGAAGATCTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GAC CCG TCG ACC GAAHC GGT GAC ATC ATC AAC GGC TT G CCC GTC TCC 768 Asp Pro Ser Thr Glu Phe Gly Asp lle lle Asn Gly Leu Pro Val Ser
245 250 255
GCCCGTAGGGGCCAGGAGATACTGCTCGGACCAGCCGACGGAATGGTC 816 Ala Arg Arg Gly Gln Glu lle Leu Leu Gly Pro Ala Asp Gly Met Val
260 265 270
TCCAAGGGGTGGAGGTT GCTGGCGCCCATCACGGCGTACGCCCAGCAG 864 Ser Lys Gly Trp Arg Leu Leu Ala Pro lle Thr Ala Tyr Ala Gln Gln
275 280 285
ACAAGGGGCCTCCTAGGGTGTATAATCACCAGCCTGACTGGCCGGGAC 912 Thr Arg Gly Leu Leu Gly Cys lle lle Thr Ser Leu Thr Gly Arg Asp
290 295 300
AAA AACCAA GCGGAGGGTGAGGTCCAGATT GTGTCAACTGCTGCC CAA 960 Lys Asn Gln Ala Glu Gly Glu Val Gln lle Val Ser Thr Ala Ala Gln
305 310 315 320
ACTTT C CTG GCA ACG TGC ATC AAT GGG GTA TGC TGG ACT GTC TAC CAT 1008 Thr Phe Leu Ala Thr Cys lle Asn Gly Val Cys Trp Thr Val Tyr His
325 330 335
GGGGCC GGAACGAGGACCCTCGCATCACCCAAGGGTCCTGTT ATCCAG 1056 Gly Ala Gly Thr Arg Thr Leu Ala Ser Pro Lys Gly Pro Val lle Gln
340 345 350
ATG TAT ACC AAT GTA GAC CAA GAC CTT GTG GGC TGG CCC GCT CCT CAA 1104 Met Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro Ala Pro Gln
355 360 365
GGT GCC CGC TCATT G ACA CCC TGC ACC TGC GGC TCC TCG GAC CTTTAC 1152 Gly Ala Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr
370 375 380
CTGGTT ACGAGGCACGCCGATGTCATT CCCGTGCGCCGGCGGGGTGAT 1200 Leu Val Thr Arg His Ala Asp Val lle Pro Val Arg Arg Arg Gly Asp
385 390 395 400
AGCAGGGGCAGCCTGCTT TCGCCCCGGCCCATT TCTTATTT GAAA GGC 1248 Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro lle Ser Tyr Leu Lys Gly 405 410 415
TCC TCG GGG GCT CCG CTG TT G TGC CCC GCG GGA CAC GCC CTG GGC ATA 1296 Ser Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly lle
420 425 430
TT CAGGGCC GCGGTGTCTA CCGTGGACTGGCTAAGGCGCTGGACTTT 1344 Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe
435 440 445
GTCCCCGTGGAGAA CCTCGAGACAACCATGAATTCGAGCTCGCTACCC 1392 Val Pro Val Glu Asn Leu Glu Thr Thr Met Asn Ser Ser Ser Val Pro
450 455 460
GGG GAT CCT CTA GAC TGC AGG CAT GCT AAG 1422
Gly Asp Pro Leu Asp Cys Arg His Ala Lys
465 470
(2) INFORMATION FOR SEQ ID NO:31 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 474 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31 :
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle 180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Glu Phe Gly Asp lle lle Asn Gly Leu Pro Val Ser
245 250 255
Ala Arg Arg Gly Gln Glu lle Leu Leu Gly Pro Ala Asp Gly Met Val 260 265 270
Ser Lys Gly Trp Arg Leu Leu Ala Pro lle Thr Ala Tyr Ala Gln Gln 275 280 285
Thr Arg Gly Leu Leu Gly Cys lle lle Thr Ser Leu Thr Gly Arg Asp 290 295 300
Lys Asn Gln Ala Glu Gly Glu Val Gln lle Val Ser Thr Ala Ala Gln 305 310 315 320
Thr Phe Leu Ala Thr Cys lle Asn Gly Val Cys Trp Thr Val Tyr His
325 330 335
Gly Ala Gly Thr Arg Thr Leu Ala Ser Pro Lys Gly Pro Val lle Gln 340 345 350
Met Tyr Thr Asn Val Asp Gln Asp Leu Val Gly Trp Pro Ala Pro Gln 355 360 365
Gly Ala Arg Ser Leu Thr Pro Cys Thr Cys Gly Ser Ser Asp Leu Tyr 370 375 380
Leu Val Thr Arg His Ala Asp Val lle Pro Val Arg Arg Arg Gly Asp 385 390 395 400
Ser Arg Gly Ser Leu Leu Ser Pro Arg Pro lle Ser Tyr Leu Lys Gly
405 410 415
Ser Ser Gly Gly Pro Leu Leu Cys Pro Ala Gly His Ala Val Gly lle 420 425 430 Phe Arg Ala Ala Val Cys Thr Arg Gly Val Ala Lys Ala Val Asp Phe
435 440 445
Val Pro Val Glu Asn Leu Glu Thr Thr Met Asn Ser Ser Ser Val Pro
450 455 460
Gly Asp Pro Leu Asp Cys Arg His Ala Lys
465 470
(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1401 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 1..1401
(xi) SEQUENCE DESCRIPTION: SEQ ID NO3: 2:
ATGAGTTTT GTG GTCATT ATT CCCGCGCGCTACGCGTCGACGCCTCTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCCGGTAAA CCATT GGTT GATATT AAC GGCAAA CCCATGATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
GTT CTT GAA CGCGCGCGTGAA TCAGCTGCCGAGCGCATCATCCTGGCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala
35 40 45
ACCGATCATGAGGATGTT GCC C GCGCCGTT GAA GCC GCTGGCGGTGAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
GTATGTATGACGCGCGCCGATCATCAGTCAGGAACAGAA CGTCTGGCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAA GTT GTC GAA AAA TGC GCA TT C AGC GAC GAC ACG GTG ATC GTT AAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
GTGCAG GGTGATGAA CCG ATG ATCCCTGCG ACAATC ATT CGTCAGGTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110 GCTGATAACCTCGCTCAGCGTCAGGTG GGTATGACGACTCTGGCGGTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Thr Thr Leu Ala Val
115 120 125
CCAATCCACAATGCGGAA GAA GCGTTT AACCCGAATGCGGTGAAA GTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TT C TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
CCTTGGGATCGTGATCGTTTT GCAGAA GGCCTT GAA ACCGTT GGCGAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
AAC TT C CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA GGC TTT ATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
CGT CGT TAC GTC AAC TGG CAG CCA AGT CCG TT A GAA CAC ATC GAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TT A GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC CAT GTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTT GCTCAGGAA GTT CCTGGCACAGGTGTGGATACCCCTGAA GATCTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GAC CCG TCG ACG AAT TCC ACC ATG GGG CATTAT CCTTGT ACC ATC AAC 768 Asp Pro Ser Thr Asn Ser Thr Met Gly His Tyr Pro Cys Thr lle Asn
245 250 255
TACACCCTGTT CAAA GTCAGGATGTACCTGGGAGGGGTCGAGCACAGG 816 Tyr Thr Leu Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg
260 265 270
CTGGAA GTT GCTTGCAACTGGACGCGGGGCGAA CCTTGTGATCTGGAC 864 Leu Glu Val Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Asp
275 280 285
GACAGGGACAGGTCCGAGCTCAGCCCGCTGCTGCTGTCC/VCCACTCAG 912 Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln
290 295 300
TGG CAG GTC CTT CCG TGTTCC TT C ACG ACC TT G CCA GCC TT G ACC ACC 960 Trp Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Thr Thr
305 310 315 320
GGC CTC ATC CAC CTC CAC CAG AAC ATC GTG GAC GTG CAA TAC TT G TAC 1008 Gly Leu lle His Leu His Gln Asn lle Val Asp Val Gln Tyr Leu Tyr
325 330 335 GGG GTG GGG TC A AGC ATT GTG TCC TGG GCC ATC AAG TGG GAG TAC CTC 1056 Gly Val Gly Ser Ser lle Val Ser Trp Ala lle Lys Trp Glu Tyr Val
340 345 350
ATC CTC TT GTT T CTC CTG CTT GCA GAC GCG CGC ATC TGC TCC TGC TT G 1104 lle Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg lle Cys Ser Cys Leu
355 360 365
TGG ATGA TG TT A CTC ATA TCC CAA GCG GAG GCA GCC TT G GAA AAC CTT 1152 Trp Met Met Leu Leu lle Ser Gln Ala Glu Ala Ala Leu Glu Asn Leu
370 375 380
CTG TT A CTC AAT GCG GCG TCT CTG GCC GGG ACG CAC GCT CTT GTG TCC 1200 Val Leu Leu Asn Ala Ala Ser Leu Ala Gly Thr His Gly Leu Val Ser
385 390 395 400
TT C CTC GTGTTT TT C TGC TTT GC A TGG TAT CTG AAG GGT AAG TGG GTG 1248
Phe Leu Val Phe Phe Cys Phe Ala Trp Tyr Leu Lys Gly Lys Trp Val
405 410 415
CCC GGA GTG GCC TAC GCC TT C TAC GGG ATG TGG CCTTT C CTC CTG CTC 1296 Pro Gly Val Ala Tyr Ala Phe Tyr Gly Met Trp Pro Phe Leu Leu Leu
420 425 430
CTG TT A GCG TT G CCC CAA CGG GCA TAC GCG CTG GAC ACG GAG ATG GCC 1344 Leu Leu Ala Leu Pro Gln Arg Ala Tyr Ala Leu Asp Thr Glu Met Ala
435 440 445
GCG TCG TCT GGC GGCG TT GT T CTT GTCGGGTT AATGGCGCTGACTCTG 1392 Ala Ser Cys Gly Gly Val Val Leu Val Gly Leu Met Ala Leu Thr Leu
450 455 460
TCA CCA TAT 1401
Ser Pro Tyr
465
(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 467 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val 100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Thr Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle 180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Asn Ser Thr Met Gly His Tyr Pro Cys Thr lle Asn
245 250 255
Tyr Thr Leu Phe Lys Val Arg Met Tyr Val Gly Gly Val Glu His Arg 260 265 270
Leu Glu Val Ala Cys Asn Trp Thr Arg Gly Glu Arg Cys Asp Leu Asp 275 280 285
Asp Arg Asp Arg Ser Glu Leu Ser Pro Leu Leu Leu Ser Thr Thr Gln 290 295 300
Trp Gln Val Leu Pro Cys Ser Phe Thr Thr Leu Pro Ala Leu Thr Thr 305 310 315 320
Gly Leu lle His Leu His Gln Asn lle Val Asp Val Gln Tyr Leu Tyr 325 330 335
Gly Val Gly Ser Ser lle Val Ser Trp Ala lle Lys Trp Glu Tyr Val
340 345 350
lle Leu Leu Phe Leu Leu Leu Ala Asp Ala Arg lle Cys Ser Cys Leu
355 360 365
Trp Met Met Leu Leu lle Ser Gln Ala Glu Ala Ala Leu Glu Asn Leu
370 375 380
Val Leu Leu Asn Ala Ala Ser Leu Ala Gly Thr His Gly Leu Val Ser
385 390 395 400
Phe Leu Val Phe Phe Cys Phe Ala Trp Tyr Leu Lys Gly Lys Trp Val
405 410 415
Pro Gly Val Ala Tyr Ala Phe Tyr Gly Met Trp Pro Phe Leu Leu Leu
420 425 430
Leu Leu Ala Leu Pro Gln Arg Ala Tyr Ala Leu Asp Thr Glu Met Ala
435 440 445
Ala Ser Cys Gly Gly Val Val Leu Val Gly Leu Met Ala Leu Thr Leu
450 455 460
Ser Pro Tyr
465
(2) INFORMATION FOR SEQ ID N0:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1851 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: circular
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATIONS ..1851
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
ATG AGT TTT GTG GTC ATT ATT CCC GCG CGC TAC GCG TCG ACG CCT CTG 48 Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
CCC GGT A AA CCA TT G GTT GAT ATT AAC GGC AAA CCC ATG ATT GTT CAT 96 Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30
GTT CTT GAA CGC GC GCG TGAA TCA GGT GCC GAG CGC ATC ATC CTG GCA 144 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
ACC GAT CAT GAG GAT GTT GCC CGC GCC GTT GAA GCC GCT GGC GGT GAA 192 Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu
50 55 60
CTA TGT ATG ACG CGC GCC GAT CAT CAG TCA GGA ACA GAA CGT CTG GCG 240 Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala
65 70 75 80
GAA GTT GTC GAA AAA TGC GCA TT C AGC GAC GAC ACG GTG ATC GTT AAT 288 Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
GTG CAG GGT GAT GAA CCG ATG ATC CCT GCG ACA ATC ATT CGT CAG GTT 336 Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val
100 105 110
GCT GAT AAC CTC GCT CAG CGT CAG GTG GGT ATG GCG ACT CTG GCG GTG 384 Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val
115 120 125
CCA ATC CAC AAT GCG GAA GAA GCG TTT AAC CCG AA T GCG GTG AAA GTG 432 Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val
130 135 140
GTT CTC GAC GCT GAA GGG TAT GCA CTG TAC TT C TCT CGC GCC ACC ATT 480 Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle
145 150 155 160
CCT TGG GAT CGT GAT CGT TTT GCA GAA GGC CTT GAA ACC GTT GGC GAT 528 Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
AAC TT C CTG CGT CAT CTT GGT ATT TAT GGC TAC CGT GCA GGC TTT ATC 576 Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle
180 185 190
CGTCGTTACGTCAACTGG CAG CCA AGT CCG TT AGAA CAC ATCGAA ATG 624 Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met
195 200 205
TT A GAG CAG CTT CGT GTT CTG TGG TAC GGC GAA AAA ATC CAT GTT GCT 672 Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala
210 215 220
GTT GCT CAG GAA GTT CCT GGC ACA GG TGT GGAT ACC CCT GAA GAT CTC 720 Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu
225 230 235 240
GAC CCG TCG ACT CGA ATT CGT AGG TCGC GCA ATT T GG GTA AGG TC A TC 768 Asp Pro Ser Thr Arg lle Arg Arg Ser Arg Asn Leu Gly Lys Val lle
245 250 255 GAT ACC CTC ACG TGC GGCTT C GCC GAC CTC ATG GGG TAC ATT CCG CTC 816 Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr lle Pro Leu
260 265 270
GTC GGC GCC CCT CTT GGA GGC GCT GCC AGG GCC CTG GCG CAT GGC GTC 864 Val Gly Ala Pro Leu Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val
275 280 285
CGG GTT CTGGAA GACGGCGTGAACTATGCAACAGGGAACCTT CCCGGT 912 Arg Val Leu Glu Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly
290 295 300
TGC TCT TT C TCT ATC TT C CTT CTG GCC CTG CTC TCT TGC CTG ACT GTG 960 Cys Ser Phe Ser lle Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val
305 310 315 320
CCC GCG TCA TCC TAC CAA GTA CGC AAC TCC TCG GGC CTT TAT CAT CTC 1008 Pro Ala Ser Ser Tyr Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val
325 330 335
ACC AAT GAT TGC CCC AAC TCG AGC ATT GTG TAC GAG ACG GCC GAT ACC 1056 Thr Asn Asp Cys Pro Asn Ser Ser lle Val Tyr Glu Thr Ala Asp Thr
340 345 350
ATC CTA CAC TCTCCG GGG TGC GTC CCT TGC GTT CGC GAG GGC AAC ACC 1104 lle Leu His Ser Pro Gly Cys Val Pro Cys Val Arg Glu Gly Asn Thr
355 360 365
TCG AAA TGT TGG GTG GCG GTG GCC CCC ACA CTG GCC ACC AGG GAC GGC 1152 Ser Lys Cys Trp Val Ala Val Ala Pro Thr Val Ala Thr Arg Asp Gly
370 375 380
AAA CTC CCC TCA ACG CAG CTT CGA CGT CAC ATC GAT CTG CTC GTC GGG 1200 Lys Leu Pro Ser Thr Gln Leu Arg Arg His lle Asp Leu Leu Val Gly
385 390 395 400
AGC GCC ACC CTC TGC TCG GCC CTC TAT CTG GGG GAC TT G TGC GGG TCT 1248 Ser Ala Thr Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser
405 410 415
GTC TT T CTT GTC AGT CM CTGTT C ACCTT C TCC CCT AGG CGC CAT TGG 1296
Val Phe Leu Val Ser Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp
420 425 430
ACA ACG CAA GAC TGC AAC TGT TCT ATC TAC CCC GGC CAT ATA ACG GGT 1344 Thr Thr Gln Asp Cys Asn Cys Ser lle Tyr Pro Gly His lle Thr Gly
435 440 445
CAC CGC ATG GCATGG GAT ATG ATG ATGAAC TGG TCC CCT ACA ACG GCG 1392 His Arg Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala
450 455 460
CTG GTA CTA GCT CAG CTG CTC AGG GTC CCA CAA GCC ATC TT G GAC ATG 1440 Leu Val Val Ala Gln Leu Leu Arg Val Pro Gln Ala lle Leu Asp Met
465 470 475 480 ATC GCA GGT GCC CAC TGG GGA GTC CTA GCG GGC ATA GCG TAT TT C TCC 1488 lle Ala Gly Ala His Trp Gly Val Leu Ala Gly lle Ala Tyr Phe Ser
485 490 495
ATG GTG GGG AAC TGG GCG AAG GTC CTG GTA GTG CTGTT G CTG TT TTCC 1536 Met Val Gly Asn Trp Ala Lys Val Leu Val Val Leu Leu Leu Phe Ser
500 505 510
GGC GTC GAT GCG GCA ACC TAC ACC A CC GGG GGG AGC GTT GCT AGG ACC 1584 Gly Val Asp Ala Ala Thr Tyr Thr Thr Gly Gly Ser Val Ala Arg Thr
515 520 525
ACG CAT GG A TT C TCC AGC TT A TT C AGT CAA GGC GCC AAG CAG AAC ATC 1632 Thr His Gly Phe Ser Ser Leu Phe Ser Gln Gly Ala Lys Gln Asn lle
530 535 540
CAG CTG ATT AAC ACC AAC GGC AGT TGG CAC ATC AAT CGC ACG GCC TT G 1680 Gln Leu lle Asn Thr Asn Gly Ser Trp His lle Asn Arg Thr Ala Leu
545 550 555 560
AAC TGT AAT GCG AGC CTC GAC ACT GGC TGG GTA GCG GGG CTC TT C TAT 1728 Asn Cys Asn Ala Ser Leu Asp Thr Gly Trp Val Ala Gly Leu Phe Tyr
565 570 575
TAC CAC AAA TT C AAC TCT TCA GGC TGC CCT GAG AGG ATG GCC AGC TGT 1776 Tyr His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys
580 585 590
AGA CCC CTT GCC GAT TTT GAC CAG GGC TGG GAA TT C GAG CTC GGT ACC 1824 Arg Pro Leu Ala Asp Phe Asp Gln Gly Trp Glu Phe Glu Leu Gly Thr
595 600 605
CGG GGA TCC TCT AGA CTG CAG GCA TGC 1851
Arg Gly Ser Ser Arg Leu Gln Ala Cys
610 615
(2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 617 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
Met Ser Phe Val Val lle lle Pro Ala Arg Tyr Ala Ser Thr Arg Leu
1 5 10 15
Pro Gly Lys Pro Leu Val Asp lle Asn Gly Lys Pro Met lle Val His
20 25 30 Val Leu Glu Arg Ala Arg Glu Ser Gly Ala Glu Arg lle lle Val Ala 35 40 45
Thr Asp His Glu Asp Val Ala Arg Ala Val Glu Ala Ala Gly Gly Glu 50 55 60
Val Cys Met Thr Arg Ala Asp His Gln Ser Gly Thr Glu Arg Leu Ala 65 70 75 80
Glu Val Val Glu Lys Cys Ala Phe Ser Asp Asp Thr Val lle Val Asn
85 90 95
Val Gln Gly Asp Glu Pro Met lle Pro Ala Thr lle lle Arg Gln Val 100 105 110
Ala Asp Asn Leu Ala Gln Arg Gln Val Gly Met Ala Thr Leu Ala Val 115 120 125
Pro lle His Asn Ala Glu Glu Ala Phe Asn Pro Asn Ala Val Lys Val 130 135 140
Val Leu Asp Ala Glu Gly Tyr Ala Leu Tyr Phe Ser Arg Ala Thr lle 145 150 155 160
Pro Trp Asp Arg Asp Arg Phe Ala Glu Gly Leu Glu Thr Val Gly Asp
165 170 175
Asn Phe Leu Arg His Leu Gly lle Tyr Gly Tyr Arg Ala Gly Phe lle 180 185 190
Arg Arg Tyr Val Asn Trp Gln Pro Ser Pro Leu Glu His lle Glu Met 195 200 205
Leu Glu Gln Leu Arg Val Leu Trp Tyr Gly Glu Lys lle His Val Ala 210 215 220
Val Ala Gln Glu Val Pro Gly Thr Gly Val Asp Thr Pro Glu Asp Leu 225 230 235 240
Asp Pro Ser Thr Arg lle Arg Arg Ser Arg Asn Leu Gly Lys Val lle
245 250 255
Asp Thr Leu Thr Cys Gly Phe Ala Asp Leu Met Gly Tyr lle Pro Leu 260 265 270
Val Gly Ala Pro Leu Gly Gly Ala Ala Arg Ala Leu Ala His Gly Val 275 280 285
Arg Val Leu Glu Asp Gly Val Asn Tyr Ala Thr Gly Asn Leu Pro Gly 290 295 300
Cys Ser Phe Ser lle Phe Leu Leu Ala Leu Leu Ser Cys Leu Thr Val 305 310 315 320
Pro Ala Ser Ser Tyr Gln Val Arg Asn Ser Ser Gly Leu Tyr His Val 325 330 335
Thr Asn Asp Cys Pro Asn Ser Ser lle Val Tyr Glu Thr Ala Asp Thr 340 345 350
lle Leu His Ser Pro Gly Cys Val Pro Cys Val Arg Glu Gly Asn Thr 355 360 365
Ser Lys Cys Trp Val Ala Val Ala Pro Thr Val Ala Thr Arg Asp Gly 370 375 380
Lys Leu Pro Ser Thr Gln Leu Arg Arg His lle Asp Leu Leu Val Gly 385 390 395 400
Ser Ala Thr Leu Cys Ser Ala Leu Tyr Val Gly Asp Leu Cys Gly Ser
405 410 415
Val Phe Leu Val Ser Gln Leu Phe Thr Phe Ser Pro Arg Arg His Trp 420 425 430
Thr Thr Gln Asp Cys Asn Cys Ser lle Tyr Pro Gly His lle Thr Gly 435 440 445
His Arg Met Ala Trp Asp Met Met Met Asn Trp Ser Pro Thr Thr Ala 450 455 460
Leu Val Val Ala Gln Leu Leu Arg Val Pro Gln Ala lle Leu Asp Met 465 470 475 480
lle Ala Gly Ala His Trp Gly Val Leu Ala Gly lle Ala Tyr Phe Ser
485 490 495
Met Val Gly Asn Trp Ala Lys Val Leu Val Val Leu Leu Leu Phe Ser 500 505 510
Gly Val Asp Ala Ala Thr Tyr Thr Thr Gly Gly Ser Val Ala Arg Thr 515 520 525
Thr His Gly Phe Ser Ser Leu Phe Ser Gln Gly Ala Lys Gln Asn lle 530 535 540
Gln Leu lle Asn Thr Asn Gly Ser Trp His lle Asn Arg Thr Ala Leu 545 550 555 560
Asn Cys Asn Ala Ser Leu Asp Thr Gly Trp Val Ala Gly Leu Phe Tyr
565 570 575
Tyr His Lys Phe Asn Ser Ser Gly Cys Pro Glu Arg Met Ala Ser Cys 580 585 590
Arg Pro Leu Ala Asp Phe Asp Gln Gly Trp Glu Phe Glu Leu Gly Thr 595 600 605
Arg Gly Ser Ser Arg Leu Gln Ala Cys
610 615

Claims

1 . A recombinant fusion protein SEQ. ID. NO. 1.
2. A recombinant fusion protein SEQ. ID. NO. 2.
3. A recombinant fusion protein SEQ. ID. NO. 3.
4. A recombinant fusion protein SEQ. ID. NO. 4.
5. A recombinant fusion protein SEQ. ID. NO. 5.
6. A polypeptide SEQ. ID. NO. 1.
7. A polypeptide SEQ. ID. NO. 2.
8. A polypeptide SEQ. ID. NO. 3.
9. A polypeptide SEQ. ID. NO.4.
1 0. A polypeptide SEQ. ID. NO.5.
1 1 . An assay for identifying the presence of an antibody immunologically reactive with an HCV antigen in a fluid sample comprising:
contacting the sample with at least one polypeptide selected from the group consisting of recombinant fusion proteins SEQ. ID. NO. 1 , SEQ. ID. NO. 2, SEQ. ID. NO.3, SEQ. ID. NO. 4, SEQ. ID. NO.5, and poiypeptides SEQ. ID. NO. 1, SEQ. ID. NO.2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5 under conditions suitable for complexing the antibody with the polypeptide; and detecting the antibody- polypeptide complex.
12. In a confirmatory assay for identifying the presence of an antibody in a fluid sample immunologically reactive with an HCV antigen wherein the sample is used to prepare first and second immunologically equivalent aliquots and the first aliquot is contacted with at least one polypeptide selected from the group consisting of recombinant fusion proteins SEQ. ID. NO. 1 , SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5, and poiypeptides SEQ. ID. NO. 1 , SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5 under conditions suitable for complexing the antibody with the polypeptide and wherein the first antibody-antigen complex is detected, and:
contacting the second aliquot with a polypeptide selected from the group consisting of recombinant fusion proteins SEQ. ID. NO. 1, SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5, and poiypeptides SEQ. ID. NO. 1 , SEQ. ID. NO.2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5 under conditions suitable to form a second antibody-antigen complex; and detecting the second antibody-antigen complex; wherein the polypeptide selected in the first aliquot is not the same as the polypeptide selected in the second aliquot.
13. In an immunodot assay for identifying the presence of an antibody immunologically reactive with an HCV antigen in a fluid sample wherein the sample is concurrently contacted with at least two poiypeptides separately bound to distinct regions of the solid support, each containing distinct epitopes of an HCV antigen under conditions suitable for complexing the antibody with the polypeptide; and detecting the antibody-polypeptide complex, and
wherein said poiypeptides are selected from the group consisting of recombinant fusion proteins SEQ. ID. NO. 1 , SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5, and poiypeptides SEQ. ID. NO. 1 , SEQ. ID. NO.2, SEQ. ID. NO.3, SEQ. ID. NO.4, SEQ. ID. NO.5.
14. In a competition assay for identifying the presence of an antibody immunologically reactive with an HCV antigen in a fluid sample wherein the sample is used to prepare first and second immunologically equivalent aliquots wherein the first aliquot is contacted with a polypeptide bound to a solid support under conditions suitable for complexing the antibody with the polypeptide to form a detectable antibody-polypeptide complex, and wherein the second aliquot is first contacted with unbound polypeptide and then contacted with said bound polypeptide wherein the polypeptide is selected from the group consisting of recombinant fusion proteins SEQ. ID. NO. 1 , SEQ. ID. NO.2, SEQ. ID. NO.3, SEQ. ID. NO. 4, SEQ. ID. NO.
5, and poiypeptides SEQ. ID. NO. 1 , SEQ. ID. NO.2, SEQ. ID. NO.3, SEQ. ID. NO.4, SEQ. ID. NO.5.
15. In a competition assay for identifying the presence of an antibody immunologically reactive with an HCV antigen in a fluid sample wherein the sample is used to prepare first and second immunologically equivalent aliquots wherein the first aliquot is contacted with a polypeptide bound to a solid support under conditions suitable for complexing the antibody with the polypeptide to form a detectable antibody-polypeptide complex and wherein the second aliquot is first contacted with unbound polypeptide and then contacted with said bound polypeptide wherein the polypeptide is selected from the group consisting of recombinant fusion proteins SEQ. ID. NO. 1 , SEQ. ID. NO.2, SEQ. ID. NO.3, SEQ. ID. NO. 4, SEQ. ID. NO. 5, and poiypeptides SEQ. ID. NO. 1, SEQ. ID. NO.2, SEQ. ID. NO.3, SEQ. ID. NO.4, SEQ. ID. NO. 5; wherein the second aliquot is contacted with unbound and bound polypeptide simultaneously.
16. In a neutralization assay for identifying the presence of an antibody immunologically reactive with an HCV antigen in a fluid sample wherein the sample is used to prepare first and second immunologically equivalent aliquots wherein the first aliquot is contacted with a polypeptide bound to a solid support under conditions suitable for complexing the antibody with the polypeptide to form a detectable antibody-polypeptide complex wherein the bound polypeptide is selected from the group consisting of recombinant fusion proteins SEQ. ID. NO. 1, SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO.5, and poiypeptides SEQ. ID. NO. 1 , SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO.4, SEQ. ID. NO.5;
and wherein the second aliquot is first contacted with unbound polypeptide and then contacted with said bound polypeptide wherein the unbound polypeptide is selected from the group consisting of recombinant fusion proteins SEQ. ID. NO. 1 , SEQ. ID. NO. 2, SEQ. ID. NO.3, SEQ. ID. NO.4, SEQ. ID. NO.5, and poiypeptides SEQ. ID. NO. 1 , SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO.5 and wherein the bound polypeptide selected is not the same as the same as the unbound
polypeptide selected.
17. In a neutralization assay for identifying the presence of an antibody immunologically reactive with an HCV antigen in a fluid sample wherein the sample is used to prepare first and second immunologically equivalent aliquots wherein the first aliquot is contacted with a polypeptide bound to a solid support under conditions suitable for complexing the antibody with the polypeptide to form a detectable antibody-polypeptide complex wherein the bound polypeptide is selected from the group consisting of recombinant fusion proteins SEQ. ID. NO. 1, SEQ. ID.
NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO. 4, SEQ. ID. NO. 5, and poiypeptides SEQ. ID. NO. 1, SEQ. ID. NO. 2, SEQ. ID. NO. 3, SEQ. ID. NO.4, SEQ. ID. NO.5;
and wherein the second aliquot is first contacted with unbound polypeptide and then contacted with said bound polypeptide wherein the unbound polypeptide is selected from the group consisting of recombinant fusion proteins SEQ. ID. NO. 1 ,
SEQ. ID. NO. 2, SEQ. ID. NO.3, SEQ. ID. NO.4, SEQ. ID. NO.5, and poiypeptides SEQ. ID. NO. 1 , SEQ. ID. NO. 2, SEQ. ID. NO.3, SEQ. ID. NO.4, SEQ. ID. NO.5;
and wherein the bound polypeptide selected is not the same as the unbound polypeptide selected;
and wherein the second aliquot is contacted with unbound and bound
polypeptide simultaneously.
1 8. An immunoassay kit comprising:
a polypeptide containing at least one HCV antigen selected from the group consisting of recombinant fusion proteins SEQ. ID. NO. 1, SEQ. ID. NO. 2, SEQ. ID. NO.3, SEQ. ID. NO. 4, SEQ. ID. NO. 5, and poiypeptides SEQ. ID. NO. 1 , SEQ. ID. NO.2, SEQ. ID. NO. 3, SEQ. ID. NO.4, SEQ. ID. NO.5;
one or more sample preparation reagents; and one or more detection and signal producing reagents.
19. A kit of claim 18 wherein the poiypeptides are bound to a solid support.
PCT/US1992/007188 1991-08-21 1992-08-21 Hepatitis c assay utilizing recombinant antigens to ns1 WO1993004088A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP92918853A EP0600009A4 (en) 1991-08-21 1992-08-21 Hepatitis c assay utilizing recombinant antigens to ns1.
JP5504658A JPH06510191A (en) 1991-08-21 1992-08-21 Hepatitis C assay using recombinant antigen against NS1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74856191A 1991-08-21 1991-08-21
US748,561 1991-08-21

Publications (1)

Publication Number Publication Date
WO1993004088A1 true WO1993004088A1 (en) 1993-03-04

Family

ID=25009968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/007188 WO1993004088A1 (en) 1991-08-21 1992-08-21 Hepatitis c assay utilizing recombinant antigens to ns1

Country Status (6)

Country Link
EP (1) EP0600009A4 (en)
JP (1) JPH06510191A (en)
AU (1) AU2513592A (en)
CA (1) CA2115926A1 (en)
TW (1) TW213924B (en)
WO (1) WO1993004088A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020664A2 (en) * 1994-01-28 1995-08-03 Abbott Laboratories Mammalian expression systems for hepatitis c virus envelope genes
EP0979867A2 (en) * 1993-11-04 2000-02-16 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
EP1211315A1 (en) * 1994-07-29 2002-06-05 Innogenetics N.V. Recombinant vectors for producing HCV envelope proteins
US7157226B1 (en) * 1993-04-27 2007-01-02 Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
US7196183B2 (en) 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
EP2062913A1 (en) 1998-05-28 2009-05-27 Abbott Laboratories Toxoplasma GONDII antigens, P35, and uses thereof
US8124747B2 (en) 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318216A1 (en) * 1987-11-18 1989-05-31 Chiron Corporation NANBV diagnostics and vaccines
EP0331961A2 (en) * 1988-03-11 1989-09-13 Abbott Laboratories Method for protein synthesis using CKS fusion proteins
EP0388232A1 (en) * 1989-03-17 1990-09-19 Chiron Corporation NANBV diagnostics and vaccines
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318216A1 (en) * 1987-11-18 1989-05-31 Chiron Corporation NANBV diagnostics and vaccines
EP0331961A2 (en) * 1988-03-11 1989-09-13 Abbott Laboratories Method for protein synthesis using CKS fusion proteins
EP0388232A1 (en) * 1989-03-17 1990-09-19 Chiron Corporation NANBV diagnostics and vaccines
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BioTechniques, Volume 8, No. 5, issued May 1990, T.J. BOLLING et al., "An Escherichia Coli Expression Vector for High-Level Production of Heterologous Proteins in Fusion with CMP-KDO Synthetase", pp. 488-492, see entire document. *
Journal of General Virology, Volume 72, issued November 1991, H. OKAMOTO et al., pp. 2697-2704, see entire document. *
Journal of General Virology, Volume 72, issued October 1991, D. KREMSDORF et al., "Partial Nucleotide Sequence Analysis of a French Hepatitis C Virus: Implications for HCV Genetic Variability in the E2/NS1 Protein", pp. 2557-2561, see entire document. *
Journal of Virology, Volume 65, No. 3, issued March 1991, A. TAKAMIZAWA et al., "Structure and Organization of the Hepatitis C Virus Genome Isolated from Human Carriers", pp. 1105-1113, see entire document. *
Proceedings of the National Academy of Sciences, Volume 87, issued December 1990, N. KATO et al., "Molecular Cloning of the Human Hepatitis C Virus Genome from Japanese Patients with Non-A, Non-B, Hepatitis", pp. 9524-9528, see entire document. *
Proceedings of the National Academy of Sciences, Volume 88, issued March 1991, Q.-L. CHOO et al., "Genetic Organization and Diversity of the Hepatitis C Virus", pp. 2451-2455, see entire document. *
See also references of EP0600009A4 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157226B1 (en) * 1993-04-27 2007-01-02 Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
EP0979867A2 (en) * 1993-11-04 2000-02-16 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
EP0979867A3 (en) * 1993-11-04 2007-06-13 Innogenetics N.V. Immunodominant human T-cell epitopes of hepatitis C virus
WO1995020664A2 (en) * 1994-01-28 1995-08-03 Abbott Laboratories Mammalian expression systems for hepatitis c virus envelope genes
WO1995020664A3 (en) * 1994-01-28 1995-12-28 Abbott Lab Mammalian expression systems for hepatitis c virus envelope genes
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
EP1211315A1 (en) * 1994-07-29 2002-06-05 Innogenetics N.V. Recombinant vectors for producing HCV envelope proteins
EP2062913A1 (en) 1998-05-28 2009-05-27 Abbott Laboratories Toxoplasma GONDII antigens, P35, and uses thereof
US7196183B2 (en) 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
US8124747B2 (en) 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof

Also Published As

Publication number Publication date
AU2513592A (en) 1993-03-16
JPH06510191A (en) 1994-11-17
EP0600009A1 (en) 1994-06-08
TW213924B (en) 1993-10-01
EP0600009A4 (en) 1995-03-01
CA2115926A1 (en) 1993-03-04

Similar Documents

Publication Publication Date Title
Selby et al. Complex processing and protein: protein interactions in the E2: NS2 region of HCV
US5372928A (en) Hepatitis C virus isolates
Falgout et al. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity
CN100365017C (en) Antigenic polypeptide of chlamydia pneumoniae
Bartenschlager et al. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions
US6593083B1 (en) Hepatitis C assay utilizing recombinant antigens
Lanford et al. Analysis of hepatitis C virus capsid, E1, and E2/NS1 proteins expressed in insect cells
ES2141081T5 (en) NEW ISOLATED FROM HCV J-1.
EP0472207B1 (en) Hepatitis C assay utilizing recombinant antigens
JPH06107687A (en) Antiviral agewt
Pilot‐Matias et al. Identification of antigenic regions in the GB hepatitis viruses GBV‐A, GBV‐B, and GBV‐C
AU716379B2 (en) Methodology to produce, purify and assay polypeptides with the proteolytic activity of the HCV NS3 protease
EP1227323B1 (en) Non-A, non-B hepatitis virus antigen, and diagnostic methods
WO1993004088A1 (en) Hepatitis c assay utilizing recombinant antigens to ns1
Pereboeva et al. Hepatitis C epitopes from phage‐displayed cDNA libraries and improved diagnosis with a chimeric antigen
US5800982A (en) Antigenic peptides for growing hepatitis C virus, kit comprising the same and methods for its grouping using the same
EP0600000A1 (en) Hepatitis c assay utilizing recombinant antigens from ns5 region
CA2070952A1 (en) Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
CA2116026C (en) Hepatitis c assay utilizing recombinant antigens to c-100 region
Gwack et al. NTPase activity of hepatitis C virus NS3 protein expressed in insect cells
JPH06507552A (en) DNA sequences and encoded polypeptides useful in the diagnosis of hepatitis diseases
Seki et al. Effective production of the hepatitis C virus core antigen having high purity in Escherichia coli
Seong et al. Characterization of the structrual proteins of hepatitis C virus expressed by an adenovirus recombinant
Khanna et al. Hepatitis C virus core protein: synthesis, affinity purification and immunoreactivity with infected human sera
Seong et al. Overexpression and simple purification of a truncated, immunologically reactive GST-HCV core (1–123) fusion protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

WWE Wipo information: entry into national phase

Ref document number: 1992918853

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2115926

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1992918853

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992918853

Country of ref document: EP